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Summary 
 
The chemical and biological evaluation of organometallic probes for nuclear 
medical applications in comparison to their purely organic analogs, or the study of 
the metal-mediated retro-Diels-Alder behaviour of derivatized cyclopentadienyl 
dimers is an overarching description of this thesis. Focussing on the synthesis of 99mTc-
labelled radiopharmaceuticals and the corresponding cold rhenium-compounds, a 
variety of organic and inorganic cyclopentadienyl derivatives have been 
synthesized. Arylsulfonamides, -sulfamides and -sulfamates for the targeting of 
human carbonic anhydrase IX, hydroxamic acids acting as HDAC-inhibitors, 
organometallic antibiotics or catechol amine derivatives have been studied.  
 
Organometallic complexes with bioactive ligands are nowadays interesting for both, 
the noninvasive imaging of biological features and the therapeutic treatment of 
diseases. While several transition metals across the periodic table are frequently used 
for therapy, 99mTc is the most prominent nuclide in nuclear medical diagnostics.[1, 2]  
It would be desirable, in a theragnostics sense (therapy and diagnostics), to have 
identical compounds for combined therapy and non-invasive diagnosis.[3, 4] Among 
transition-metals, rhenium and technetium belong to the same triad. Therefore it is 
possible to use identical compounds for combined therapy and imaging.[3-5] While 
Re-based compounds can be used for therapy, the homologous compounds with 
99mTc can serve as imaging agents for Single Photon Emission Computed 
Tomography (SPECT).[1, 2, 6] 
[(CpR)M(CO)3]-type compounds are considered as very stable complexes under 
various conditions and can synthetically be treated like aromatic organic molecules. 
Re-compounds are therefore usually synthesized starting from [(Cp)Re(CO)3] and 
using standard organic synthesis procedures, whereas for the corresponding 99mTc-
complexes, the uncoordinated HCp-ligand is prepared prior to complexation, either 
as a monomer or in its dimeric form. 
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Zusammenfassung 
 
Die chemische und biologische Evaluation von organometallischen Stoffen für 
nuklearmedizinische Anwendungen, verglichen mit ihren rein organischen Analogas 
und die Untersuchung des Metall-vermittelten retro-Diels-Alder Verhaltens von 
derivatisierten Cyclopentadienyl-dimeren ist eine zusammenfassende Beschreibung 
dieser Dissertation. Mit einem Hauptaugenmerk auf die Synthese von 99mTc-
markierten Radiopharmaka, wurde eine Vielfalt an organischen und anorganischen 
Cyclopentadienyl Derivaten hergestellt. Arylsulfonamide, -sulfamide und -sulfamate, 
die an die Carboanhydrase IX binden, Hydroxamsäuren, welche als HDAC-
Inhibitoren dienen, organometallische Antibiotika oder Catecholamin Derivate 
wurden untersucht. 
 
Organometallische Komplexe mit biologisch aktiven Liganden sind heute sowohl für 
die Anwendung der nicht-invasiven Bildgebung, als auch für therapeutische 
Behandlungen interessant. Während eine Vielzahl an Metallen quer durch das 
Periodensystem regelmässig für therapeutische Zwecke verwendet werden, ist 99mTc 
das meist verwendete Nuklid in der nuklear medizinischen Diagnostik.[1, 2] In einem 
theragnostischen (Therapie und Diagnostik) Kontext wäre es wünschenswert, 
identische Verbindungen für kombinierte Therapie und nicht-invasive Diagnose zu 
haben.[3, 4] Unter den Übergangsmetallen gehören Rhenium und Technetium zu 
derselben Triade. Daher ist es möglich, identische Verbindungen für kombinierte 
Zwecke der Therapie und der Diagnostik zu verwenden.[3-5] Während Rhenium-
basierte Verbindungen für die Therapie eingesetzt werden, können die homologen 
Verbindungen mit Technetium-99m als Marker für die Photon Emission Computed 
Tomography (SPECT) dienen.[1, 2, 6] 
Verbindungen vom Typ [(CpR)Re(CO)3] werden allgemein unter den 
verschiedensten Bedingungen als sehr stabil angesehen und können synthetisch wie 
aromatische organische Moleküle behandelt werden. Re-Verbindungen werden 
daher üblicherweise ausgehend von [(Cp)Re(CO)3] unter verwendung von standard 
organischer Synthesemethoden hergestellt, während für die entsprechenden 99mTc-
Verbindungen der unkoordinierte HCp-Ligand, entweder als monomer oder in seiner 
dimeren Form vorgängig synthetisiert wird.  
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1. Introduction 
 
1.1 Metals in Medicine 
 
Medicinal inorganic chemistry is a relatively young field of research, which has 
emerged tremendously since the successful development of Cisplatin in the late 
1960s. During the past 50 years, a multitude of metal containing anticancer, 
antirhumatismal, antiparasital, antimalarial and antibacterial compounds, enzyme 
inhibitors and MRI-contrast agents have been exploited and investigated.[7, 8] 
However, the vast majority of the pharmaceuticals on the market are based on 
organic agents, acting for example as inhibitors for receptors. Most of the 
organometallic or inorganic drugs act in a "Cisplatin manner", using the versatile 
reactivity of the metal center in biochemical environment. One reason for this might 
be the consequence of man's will to adopt to nature, where the rich redox chemistry 
and the relatively weak bonding interactions between metals and small molecules 
(the ligand binding energy in a typical coordination M-L bond is 50-150 kJ/mol) 
enables reversible binding, in contrast to the energetically stronger covalent bonds 
(energy of a single C-C bond is 300-400 kJ/mol) formed within organic molecules.[7] 
Structural changes imposed by metal cations such as Ca2+ or Zn2+ on proteins or 
nucleic acids are essential for the initiation of biological processes.[6] Binding sites in 
the binding pocket of proteins or receptors often contain metals as well. However, 
metal complexes are rarely found as structural recognition sites in receptor binding 
molecules, whereas this is exactly how most organic molecules and drugs tend to 
work. Covalent interactions of organic molecules with the biological environment 
only rarely take place.  
Only recently inorganic compounds came into the scope of such applications. The 
structural complexity of metal containing compounds that are stable in biological 
systems was recognized to have an underestimated and unexplored potential for 
medicinal applications.[8] Ferrocene containing antimalarial[9, 10] or anticancer[11] 
compounds or chromium antibacterial agents[12] are recent examples for 
organometallic complexes acting via structural recognition (Figure 1). 
In consequence to this development, metal containing compounds are nowadays 
found both, in the therapeutic treatment of diseases and in the noninvasive 
visualization of biological features. Comprising radioactive elements, 
Introduction 2013 
 
2 
 
radiopharmaceuticals are known as small molecules or also as macromolecules like 
proteins or antibodies.[13] As a function of their biochemical behavior, they 
accumulate in particular regions of the body or in certain tissues. Depending on the 
radionuclides that are introduced, radiopharmaceuticals are designed for 
therapeutic treatment of diseases, for diagnosis or for combined clinical 
applications. Striking therapeutic elements are - or --particle emitters, delivering a 
cytotoxic radiation dose to the target tissue. Incorporating +- (for Positron Emission 
Computed Tomography, PET) or - (for Single Photon Emission Computed 
Tomography, SPECT) emitting elements, radiopharmaceuticals follow a diagnostic 
purpose, providing detailed information of pathological structures or of physiological 
functions. Combining diagnostic radiopharmaceuticals with therapy, the effect and 
the progress of a treatment can be monitored in a noninvasive way. In the following 
course of this thesis, radiotherapeutic agents are not discussed but imaging agents 
with 99mTc will be in the scope. Combining such radiotracers with the corresponding 
cold Re-analogues, the "Theragnostic" (therapy and diagnostic) application of metal 
complexes will be discussed. 
 
Figure 1: Organometallic complexes acting via structural recognition. A) Ferroquin – passed phase II 
clinical trials as an anti-malarial drug. B) Ferrocifen (R = H, n = 2-8) – anti-estrogens in MCF-7 breast 
cancer cell lines and against estrogen-dependent tumor xenografts in nude mice. C) Chromium based 
analogue of Platensimycin – inhibits the FabF enzyme in bacterial fatty acid biosynthesis. 
 
1.2  99mTc and Labeling 
 
The eligibility criteria for radionuclides that are suitable for clinical use are demanding 
and versatile and confine therefore the assortment of possible nuclides dramatically. 
From a synthetic point of view, the preparation of a radiopharmaceutical must be 
fast in the timescale of the half life time of the radionuclide.[14] It should consist of one 
or at most of two steps in synthesis, which can be accomplished with a minimum of 
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complexity just before application and on-site. Beside synthetic strains, the half-life 
time of the radionuclide must match the pharmacology of the vector. It should be 
sufficiently long allowing dose preparation, administration to the patient, 
accumulation in the target tissue and collection of images. The energy of the 
emitted particles should be high enough to allow good quality images but as low as 
possible to minimize the radiation dose delivered to the patient. Commercial aspects 
like price and availability are other crucial points for routine clinical use. 
Among transition metals, many different nuclides suit at least some of these 
demands. 94mTc, 99mTc, 111In, 201Tl, 60Cu, 61Cu, 64Cu, 66Ga, 67Ga, 68Ga, 44Sc, 86Y, 86Zr and 
89Zr are examples of which some are more and others less studied and explored.[15-18] 
99mTc is the most prominent nuclide in nuclear imaging.[2, 19-21] Roughly 85 % of the 
clinically administered radiopharmaceuticals consist of 99mTc complexes. With a half-
life time of about 6h, the emission of pure -photons of 140 keV (accompanied by 
internal conversion and Auger electrons) and a few stable oxidation states it is 
suitable for versatile chemistry and for scintigraphy.[14] It is availabile as Na[99mTcO4] in 
low concentrations of 10-8 to 10-9 M in physiological saline from the 99Mo/99mTc 
generator which simplifies clinical handling tremendously compared to nuclides that 
are generated by cyclotron. 99Mo is produced from nuclear reactors, making it 
cheap. 
Depending on the metal core fraction and on the ligand system which is 
coordinated, three different types of imaging agents are discriminated according to 
their mechanism of action in vivo.[14]  
 Perfusion agents are chemically innocent coordination compounds, which do 
not contain a direct pharmaceutical function. They follow a certain biological 
pathway due to physico-chemical properties, which are predominantly 
defined by the ligand sphere surrounding the metal core.  
 Biomimetics are organometallic complexes, comprising structural mimetics of 
biological or pharmaceutical lead structures. They bind to the same receptors 
or enzymes as the lead structures, and the metal contributes to the binding as 
an integrated part of the molecule. 
 Targeting agents incorporate a targeting vector with a directly related 
biological function. This function is conjugated to, or integrated into a certain 
type of chelator, which coordinates to the metal center.  
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Introducing a metal complex into a biologically active function will change 
the structural- and also the biological properties of the vector. Keeping a 
radiochemically labeled agent biologically active is therefore challenging, 
especially for small molecules compared to labeled peptides, proteins or 
antibodies. A large number of techniques have been developed for 99mTc-
labeling, which are classified into categories.[22] In the direct labeling 
approach the presence of disulfide bridges in peptides is used, for proteins 
and antibodies to incorporate a metal complex. By reduction with SnCl2 free 
thiols are formed, which bind strongly to the Tc-core. 
The formation of a 99mTc-chelate prior to coupling to the targeting function is 
called pre-labeling, and prevents the targeting function from being exposed 
to the sometimes harsh labeling conditions. This strategy is often applied for 
the labeling of antibodies.[23] 
In the post-labeling approach, a targeting vector is coupled via a linker to a 
chelator, which binds the metal center. The bifunctional chelator (BFC) is 
formed before complexation. Radiolabeling can be accomplished in the 
presence of the BFC. This strategy is often applied for the labeling of small 
molecules (Figure 2). 
 
 
Figure 2: Schematic representation: imaging with the BFC-approach 
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Different core fractions with 99mTc comprising different oxidation states, chemistry, size 
and hydrophobicity are focused for applications in nuclear medicine. Clinically 
applied imaging agents frequently consist of a [99mTcVO]3+ or [99mTcVO2]+ core, 
thermodynamically stabilized by tetradentate ligands with mixed N-, S- and O-
donors.[19] Examples are diethylene-triamine-pentaacetic acid (DTPA), mercapto-
acetyl-glycine-glycine-glycine (MAG3) or oxime-bridged hexamethyl-propylene 
amin oxime (HMPAO) (Figure 3). Currently extensively investigated 99mTc-fragments 
are the fac-{99mTcI(CO)3}+-, the {99mTcVN(PNP)}2+- or the fac-{99mTcVIIO3}+-core (Figure 
4).[24-26] Molecules labeled with these fragments often follow the concept of targeted 
imaging with the bifunctional chelator (BFC) approach.[14] Such complexes are often 
generated from a robust core fraction with a few coordination sites occupied by 
weakly bound substitution-labile ligands. These ligands correspond for example to 
the water molecules in [99mTc(OH2)3(CO)3]+[27, 28] or to the halides in [99mTcN(PNP)Cl2][24] 
respectively. Tridentate - or -donors, coupled to a targeting vector are popular 
ligand systems for fac-{99mTcI(CO)3}+.[21, 29-31] [99mTc(NS3)L] containing targeting 
molecules are formed in a 4+1-approach from [99mTc(EDTA)]- in one pot together with 
the NS3-chelator and an additional bifunctional ligand L.[32-36] Fac-{99mTcO3}+-cores 
can be used as a derivatized [99mTcO3(TACN)]+ moiety, where the biologically active 
functionality is either introduced with the 1,4,7-triazacyclononane (TACN) or, via 3+2 
cyclo-addition, to two oxygen atoms.[37, 38]  
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Figure 3: Preferred ligand systems for Re and Tc-chemistry in nuclear medicine. A) PnAO, B) HMPAO, C) 
DTPA, D) DADS, E) DADT, F) MAG3, G) MAMA, H) Diphos, I) DTC J) HIS, K) Cp. 
 
 
Figure 4: Investigated 99mTc-fragments. A) Square pyramidal Tc-oxo complexes ([99mTcVOL4]3+) with 
tetradentate chelators, such as DADT, MAG3, DADS and MAMA. B) Square pyramidal Tc-nitrido 
complex of the form [99mTcVN(PNP)L]2+ with various chelators. PXP ligands are used for stabilisation of the 
{99mTcVN}-core. C) {TcV/III}HYNIC-HYNIC can occupy one or two coordination sites (depending on R), 
which can influence the oxidation number of the metal. A coligand L, is needed to complete the 
coordination sphere. D) [99mTcVO2]+, E) [99mTcIII(NS3)L], F) fac-{99mTcI(CO)3L3]+ with bidentate and 
tridentate chelators containing imidazoles, pyridines, amides, amines, carboxylic acids or others. G) fac-
{99mTcVIIO3L3]+. 
 
Among transition-metals, rhenium and technetium belong to the same triade. 
Therefore it is possible to use identical compounds for combined therapy and 
imaging in a theragnostics approach.[3-5, 39] While Re-based compounds can be used 
for therapy, the homologous compounds with 99mTc can serve as imaging agents for 
single photon emission computed tomography (SPECT).[2, 4, 6, 19, 40] Following a BFC 
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approach with targeting agents, it is also possible to apply "cold" non-radioactive 
185Re for common chemo therapy, instead of the radiotherapy nuclides 186/188Re.  
 
1.3 The Targeted Approach: Inhibitors and Selectivity 
 
Within organometallic agents, several targets like DNA, mitochondria, cell 
membranes, receptors, enzymes or proteins are focused. The selection of an 
appropriate target is crucial for inducing the anticipated effect and strongly 
depends on the function or disease of interest. 
Diagnosis and therapeutic treatment of many diseases requires molecules designed 
for binding to receptors and enzymes. Upon binding they interfere with biological 
processes related to these diseases, by acting as agonists or as antagonists. In this 
context, activators can induce the biosynthesis of compounds needed to overcome 
a malfunction. Leading to cell death on the other hand, inhibitors possess a 
competitively regulative aspect and are often studied in the treatment of cancer, 
where excessive proliferation can be opposed. 
In contrast to healthy cells, metabolism is defective in diseased cells in many 
malfunctions. Therefore certain receptors or enzymes can be strongly overexpressed. 
Especially in cancer related tissues overexpression is frequently observed. Allowing 
selective accumulation of a targeting agent, these biomolecules are therefore of 
high interest for both, therapy or diagnosis. However, since nature has developed an 
enormous realm of functionally and structurally similar receptors and enzymes, 
selectivity for a specific target is a key criterion for the quality of an inhibitor.[41] As 
mentioned above, inhibitors are typically of organic nature but Meggers et al. 
recently showed that high selectivity does not only depend on intermolecular 
interactions but also on a versatile and directed three dimensional arrangement of 
different functionalities. As exemplified with organometallic protein kinase 
inhibitors,[42-44] chemically inert organometallic complexes offer the enhanced 
opportunity to populate biologically relevant chemical space compared to similar 
inhibitors with a purely organic scaffold. Therefore, bioorganometallic complexes 
exhibit a high potential as chemical probes.[42, 45-48]  
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1.4 Cp & Thiele's Acid 
 
99mTc is available as Na[99mTcO4] in physiological saline. Any chemistry must therefore 
be performed in aqueous solution, which can be demanding and is not always 
straightforward for organometallic synthesis. Cyclopentadiene (HCp) is for imaging a 
conceptually and structurally uncommon ligand. It does not contain any 
heteroatoms, which renders the molecule hydrophobic and therefore in fact 
unsuitable for aqueous syntheses. Moreover HCp and many derivatives are unstable 
as a monomer and undergo Diels-Alder polymerization. However, Hanzlik et al. 
exemplified in the late 1970s with -Ferrocenylalanine as an inhibitor of the 
phenylalanine decarboxylase, that organometallic Cp- sandwich-complexes can be 
tolerated in biological systems, when replacing phenyl rings.[49] Years later, Jaouen 
and coworkers confirmed this observation. They developed a variety of highly potent 
selective estrogen receptor inhibitors by replacing a phenyl ring in Tamoxifen with 
ferrocene or with [(Cp-R)Re(CO)3]. The resulting molecules retained a high binding 
affinity for the estrogen receptor.[11, 50-55] With this example, beside ferrocene, Cp--
complexes of the group 7 transition metal tricarbonyls became very popular for 
medicinal inorganic research. Bioorganometallic complexes containing ferrocene or 
[(Cp-R)M(CO)3] (M = Re or 99mTc) exhibit a high potential as therapeutic agents or 
also as imaging agents as the Cp-complex can act as a structural analogue of 
phenyl rings. Additionally, [(Cp-R)M(CO)3] (M = Re or 99mTc) is small in size and 
minimizes therefore steric interference with the biological environment in the binding 
site, which contributes to the retention of the function of the targeting vector. 
Another inherent advantage is the stability of these half sandwich complexes under 
physiological conditions. However, whereas ferrocene-based organometallic 
compounds have a high potential for therapy, their in vivo diagnostic use is limited 
since radionuclides such as 18F or 11C (PET) cannot easily be introduced or lead to 
substantial alteration of the chemical authenticity of the compound. As mentioned 
above, in a theragnostic sense, the bio-isosteric replacement of organic 
functionalities by group 7 transition metal complexes (Re or 99mTc) is interesting for 
both, therapy and diagnosis.  
Drawbacks for the application of Cp--containing 99mTc-complexes for imaging arise 
from the synthetic properties of the HCp-ligand. Whereas macroscopic amounts of 
cold [(Cp-R)Re(CO)3] complexes are accessible along classical organic and 
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organometallic methods, the 99mTc analogues must be prepared from aqueous 
buffer solutions and require the uncoordinated ligands to be synthesized in advance. 
HCp contains two conjugated double bonds and derivatives are therefore, in 
principle, easily accessible. But its tendency to undergo fast Diels-Alder di- or 
polymerization makes derivatization demanding. Beside this, 5-coordination to fac-
{Tc(CO)3} requires deprotonation of HCp. A pKa of roughly 14 of unsubstituted HCp is 
for pure hydrocarbons relatively low, but still too high for organometallic synthesis in 
water at physiological pH. In order to overcome these drawbacks, several multistep 
labelling procedures have been proposed.[56-59] But these syntheses include 
autoclave reactions in organic solvents and are therefore unacceptable for routine 
application. 
However, electron withdrawing substituents have been shown to lower the pKa of 
monomeric HCp-compounds, tremendously.[60-62] At a physiological pH of 7.4, the 
amount of deprotonated Cp- in solution is therefore increased and coordination to 
the fac-{Tc(CO)3}-core is relieved. The pKa of acetyl-HCp for example is 8.6, which is 
lower by 5 orders of magnitude relative to unsubstituted HCp. Also other -keto 
substituted HCp-compounds have pKa-values in the same range and are stable as 
deprotonated sodium salts in aqueous solutions for hours, even when exposed to air 
(Figure 5).[60]  
 
 
Figure 5: Deprotonation of Cp-derivatives. -keto substitution of HCp lowers the pKa by roughly 5 orders 
of magnitude – aqueous complexation with fac-{Tc(CO)3} is now possible. 
 
[(Cp-R)99mTc(CO)3]-type complexes are therefore accessible in aqueous solution at 
temperatures below 100 °C with -keto substituted HCp-compounds, which are 
stable as monomers for a sufficient long period. The same principle is true for the -
carboxylic acid HCp-COOH.[61] But unlike HCp-ketons, HCp-COOH tends to dimerize 
relatively fast and is not cracked at temperatures below 160 °C, making 
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derivatization of the acid with a targeting vector difficult. Stabilization as a ring-
deprotonated sodium salt is not possible, due to the high acidity of the carboxylic 
acid function. However, the unexpected formation of [(CpCOOH)99mTc(CO)3] using 
"Thiele's Acid", the Diels-Alder dimer of HCp-COOH, showed that the metal-mediated 
retro Diels-Alder reaction is a convenient synthesis, as Thiele's Acid can be regarded 
as a protected HCp-COOH. Based on this result, the general synthetic route to [(Cp-
R)99mTc(CO)3]-type complexes has been developed by derivatization of the acid 
function via amide coupling to biotargeting vectors. This procedure allows a fully 
aqueous preparation of a variety of bioactive compounds (Scheme 1).[61, 63] The 
metal mediated retro Diels-Alder reaction of (HCp-R)-dimers with [99mTc(OH2)3(CO)3]+ 
or directly with [99mTcO4]- permitted to transfer the principle of replacing phenyl rings 
in bioactive substances to 99mTc-labeled compounds as demonstrated with melanin 
targeting agents or with high affinity carbonic anhydrase inhibitors, which are part of 
this thesis.[5, 64] 
 
 
Scheme 1: Metal mediated retro Diels-Alder. Thiele's Acid derivatives do not cleave thermally below 160 
°C. The retro Diels-Alder reaction with [99mTc(OH2)3(CO)3]+ or directly with [99mTcO4]- therefore must be 
metal mediated. 
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2.2 Cp-derivatization  
 
The derivatization of cyclopentadiene or of complexes thereof has a long history in 
organic and organometallic chemistry. Many different substituents have been 
described in literature.[65-71] However, the number of reports, where these derivatives 
have been used to couple biologically active targeting vectors is comparably small.  
Being part of the spacer between the chelator and the targeting vector, the 
functional group directly attached to the Cp is of high importance. This part of the 
bifunctional chelator (BFC) can influence interactions between the target and the 
targeting agent to a large extend. Beside physical properties, this functionality can 
influence also the chemical properties of the BFC. Depending on the electronic 
characteristics of the derivative, in uncoordinated HCp-compounds it can influence 
the electron density on the adjacent double bond and therefore also the bond 
lengths and electro- or nucleophilicity. This again has an influence on the monomer 
stability and dimerization rate, as well as on the acidity of the ring protons. 
In the following chapter, the synthesis and the characteristics of different Cp-
functionalities are discussed. In some cases, the free HCp-derivative was prepared 
along with the corresponding Re- and the 99mTc-complexes. Derivatives of some of 
these functional groups have been prepared as simple model compounds, and do 
not have any biological target.  
Electron withdrawing substituents lower the electron density at the metal center. 
Therefore also the -backdonation to the CO-ligands is diminished. This again has an 
impact on the C-O-bonding distance and on the IR-CO-frequency.  
Increased electron acceptance properties, means increased deshielding of 
neighbouring protons. This can be observed in the 1H-NMR as a shift of the 
corresponding peaks towards lower field (higher ppm). 
The electronic properties of the derivatives bound to the Cp influence therefore the 
electron density on neighbouring positions within the molecule. Therefore, the 
compounds can be classified by looking at the 1H-NMR chemical shifts of proximate 
protons or at IR-CO-bands. 
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2.2.1 Cp-COOH 
 
A simple but at the same time very prominent and versatile way of introducing 
derivatives into organic molecules is the derivatization of carboxylic acids. Similar to 
aldehydes or ketones, the carbon atom of the carbonyl-group can be attacked by 
nucleophiles or by other chemical functions. However, the hydroxyl-part of the 
carboxy-group, which is substituted, is in fact a poor leaving group. Therefore, such 
reactions are usually either acid/base catalysed or require the activation by 
introduction of a better leaving group. 
Besides the versatile chemical properties and opportunities that carboxylic acids 
offer, the physicochemical characteristics of this functional group can be of high 
importance as well, as they can influence the characteristics of the whole molecule.  
 
The Ligand 
The carboxylic acid of cyclopentadiene can be synthesized by addition of dry ice to 
a solution of NaCp in THF. The deprotonated Cp- acts as a nucleophile and attacks 
the carbon atom of the solvated CO2, to form after protonation HCp-COOH in three 
possible isomers a, b and c (Scheme 2).[70] These products undergo Diels-Alder 
dimerization or polymerization, to form 16 different isoforms of "Thiele's Acid" (1).[72-74] 
Purification by silica gel column chromatography yields selectively the main product, 
the 3'9'-endo-derivative, which is the only isoform used for further reactions in the 
course of this thesis. Similar to acetyl-Cp (HCp-COCH3), the electron withdrawing 
carbonyl in HCp-COOH lowers the pKa-value of the ring proton from 14 to a range of 
8 to 9, which is of high importance from a synthetic point of view.[60-62]  
The olefinic protons in the 1H-NMR (MeOD) of Thiele's Acid are observed at 6.85 and 
at 6.52 ppm respectively. These shifts are reference values, with which derivatives will 
be compared. 
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Scheme 2: Synthesis of Thiele's Acid. HCp-COOH undergoes quick Diels-Alder dimerization and forms 16 
different isomers. 
 
The Rhenium Complex 
The classical method to prepare the carboxylic acid substituted cyclopentadienyl 
rhenium tricarbonyl half-sandwich complex [5-(CpCOOH)Re(CO)3] is to add CO2 in 
the form of dry ice to the deprotonated nucleophile [5-(CpLi)Re(CO)3].[70] Newer 
approaches synthesized this complex from [Re2(CO)10] or from [BrRe(CO)5] at 
temperatures around 165 °C, using the free ligand HCp-COOH as a monomer or as a 
dimer (1).[70] [(CpCOOH)Re(CO)3] (2) is a remarkably stable compound and can 
synthetically be treated like an organic carboxylic acid. Therefore derivatives like 
amides or esters are accessible along common organic syntheses (Scheme 3). 
Considering the small size of [(Cp)Re(CO)3], its stability and the possibility to replace 
phenyl rings in bioactive substances, 2 is very useful for the development of new 
targeting molecules along the BFC-approach. 
The IR-CO-bands (KBr) of 2 (2032 and 1916 cm-1) are shifted towards higher 
frequencies compared to unsubstituted [(Cp)Re(CO)3] (2018 and 1897 cm-1), which 
indicates the electron accepting properties of the carboxylic acid portion. 
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Scheme 3: Synthesis of [(CpCOOH)Re(CO)3]. 2 can be treated like an organic carboxylic acid to form 
derivatives like esters or amides. 
 
The Technetium Complex 
[(CpCOOH)99mTc(CO)3] (3) is accessible similar to the rhenium complex directly from 
the protonated free ligand HCp-COOH or from Thiele's Acid (1).[61] However in 
contrast to the rhenium synthesis, the quantitative preparation of the 99m-
technetium analogue works at temperatures below 100 °C and does not require any 
organic solvents. As Thiele's Acid does not cleave thermally at these temperatures, 
the retro Diels-Alder reaction is suggested to be metal mediated. Mechanistically, 
the oxygens of the carbonyl groups serve as preliminar anchor groups, which bind to 
the metal center in a bidentate way (Scheme 4). The formation of an enolate, and 
therefore the generation of an intermediate carbo-cation, leads to the retro Diels-
Alder rearrangement and to the separation of the two HCp-rings. Upon 
deprotonation, one of the two HCp-molecules coordinates 5 to the metal center. 
Alternatively, instead of the oxygens of the carbonyl groups, preliminar coordination 
via the two double bonds of the HCp-dimer would also be a possible initial step. 
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Scheme 4: Synthesis of [(CpCOR)99mTc(CO)3] (R = OH or NHR'). [(CpCOOH)99mTc(CO)3] (3) or derivatives 
are accessible from the protonated free ligands HCp-COR or from their dimers at temperatures below 
100 °C in water. 
 
Macroscopic amounts of the corresponding Re- or 99Tc-complexes are synthetically 
not accessible along the same procedure. Though, except for the redox-properties, 
ReI and TcI have very similar chemical characteristics. Suggesting the chelation of 
the metal center by the oxygen atoms of the HCp-dimer to be the rate determining 
step, then the low concentration of the metal compared to the ligand plays a 
crucial role for the kinetics of the reaction. Therefore, the study of the analogous 
reaction with microscopic amounts of Re or 99Tc will be part of future mechanistic 
investigations. 
 
In conclusion, carboxylic acid derived Cp-compounds have been described in 
literature in the form of the uncoordinated ligand (monomer or dimer 1) and as 5-
coordinated Re- or 99mTc tricarbonyl complexes. The compounds are stable under 
ambient conditions and allow a wide range of synthetic manipulations at the 
carboxylic acid portion, even in aqueous solvents. Therefore they exhibit a high 
importance for synthetic or for biological radiopharmaceutical investigations. 
Synthetically, the Re- or 99mTc tricarbonyl complexes are accessible from Thiele's Acid 
1. But unlike the metal mediated retro Diel's-Alder synthesis of the 99mTc-complex, the 
corresponding Re-compound 2 is formed after thermal cleavage of the dimer 1 at 
high temperatures. 
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2.2.2 Cp-SO3 
 
In organic synthesis, sulfonates (RSO3-) are often used in substitution reactions. Their 
conjugated acids are considered as very strong, mainly due to resonance 
stabilisation of the deprotonated anions. For this reason, sulfonates are known as 
good leaving groups during substitution reactions. Moreover, Alkyl-sulfonic acids, 
similar to carboxylic acids can be derivatized by substitution of the hydroxyl-anion. 
Activation for example by halogenation is therefore indispensable. Sulfonic acids 
and derivatives (RSO2R') are electron withdrawing substituents and are expected to 
have similar effects on the pka of a Cp-ring as carbonyls, which makes them 
interesting for organometallic chemistry. 
From a biological point of view, sulfonic acids or derivatives like sulfonamides can 
form versatile hydrogen bond interactions with biomolecules. Sulfone derivatives can 
contribute to important parameters like selectivity or binding constants. Therefore, 
the -SO2R-group is an interesting building block for the spacer part in a BFC.  
As an example, the reaction of alkyl-sulfonyl chlorides (RSO2Cl) with primary or 
secondary amines leads to the formation of internal sulfonamides, which have been 
used as antibiotics (see section 2.2.3). Their mechanism of action is related to the 
inhibition of bacterial enzymes, catalysing the folic acid synthesis. Terminal 
sulfonamides are nowadays extensively studied as carbonic anhydrase (CA) 
inhibitors, which are involved in many malignancies (see section 2.2.2). 
 
The Rhenium Complexes 
[(CpSO3)Re(CO)3]- is described as its p-toluidine-salt and was synthesized along 
literature procedure (Scheme 5).[71] Sulfuric acid serves as a source for sulfonation 
and is nucleophilically attacked by [(Cp)Re(CO)3]. Precipitation from water by the 
addition of p-toluidine afforded compound 4. In order to derivatize the sulfonate 
with a targeting vector, the sulfonyl chloride 5 was prepared by mixing 4 with PCl5 
without solvents. The two solids melted upon mixing and 5 was obtained by 
crystallization form CH2Cl2/hexane (Figure 6).[71] 
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Scheme 5: Synthetic conditions: i) H2SO4, acetic anhydride. ii) p-toluidine, H2O, 90 %. iii) PCl5, toluene, 70 
%. 
 
IR-CO-bands (KBr) of 4 were observed at 2032 and at 1939 cm-1. Compared to 
carbyxylic acid 2 (2032 and 1916 cm-1), the asymmetric band is shifted towards 
higher frequencies, indicating even stronger electron acceptance of the sulfonic 
acid, compared to the carboxylic acid.  
5 crystallized as light yellow plates in the triclinic crystal system P-1. The Cp--ligand is 
5-coordinated to the central rhenium(I) tricarbonyl-core and the geometry around 
the metal is distorted octahedral. No unusual inter- or intramolecular contacts are 
observed. The overall geometry corresponds to a typical piano-stool complex.[75] The 
M-C (CO) and C-O bonds lengths are in the expected ranges of 1.91-2.15 and 1.10-
1.15 Å for metal carbonyl groups.[75-79] Analyzing the individual M-C bond lengths to 
the Cp ligand reveals a small variation, from 2.261(2) to 2.324(3) Å. The longer M-C 
bonds are the ones opposite to the derivatized Cp-carbon, which forms the shortest 
bond. The bond length between C4 and S1 is 1.723(3) Å. The angle between C4-S1-
Cl1 is 102.18(10)° referring to a distorted tetrahedral arrangement of the substituents 
around the sulfur atom. An Ortep-plot with important bond lengths and angles is 
given in figure 6. 
 
 
Figure 6: ORTEP representation of 5. Relevant bond lengths (Å) and angles (°): Re(1)-C(1) 1.911(3), Re(1)-
C(2) 1.919(3), Re(1)-C(3) 1.919(3), Re(1)-C(4) 2.261(2), Re(1)-C(5) 2.306(2), Re(1)-C(6) 2.324(3), Re(1)-C(7) 
2.323(3), Re(1)-C(8) 2.296(3), C(1)-O(1) 1.152(4), C(2)-O(2) 1.148(4), C(3)-O(3) 1.154(4), C(4)-S(1) 1.723(3), 
S(1)-O(4) 1.420(3), S(1)-O(5) 1.417(3), S(1)-Cl(1) 2.040(3), C(4)-S(1)-Cl(1) 102.18(10). 
 
Results & Discussion 2013 
 
25 
 
As a model for compound internal sulfonamides of the type [(CpSO2NHR)Re(CO)3], 
compound 6 was prepared according to a literature procedure by refluxing a 
solution of 5 with p-toluidine (Scheme 6).[71] Silica gel column chromatography 
afforded 6 in moderate yields. Using ethylene diamine and applying the same 
synthetic conditions did not form the desired compound (Scheme 6). Crystallization 
upon slow evaporation of the solvent, only revealed the hydrolysis product 4 (Figure 
7). Unlike at room temperature, 5 is prone to hydrolysis at increased temperatures. 
However, the synthesis of the model compound was not optimized. 
  
 
Scheme 6: Synthetic conditions: i) p-toluidine, reflux, EtOH, 49 %. ii) ethylene diamine, reflux, EtOH. 
 
An ORTEP presentation of the crystal structure of 4 is depicted in figure 7. The 
compound crystallized as a colourless block in the monoclinic crystal system P21/c as 
its ethylene diammonium salt, half of which belongs to the asymmetric unit. Cp-
(SO3)2- is 5-coordinated to the fac-{ReI(CO)3}-core and the geometry around the 
rhenium is distorted octahedral, showing a piano stool complex. The bond length C4-
S1 is 1.774(5) Å and therefore very similar to 5. The angles between C4-S1-O4 to -O6 
are 105.1-105.6°, showing a distorted tetrahedral geometry around the sulfur. 
Comparable to 5, a small variation from 2.279(4) to 2.319(5) Å is observed in the 
length of the individual M-C bonds to the Cp ligand. The longer bonds are the ones 
opposite to the derivatized Cp-carbon, which forms the shortest bond. 
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Figure 7: ORTEP representation of 4. Relevant bond lengths (Å) and angles (°): Re(1)-C(1) 1.937(5), Re(1)-
C(2) 1.934(7), Re(1)-C(3) 1.937(7), Re(1)-C(4) 2.279(4), Re(1)-C(5) 2.299(4), Re(1)-C(6) 2.319(5), Re(1)-C(7) 
2.314(5), Re(1)-C(8) 2.298(5), C(1)-O(1) 1.131(7), C(2)-O(2) 1.137(10), C(3)-O(3) 1.144(8), C(4)-S(1) 
1.774(5), S(1)-O(4) 1.462(3), S(1)-O(5) 1.458(4), S(1)-O(6) 1.445(4), C(3)-Re(1)-C(2) 90.5(3), C(3)- Re(1)-C(1) 
89.7(2), C(2)- Re(1)-C(1) 90.9(2), O(6)- S(1)-O(5) 113.3(2), O(6)- S(1)-O(4) 112.9(2), O(6)- S(1)-O(4). 
 
The Ligands  
In order to introduce a variety of substituents or targeting vectors and to prepare the 
99mTc imaging agents thereof, cyclopentadienyl sulfonic acid (HCp-SO3H) is desired, 
which has been described in literature.[80] However, all attempts to reproduce the 
synthesis starting from the cyclopentadienyl monomer and refluxing with pyridine-
SO3-complex or with DMF-SO3-complex respectively, failed. Therefore, alkyl-sulfone 8 
was synthesized as an alternative model compound, in order to investigate the 
complexation behaviour of HCp-sulfones with fac-{99mTc(CO)3}. 8 was described in 
literature and was prepared in a two-step synthesis.[68] The cycloalkylation of bis-
phenylsulfonyl-methane with cis-1,4-dichloro-2-butene proceeded very slow but neat 
under basic conditions and at room temperature to form the di-substituted 
cyclopentene 7. 1'2'-elimination of one phenylsulfinate upon treatment with KtBuO 
afforded HCp-SO2Ph, which dimerized quickly to from compound 8 (Scheme 7). 
 
 
Scheme 7: Synthetic conditions: i) NaOH, catalytic amount of TBAF, Toluene, 90 %. ii) KtBuO, THF, 70 %.  
 
The 1H-NMR of 8 shows three protons in the olefinic range, whereas the signal for one 
proton on the bridged carbon is missing, in comparison to the Thiele's Acid isomer 
described above. This indicates therefore, that 8 is predominantly formed in the 5'9' 
or in the 5'10' substituted isoform as drawn in scheme 7. 
The Technetium Complexes 
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In order to show that sulfones, besides carboxylic acids and their amides, can initiate 
a metal mediated retro Diels-Alder reaction, the usual labeling conditions for HCp-
derivatives were applied to dimer 8. Unfortunately no product formation was 
observed under these standard conditions, consisting of a self-made Isolink kit, a 
millimolar concentration of the HCp-ligand and heating of the basic aqueous 
solution at temperatures from 90 to 95 °C. The reason for the lack of product 
formation was not further investigated. However, whereas Thiele's Acid is usually 
isomerically purified, to obtain the 3'9'-substituted isoform, 8 is in the 5'9' or in the 5'10' 
substituted dimer present. Calculating the closest O-O distance of the two sulfone 
groups of 8, a value of 4.734 to 5.797 Å was determined, depending on the 
isoform.[81] This distance is in the same range as measured for the methyl ester of 
Thiele's Acid, which revealed a value of 4.974 Å.[63] Therefore, the lack of product 
formation is not likely to be a consequence of an unsuitable distance of the donor 
atoms in the chelating group. However, 5' substituents do not contain a conjugated 
double bond with respect to the substituent. Therefore, the aforementioned 
mechanism (Scheme 4) is probably not adaptive to compound 8. 
 
Using the same quantities in a microwave synthesis at 130 °C, after 10 minutes one 
major new product was observed with 44 % yield (Scheme 8). 37 % of the activity was 
still unreacted [99mTc(OH2)3(CO)3]+, 2 % was identified as [99mTcO4]-, and 17 % of 
unknown side products were formed. However, until today the corresponding 
rhenium reference compound has not been synthesized. Therefore, the structure of 
the observed major HPLC-peak still needs to be confirmed with the corresponding 
Re-compound.  
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Scheme 8: Microwave assisted metal mediated retro Diels-Alder reaction of HCp-dimer sulfones. 
 
In summary, the sulfonic acid of the [CpRe(CO)3]-complex and some limited 
derivatives are available according to literature procedures. The obtained 
complexes are not sensitive to aqueous treatment and are acid/base resistant. 
However, even though the sulfonyl chloride is stable in aqueous solutions at low 
temperatures, it is prone to hydrolysis at increased temperatures.  
The protonated uncoordinated HCp-sulfonic acid, which was described in 
literature,[80] was not accessible. Therefore, the corresponding 99mTc complexes were 
also not synthesized in the course of this thesis.  
The sulfone-dimer 8 was prepared and its labeling behaviour with 99mTc was studied. 
Product formation was only observed in a microwave synthesis at 130 °C. However, 
the authenticity of the product must still be confirmed by comparison with the 
corresponding rhenium complex. As the temperature during the microwave synthesis 
was higher than the usually applied 90-95 °C, thermal cleavage of 8 instead of the 
metal mediated reaction can not be excluded and needs further investigation. 
 
2.2.3 Cp-NO2  
 
One of the most electron withdrawing functional groups known in organic molecules 
is the nitro group.[82] Therefore, a tremendous impact on the pKa value of 
neighbouring protons can be expected, which makes this functionality interesting for 
99mTc-synthesis. Moreover, comparable to the enolate form of a ketone or to a 
carboxylic acid, the nitro group has a formal negative charge at one of the oxygen 
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atoms (Figure 8). Therefore, this group could serve as an initial anchor, which 
preliminary coordinates to the [99mTc(OH2)3(CO)3]+-precursor and initiates the 
formation of the 5-coordinated compound under similar conditions used for other 
Cp-compounds. 
However, unlike ketones, carboxylic acids or sulfonic acids, the nitro group does not 
offer the possibility of derivatization. 
 
 
Figure 8: Resonance form of the nitro group. 
 
Cp-NO2 has been known since the early 1900 in the form of its ring deprotonated 
sodium salt.[73] The pKa of the nitro derivative of HCp has been kinetically determined 
to be 3.25, which is a remarkable low value for a carbon acid.[62] The corresponding 
99mTc-compound is still unknown.  
 
The Ligand 
As mentioned, Cp-NO2 is known in the form of its ring deprotonated sodium salt.[65, 73] 
The compound was synthesized following the published procedures. 10 was isolated 
from a reaction mixture of isopropyl nitrate and in situ generated NaCp (Scheme 9). 
The 1H-NMR of the orange solid was identical with the literature description.  
 
 
Scheme 9: Synthesis of 10. Nitro-Cp has been known since the beginning of the 20th century. 
 
Another approach for the preparation of 10 was assessed by using a similar setup as 
described for the synthesis of 8. Phenylsulfonyl-nitromethane is commercially 
available. Cycloalkylation with cis-1,4-dichloro-2-butene formed the heterogeneously 
di-substituted cyclopentene ring 9, analogously to the preparation of 7. Crystals were 
grown by slow diffusion of hexane into a solution of 9 in a minimum of CH2Cl2 (Figure 
9) and the molecule was characterized by ESI-MS, 1H-NMR and elemental analysis.  
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The 1H-NMR in CDCl3 is very similar to 7. But the signals for the olefinic and for the 
aliphatic protons of 9 sifted towards lower field (by 0.2 and 0.04 ppm respectively), 
due to the more electron withdrawing nitro group.  
9 crystallized as a colourless plate in the monoclinic crystal system with space group 
P21/n. Two molecules are found in the asymmetric unit, upon only one is discussed, 
due to crystallographic identity. The bond between C3 and C4 is 1.309(3) Å, which is 
in the range of a common C=C double bond, in contrast to the C-C single bonds 
between the other carbons in the five-membered ring (1.492(3) to 1.541(2) Å).[79] 
Other bond lengths and angles are given along with an ORTEP-plot in figure 9. 
 
 
Figure 9: ORTEP representation of 9 (two molecules were present in the asymmetric unit, upon only one is 
shown here, due to crystallographic identity). Relevant bond lengths (Å) and angles (°): C(1)-N(1) 
1.512(2), C(1)-S(1) 1.8453(16), C(3)-C(4) 1.309(3), C(2)-C(3) 1.492(3), C(4)-C(5) 1.496(3), C(1)-C(5) 
1.535(2), C(1)-C(2) 1.541(2), N(1)-O(2) 1.2145(19), N(1)-O(1) 1.2259(19), O(3)-S(1) 1.4370(13), O(4)-S(1) 
1.4295(13), O(2)-N(1)-O(1) 123.56(16), O(4)-S(1)-O(3) 120.04(9), N(1)-C(1)-C(5) 112.31(14), N(1)-C(1)-C(2) 
112.28(14), N(1)-C(1)-S(1) 105.09(10). 
 
Upon elimination the nitro group proved to be a better leaving group than the 
phenylsulfinate and the isolated product corresponded to 8 (Scheme 10). 10 was 
therefore not obtained with this method. 
 
 
Scheme 10: Synthetic conditions: i) NaH, DMF, 80 %. ii) KtBuO, THF, 65 %. 
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The Technetium Complex 
Sodium complex 10 was added to a saline solution of [99mTc(OH2)3(CO)3] at a 
physiological pH value. Heating at temperatures of 90-95 °C did not lead to the 
formation of the desired product and only starting compounds were recovered. 
Variations in the pH (3-7) did not improve the result. The lack of product formation 
was not further investigated. 
 
With a pKa of 3.25,[62] under labeling conditions at a physiological pH of about 7.4 
nitro-Cp is present in its deprotonated form to a large extend. Additionally, as known 
from its resonance structures, similar to carbonyl derivatized HCp-compounds it offers 
the possibility of an anchoring group, which can be useful for the formation of the 
{99mTc(CO)3}-complex. The sodium salt 10 was prepared along literature procedure 
and is readily soluble and stable in water.[65, 73] Nonetheless, the transmetallation 
reaction of 10 to the 99mTc-core was not observed.  
The alternative synthesis of 10 via preparation of the heterogeneously di-substituted 
cyclopentene ring 9 followed by elimination of phenylsulfinate failed, as the nitro 
group proved to be a better leaving group. The corresponding Re-complex was not 
prepared. 
 
2.2.4 Cp-NH2 
 
In contrast to the functional groups discussed before, the amino group has electron 
donating properties. For this reason, HCp-amino-compounds might not have suitable 
pka values for organometallic synthesis as discussed before. However, many 
pharmacological active compounds and natural substances are aniline derivatives 
and contain the amino group in the form of amides or as internal sulfonamides, 
coupled to sulfones. Replacement of such anilines by the organometallic congener 
[(CpNH2)M(CO)3] (M = Re or 99mTc) would therefore increase the field of application 
and the possibilities for these compounds in therapy and in diagnostics 
tremendously. 
Coupling of a hypothetic HCp-NH2 to carboxylic acids has the advantage of a 
carbonyl group in close proximity to the HCp-ring. As shown with ketones and 
carboxylic acids, the carbonyl group in -position to the HCp can serve as an 
anchoring group, binding to [99mTc(OH2)3(CO)3]+ as an initial step for the retro Diels-
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Alder reaction and the formation of 5-coordinated Cp--complexes. Using HCp-NH2 
as a building block, the carbonyl group would be in the -position, which might still 
be close enough, to fulfil the task as an anchoring group. 
 
The Rhenium Complexes 
The rhenium complex [(CpNH2)Re(CO)3] has been described in literature.[69] 
Activation of [(Cp)Re(CO)3] with nBuLi, followed by nucleophilic attack of p-toluene 
sulfonyl azide, and reduction with NaBH4, formed the desired compound (Scheme 
11). 11 is stable under ambient conditions and in water.  
IR-measurement (KBr) revealed the CO-bands of the amine 11 at 1995 and 1874 
cm-1, compared to 2018 and 1897 cm-1 for unsubstituted [(Cp)Re(CO)3]. The shift 
towards lower frequencies indicates higher electron density on the metal center and 
a longer C-O bonding distance of the carbonyl ligands. This is in accordance with 
the assumption of electron donating properties of the NH2-group. 
 
 
Scheme 11: Synthetic conditions: i) nBuLi, THF, -78 °C. ii) ToSN3, THF. iii) NaBH4, EtOH, 69 % 
 
Compounds 12 and 13 were synthesized as model compounds, to explore the 
synthesis and the physical properties of complexes containing an internal 
sulfonamide function (Scheme 12). Inverting the sulfonamide moiety, 12 corresponds 
to the model compound 6. Analogous structural variations for biologically active 
derivatives could give interesting information about binding modes, when the 
biological data are compared. 
12 and 13 both were synthesized by stirring a solution of 11 and the appropriate 
sulfonyl chloride. Unlike 12, 13 required refluxing temperature. 
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Scheme 12: Synthetic conditions: i) benzenesulfonyl chloride, CH2Cl2, RT, 95 %. ii) p-Toluenesulfonyl 
chloride, CH2Cl2, reflux, 95 %. 
 
The 1H-NMR-spectrum of 12 and 13 (CDCl3) clearly indicated the presence of the 
internal sulfonamide bond adjacent to the Cp- with two sets of pseudo triplets at 5.23 
and at 5.03 ppm for 12 and at 5.32 and at 5.11 ppm for 13 respectively, in 
comparison to the starting compound 11 (4.53 and 4.28 ppm). The shifts of the 
characteristic Cp--protons towards lower field show, that the introduction of the SO2-
Ar-substituent has an impact on the Cp--ring, as it decreases electron density. 
 
The Ligands 
Unlike the rhenium complex, the corresponding free HCpNH2-ligand has not been 
prepared before. It is arguable, if such a compound could exist, considering the 
possibility of the formation of the imine-form of the compound (Figure 10). It is also 
not known, how stable the monomer would be and how fast polymerization would 
occur. 
 
 
Figure 10: HCp-NH2 can form the corresponding imine. 
 
Therefore the amine in the form HCp-NH2 was not synthesized in during this thesis, 
even though this would be the most comfortable form for derivatization with 
targeting vectors or others. Synthetic access to in situ derivatized amines in their 
dimeric form was aimed in order to prevent side reactions. With this strategy, the 
uncontrolled formation of a diversity of polymers is excluded. Moreover, introducing 
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electron withdrawing derivatives at the amine could prevent the molecule from 
forming the imine. 
Starting from the defined structure of Thiele's Acid, the target compound was 
synthesized by Curtius Rearrangement. The Curtius Rearrangement is the thermal 
decomposition of carboxylic azides to form isocyanates. These intermediates can be 
treated with a nucleophile, like alcohols or amines, to form the corresponding urea 
or, if hydrolysed with water, the corresponding carbamic acids (Scheme 13).[83] 
The Curtius Rearrangement is nowadays widely used and investigated.[84-88]  
 
 
Scheme 13: Schematic overview of the Curtius Rearrangement. 
 
Using diphenylphosphoryl azide, Thiele's Acid was converted to the corresponding 
acid azide 14, which was isolated, purified by silica gel column chromatography and 
analysed by ESI-MS, 1H-NMR and IR. Upon heating, the rearrangement occurred and 
the isonitrile 15 was formed. 15 was not isolated, due to decomposition of the 
compound, but the isonitrile group was identified by liquid IR-measurement. Addition 
of the nucleophiles a to f, in situ generated the final products (Scheme 14). 
Compounds 16a-b were characterized by ESI-MS, IR and 1H-NMR analysis. However, 
no evidence for the formation of 16c-f was found, as characterization was not 
conclusive. 
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Scheme 14: Synthetic conditions: i) Diphenylphosphoryl azide (DPPA), NEt3, toluene 80 %. ii) Heated to 80 
°C, toluene. iii) addition of the nucleophiles a-f, toluene. 
 
The progress of the reaction was followed by time resolved IR-measurement and by 
1H-NMR (Figure 11-13). Therefore, 14 was dissolved in toluene for the IR-experiment or 
in deuterated toluene-d8 for the 1H-NMR-experiment respectively. The measurement 
was started, when the reaction temperature of 80 °C was reached. IR-spectra were 
recorded every 2 minutes and 1H-NMR were measured every 10 minutes during the 
reaction process and directly from the reaction mixture. 1H-NMR measurement is 
more sensitive compared to IR-measurement. Therefore, reaction times in the two 
experiments can differ. 
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Figure 11: Time resolved IR-measurement of the curtius rearrangement of 14 to 15 and the following 
nucleophilic addition of MeOH to form 16a. 
 
Time resolved IR clearly showed the disappearance of the CO and the N3 IR-bands 
of the acid azide at 1681 cm-1 and at 2130 cm-1 respectively. At the same time, a 
new band was growing in intensity at 2267 cm-1, indicating the formation of the 
isonitrile. Nearly full conversion was reached after 20 minutes. 25 minutes after the 
beginning of the measurement methanol was added, whereupon the isonitrile band 
decreased rapidly and a new, broad signal in the range of 1726 appeared. This was 
interpreted as the stretching frequency of the urea-carbonyl, which was formed 
(Figure 11 and 12). 
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Figure 12: IR spectrum of 14 (A), 15 (B) and 16a (C) in toluene.  
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Figure 13: 1H-NMR-spectra (toluene-d8): A) no isonitrile formed yet, t=0 minutes B) partially formed 
isonitrile, t=33minutes C)full conversion of 14 to 15 after 41 minutes 
 
A similar behaviour was observed, when the reaction was recorded in the 1H-NMR. 
The process can be followed by looking at the chemical shifts of the olefinic protons, 
which are in close proximity to the reaction centers (Figure 13). The signals for 14 
disappeared completely after roughly 40 minutes (higher sensitivity compared to the 
IR-measurement) and the formation of two new signals in the olefinic region 
indicated the formation of the isonitrile 15. Upon addition of MeOH, these peaks 
decrease again and the formation of two new peaks shows the formation of 16 
(Figure 14). 
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Figure 14: 1H-NMR-spectra (toluene-d8): The signals for 15 disappear upon MeOH addition and two new 
signals for 16 are rising in the olefinic region. 
 
The aniline analogue 11 was prepared according to literature.[69] The complex is 
stable under ambient or aqueous conditions and is also not prone to decomposition 
at increased temperatures or under acidic and basic treatment. Synthetically, it can 
be treated like aniline and nucleophilic coupling reactions are suitable methods for 
derivatization. 
In situ derivatized HCp-amines in their dimeric form were prepared from Thiele's Acid 
applying the Curtius Rearrangement. The reaction progress was investigated by time 
resolved IR-measurement and by 1H-NMR. Using diphenylphosphoryl azide, Thiele's 
Acid was converted to the corresponding acid azide 14, which is stable under 
ambient conditions. Stability towards aqueous solutions was not assessed. Upon 
heating, the rearrangement occurred and the isonitrile 15 was formed. 15 was not 
isolated, due to decomposition of the compound, but the isonitrile group was 
identified by liquid IR-measurement. Addition of nucleophiles like alcohols or amines, 
in situ generated the compounds 16a-b. No evidence for the formation of 16c-f was 
found, as characterization was not conclusive. The 99mTc-labeling behaviour of 16a-
b is subject of on-going investigations. 
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2.2.5 Cp-CH2COOH & Cp-CH2CH2COOH  
 
Similar to amines, alkyl substituents on the HCp-ring are electron donating 
derivatives. Due to hyper conjugation, electron density can be transferred from -
orbitals of the alkyl substituent into free or partially filled antibonding -orbitals of the 
conjugated double bond of the HCp. Coupled to a carboxylic acid function, such 
Cp-compounds are interesting for organometallic syntheses. The possibility of an 
anchoring group for the preparation of 5-coordinated Cp--complexes of the fac-
{99mTc(CO)3}-core is retained. Using HCp-(CH2)n-COOH with n = 1 or 2 as a building 
block, the carbonyl group is in - or in -position to the HCp-ring. This might still be 
close enough, to serve as an anchoring group for complexation, in terms of bringing 
the HCp-moiety in close proximity to the metal. Similar to Thiele's Acid, such 
compounds could be easily and versatile derivatized with bioactive components.  
From a biological point of view, with methylene groups between the HCp and the 
carboxylic acid, a new way of altering the spacer in a BFC is introduced; before and 
after the coupling function. This way of variation represents a new factor for 
interesting structure activity relationships (SARs).  
In general, the scaffold Ar-(CH2)n-CONHR is very common in biological systems and in 
pharmaceuticals. Organometallic analogues of this moiety represent therefore 
potential building blocks in the development of new pharmaceuticals or imaging 
agents.  
 
The Ligands 
The uncoordinated HCp-compounds 17 and 19 have both been prepared before.[66, 
89] Using bromoacetic acid methylester or methyl-3-brompropionate respectively, the 
two compounds were synthesized along a similar route (Scheme 15). Both ligands 
were obtained as the methyl esters after distillation under reduced pressure. The 
compounds were characterized by NMR and were identified as an isomeric mixture. 
17 and 18 were not observed in the ESI-MS measurement, alluding to insufficient 
ionizing properties of the compounds. Hydrolysis was performed with a solution of 
LiOH in a solvent mixture of MeOH, THF and H2O to form the carboxylic acids 18 and 
20. 
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Scheme 15: Synthetic conditions: i) bromoacetic acid, THF, 30-50 %. ii) methyl-3-brompropionate, THF, 
30-50 %. iii) LiOH, THF/MeOH/H2O 69-74 %. 
 
18 was coupled to a benzyl amine or to glycine methyl ester respectively, to form 
amides 21a-b as model compounds for derivatized HCp-CH2CONHR-type of ligands. 
Therefore, 18 was activated with O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HATU) in DMF in situ, and was then mixed 
with the appropriate amine (Scheme 16). Products were formed in moderate yields 
of 20 and 55 % respectively. 21a-b were characterized by ESI-MS and 1H-NMR. 21a 
was crystallized from CH2Cl2/Hexane and the structure was analysed by x-ray 
diffraction. 
 
 
Scheme 16: Synthetic conditions: i) HATU, DMF. ii) NH2R, DMF, 20-55 % 
 
The 1H-NMR revealed three sets of multiplets in the olefinic region and two sets of 
multiplets in the aliphatic region. This speaks for the formation of an isomerically pure 
product, which is not in accordance with the utilization of an isomerically mixed 
starting compound. Taking the acidity of the -proton of the methylene group into 
account, a rearrangement of the cyclopentadiene double bond could be an 
explanation for this observation. This assumption was confirmed by the crystal 
structure of 21a (Figure 15). Two molecules were present in the asymmetric unit, upon 
only one is discussed here, as they are crystallographically identical. The C1-C2 bond 
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length in compound 21a is 1.338(2) Å and is therefore in the range of an usual C=C 
double bond.[79] All the other bonds in the HCp-ring are within 1.4583(17) and 
1.5337(19) Å in lengths and correspond therefore to carbon-carbon single bonds. In 
agreement with the suggested isomerisation is the bond distance between C5 and 
C6 with 1.3401(17) Å, revealing a C=C double bond. As compound 21b shows the 
same pattern in the 1H-NMR, a similar rearrangement of the structure can be 
assumed. Due to this isomerisation, amides of the form of HCp-CH2CONHR were not 
observed. 21a crystallized in the triclinic crystal system P-1. Important bond lengths 
and angles are given in figure 15.  
 
 
Figure 15: ORTEP representation of 21a. Relevant bond lengths (Å) and angles (°) (of only one molecule, 
due to crystallographic identity): C(1)-C(2) 1.338(2), C(1)-C(5) 1.4583(17), C(2)-C(3) 1.485(2), C(3)-C(4) 
1.5337(19), C(4)-C(5) 1.5078(17), C(5)-C(6) 1.3401(17), C(6)-C(7) 1.4684(16), C(2)-C(1)-C(5) 110.99(13), 
C(1)-C(2)-C(3) 112.31(13), C(2)-C(3)-C(4) 104.11(12), C(5)-C(4)-C(3) 105.66(11), C(5)-C(6)-C(7) 
123.98(10), O(1)-C(7)-N(1) 121.42(11). 
 
HCp-COOH undergoes rapid Diels-Alder dimerization to form Thiele's Acid. This dimer 
or amides thereof react via metal mediated retro Diels-Alder reaction with 
[99mTc(OH2)3(CO)3]+ and can form [(Cp-COR)99mTc(CO)3]-type complexes. They are 
therefore of high value for aqueous organometallic chemistry and for the 
development of new BFCs. In this context, it woud be utterly interesting, if the dimers 
of the carboxylic acids 18 and 20 would behave in a similar way, when reacted with 
[99mTc(OH2)3(CO)3]+. Containing methylene groups directly attached to the HCp-ring, 
dimerization of the compounds 18 and 20 does not occur with the same rate as for 
HCp-COOH. The reaction products, which were formed by keeping the ester 17 
without additives at temperatures from 4-25 °C or at -20 °C respectively were 
analysed (Scheme 17). 1H-NMR revealed that at -20 °C a mixture of the 
rearrangement product 22 and dimer 23 was formed after roughly two months, 
whereas at temperatures from 4 to 25 °C, almost exclusively the dimeric form 23 was 
obtained in a comparable timescale (Figure 16). 
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Scheme 17: Synthetic conditions: i) -20 °C. ii) 4-25 °C 
 
  
Figure 16: 1H-NMR-spectra (CDCl3). A) 17 stored at -20 °C forms a mixture of rearrangement product 22 
and an isomeric mixture of dimer 23. B) 17 stored at 4-25 °C forms an isomeric mixture of dimer 23 and 
no 22. 
The Rhenium complexes 
Results & Discussion 2013 
 
44 
 
Using [(Cp)Re(CO)3], the synthesis of the Re-complex 24a with bromoacetic acid 
failed (Scheme 18). The nucleophilic attack by the nBuLi-deprotonated Cp- occurred 
unexpectedly at the carbonyl of the ester, instead of the brominated -carbon. The 
methoxy group was therefore substituted by [(Cp)Re(CO)3]. Moreover, another 
nucleophilic attack occurred at the same carbonyl to finally form a binuclear 
complex. 24b was purified by silica gel column chromatography, analysed by 1H-
NMR and IR and was crystallized from CH2Cl2/Hexane (Figure 17). 
 
 
Scheme 18: Synthetic conditions: i) nBuLi, THF, -78 °C. ii) methyl bromoacetate, THF, 50 % 
 
The 1H-NMR (CDCl3) of 24b shows three sets of Cp-signals, each as a multiplet, at 5.71 
ppm, at 5.56 ppm and at 5.30 ppm respectively, corresponding to 8 protons in total. 
The methylene singlet was observed at 3.72 ppm and the singlet of the hydroxyl 
proton can be found at 2.41 ppm. Characteristic IR-CO-bands were observed at 
2018 and at 1921 cm-1 (KBr). In comparison to unsubstituted [(Cp)Re(CO)3] (2018 and 
1897 cm-1), only the frequencies of the asymmetric motion of the carbonyls shifted 
towards higher frequencies, which is related to the substituents on the -carbon of 
24b. 
The binuclear complex 24b crystallized in the monoclinic crystal system with space 
group P21/c as a colourless plate. The central rhenium(I) atoms are 5-coordinated 
by the Cp--ligands. The coordination geometry around the metal centers are 
distorted octahedrons. The overall geometry corresponds to typical piano-stool 
complexes.[75] C-O bond lengths of the carbonyl ligands are for both complexes very 
similar and are within 1.146(5) and 1.152(4) Å.[75-79] They are therefore comparable to 
those found for compound 4. Unlike 4 and 5, the individual M-C bond lengths to the 
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Cp ligand do not show a significant variation and range from 2.295(3) to 2.314(4) Å. 
Selected bond lengths and angles are given in figure 17. 
 
  
Figure 17: ORTEP representation of 24b. Relevant bond lengths (Å) and angles (°): Re(1)-C(1) 1.908(4), 
Re(1)-C(2) 1.914(4), Re(1)-C(3) 1.922(4), Re(1)-C(5) 2.295(3), Re(1)-C(6) 2.299(4), Re(1)-C(7) 2.303(4), 
Re(1)-C(4) 2.306(3), Re(1)-C(8) 2.314(4), Re(11)-C(11) 1.912(4), Re(11)-C(13) 1.914(4), Re(11)-C(12) 
1.924(4), Re(11)-C(18) 2.308(3), Re(11)-C(17) 2.308(4), Re(11)-C(15) 2.313(4), Re(11)-C(14) 2.317(3), 
Re(11)-C(16) 2.317(4), C(1)-O(1) 1.152(4), C(2)-O(2) 1.147(5), C(3)-O(3) 1.151(4), C(4)-C(5) 1.427(5), C(4)-
C(8) 1.446(5), C(4)-C(19) 1.513(5), C(5)-C(6) 1.424(5), C(6)-C(7) 1.408(5), C(7)-C(8) 1.426(5), C(11)-O(11) 
1.150(4), C(12)-O(12) 1.151(4), C(13)-O(13) 1.146(5), C(14)-C(15) 1.420(5), C(14)-C(18) 1.438(5), C(14)-
C(19) 1.516(5), C(15)-C(16) 1.424(5), C(16)-C(17) 1.435(6), C(17)-C(18) 1.420(5), C(19)-O(14) 1.427(4), 
C(19)-C(20) 1.537(5), C(20)-Br(1) 1.964(4), C(1)-Re(1)-C(2) 90.29(17), C(1)-Re(1)-C(3) 88.86(16), C(2)-
Re(1)-C(3) 91.59(16), C(11)-Re(11)-C(13) 88.57(16), C(11)-Re(11)-C(12) 89.62(15), C(13)-Re(11)-C(12) 
86.93(16), O(14)-C(19)-C(4) 105.4(3), O(14)-C(19)-C(14) 111.3(3), C(4)-C(19)-C(14) 109.7(3), O(14)-C(19)-
C(20) 111.7(3), C(4)-C(19)-C(20) 103.1(3), C(14)-C(19)-C(20) 114.9(3), C(19)-C(20)-Br(1) 113.3(2). 
 
The desired compound 24a was synthesized in a rather uncommon way for 
organometallic complexes. Similar to the 99mTc-labeling of HCp-compounds, ligand 
18 was reacted with (NEt4)2[Re(Br)3(CO)3] in water, in presence of Borax 
(Na2B4O7*10H2O) at 95 °C. This reaction represents therefore one of the rare 
examples, of aqueous synthesis of a [(CpR)Re(CO)3] complex, where the Re-
complex is prepared analogously to the 99mTc-complex (Scheme 19). However, yields 
were low (20 %), as [Re(Br)3(CO)3]2- is known for its cluster formation under basic 
aqueous conditions.[90] 
24a was analysed by IR (KBr), NMR (CDCl3), ESI-MS (CH3OH) and elemental analysis. 
Crystals were grown from CH2Cl2/Hexane and the structure was elucidated (Figure 
18).  
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Scheme 19: Synthetic conditions: i) Na2B4O7*10H2O (Borax), H2O, 95 °C, 20 %. 
 
Characteristic IR-CO-bands were observed at 2020 and at 1911 cm-1 (KBr). In 
comparison, carboxylic acid 2 revealed higher frequencies (2032 and 1916 cm-1), 
which is in accordance with the assumption of the electron donation by the 
methylene spacer in 24a. However, comparing 24a to [(Cp)Re(CO)3] (2018 and 1897 
cm-1) the IR-CO-bands are not shifted towards lower frequencies, but are found 
higher. The electron acceptance by the carboxylic acid affects therefore the 
electron density on the metal to a larger extend than the donating nature of the 
methylene group, despite of the larger distance of the carboxylic acid function. 
The compound crystallized as colourless block in the triclinic crystal system P-1. The 
structure shows a 5-coordinated Cp--ligand, bound to the rhenium(I) atom, 
therefore the geometry around the metal center is distorted octahedral, exhibiting a 
typical piano-stool complex.[75] The carboxylic acid function is with a torsion angle of 
78.9(3)° between C5-C4-C9-C10 close to perpendicular to the plane of the Cp--ring. 
In accordance with the lower IR-CO-frequencies, the C-O bond lengths of the 
carbonyl ligands of 24a (1.149(3)-1.152(3) Å) are longer than those found for 
compound 4 (1.131(7)-1.144(8) Å), but compare well to those of 24b (1.146(5)- 
1.152(4) Å). Other important bond lengths and angles are given in figure 18. 
 
 
Figure 18: ORTEP representation of 24a. Relevant bond lengths (Å) and angles (°): Re(1)-C(1) 1.912(2), 
Re(1)-C(3) 1.913(2), Re(1)-C(2) 1.917(2), Re(1)-C(7) 2.299(2), Re(1)-C(6) 2.3002(19), Re(1)-C(5) 2.301(2), 
Re(1)-C(4) 2.3053(19), Re(1)-C(8) 2.308(2), C(1)-O(1) 1.152(3), C(2)-O(2) 1.149(3), C(3)-O(3) 1.151(3), 
C(4)-C(5) 1.419(3), C(4)-C(8) 1.436(3), C(4)-C(9) 1.499(3), C(5)-C(6) 1.423(3), C(6)-C(7) 1.425(3), C(7)-C(8) 
1.419(3), C(9)-C(10) 1.508(3), C(10)-O(5) 1.246(3), C(10)-O(4) 1.270(3), C(1)-Re(1)-C(3) 89.86(10), C(1)-
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Re(1)-C(2) 88.55(9), C(3)-Re(1)-C(2) 91.13(10), C(4)-C(9)-C(10) 114.63(18), O(5)-C(10)-O(4) 124.0(2), O(5)-
C(10)-C(9) 118.6(2), O(4)-C(10)-C(9) 117.28(18). 
 
Surprisingly, carboxylic acid complex 27 was not accessible by the same synthetic 
pathway using its uncoordinated ligand 20. However, the corresponding ferrocene-
complex has been synthesized by Horner-Wardsworth-Emmons olefination.[91] The 
same synthetic strategy was applied to [(Cp)Re(CO)3] and carboxylic acid 27 was 
obtained. [(CpCOH)Re(CO)3] was prepared according to literature from 
[(Cp)Re(CO)3].[92] Treatment with triethyl phosphonoacetate in methanol gave olefin 
25 in 80 % yield. Hydrogenation of the double bond with H2 on Pd under an 
atmosphere of H2, followed by ester hydrolysis with LiOH gave the desired complex 
27 (Scheme 20). The compounds were analysed by IR (KBr), NMR (CDCl3), ESI-MS 
(CH3OH) and elemental analysis. Crystals were grown from CH2Cl2/Hexane and the 
structure was elucidated (Figure 19). 
 
 
Scheme 20: Synthetic conditions: i) Triethyl phosphonoacetate, MeOH, 80 %. ii) H2/Pd/C, EtOAc. iii)LiOH, 
H2O/MeOH/THF 
 
In the 1H-NMR (CDCl3) the pseudo triplets of the aromatic Cp-protons were detected 
at 5.31 and at 5.26 ppm respectively. In comparison to 24a (5.46 and 5.31 ppm), 
these signals are shifted towards higher field, which is in accordance with the 
increased distance to the deshielding carboxylic acid function. IR-CO-bands were 
observed at 2023 and at 1912 cm-1, and are thus about the same as for 24a. 
27 crystallized in the triclinic crystal system P-1 as a colourless block. The bond 
distances between the first methylene group C9 and the Cp-ring carbon C4 is 
1.504(4) Å and the bond length between the methylene carbons C9 and C10 is 
1.515(4) Å. The distance from C10 to the carbonyl C11 is slightly shorter with 1.492(4) 
Å. These values compare well to those found in structure 24a. Other bonding 
distances and angles are given in figure 19. 
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Figure 19: ORTEP representation of 27. Relevant bond lengths (Å) and angles (°): Re(1)-C(2) 1.910(3), 
Re(1)-C(3) 1.919(3), Re(1)-C(1) 1.919(3), Re(1)-C(6) 2.287(3), Re(1)-C(5) 2.291(3), Re(1)-C(7) 2.304(3), 
Re(1)-C(8) 2.311(3), Re(1)-C(4) 2.324(2), C(1)-O(1) 1.154(4), C(2)-O(2) 1.148(4), C(3)-O(3) 1.148(4), C(4)-
C(9) 1.504(4), C(9)-C(10) 1.515(4), C(10)-C(11) 1.492(4), C(11)-O(5) 1.224(3), C(11)-O(4) 1.301(3), C(2)-
Re(1)-C(3) 1.33(12), C(2)-Re(1)-C(1) 90.10(12), C(3)-Re(1)-C(1) 90.61(12), O(5)-C(11)-O(4) 123.5(3), O(5)-
C(11)-C(10) 123.2(3), O(4)-C(11)-C(10) 113.3(2). 
 
The Technetium Complexes 
As discussed above, HCp-compounds with a carboxylic acid function can be 
labelled as monomers or as dimers with 99mTc. The deprotonated hydroxyl part can 
serve as a preliminary anchoring group for the metal center.[61] With the ligands 18 
and 20 this anchoring group is retained. However, the carbonyl group is in - or in -
position relative to the HCp-ring. Therefore their distance to the HCp-chelator is larger 
than in the compounds discussed above, but might still be close enough, to serve as 
an anchoring group and to initiate complex formation. Similar to Thiele's Acid, such 
compounds could be easily and versatile derivatized with bioactive targeting 
functions. Unfortunately, a rearrangement of the double bonds in the HCp-ring was 
observed upon amide coupling of compound 18. Therefore, the desired 99mTc-
complexes with these ligands were not accessible along the classical route.  
 
However, carboxylic acids 18 and 20 were used under the general reaction 
conditions for the labeling of HCp-derivatives, in order to investigate their 
complexation properties. Ligands were present in their monomeric form and in 
millimolar concentrations. The reactions were studied in a one-pot procedure, where 
the ligand and the self-made Isolink Kit were sealed in a vial and [99mTcO4]- was 
injected, and in a two-step reaction, where [99mTc(OH2)3(CO)3]+ was synthesized 
before and added to the ligand in a separate step. Both procedures resulted in the 
neat formation of the desired 99mTc-complexes 28 and 29 respectively (Scheme 21 
and 22). No substantial side products were observed in all cases. The products were 
analysed by coinjection with the corresponding Re-complexes. Esters are usually 
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hydrolysed during the labeling, thus the same results were observed when the methyl 
esters 17 and 19 were used instead of the acids 18 and 20.  
However, conversion rates of the 99mTc starting compounds were very different for 
the ligand 18 compared to 20. Whereas 18 caused quantitative product formation 
after 30 minutes (Scheme 21), the reaction with 20 reached only 7 % conversion after 
the same time and 62 % after 5 hours. Much higher rates were observed, when the 
labeling with 20 was performed in a microwave reactor. At temperatures of 130 °C, 
65 % conversion to 29 was observed after 30 minutes. 16 % of the [99mTc(OH2)3(CO)3]+ 
was oxidized to [99mTcO4]- and 19 % was still unreacted starting compound (Scheme 
22). 
 
 
Scheme 21: Bottom-up trace: -trace of the one-pot labeling of 18 with [99mTcO4]- and Isolink Kit. Top-
down trace: UV-trace of Re-compound 24. Quantitative and radiochemically pure conversion of 
[99mTcO4]- to complex 28. 
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Scheme 22: Bottom-up trace: -trace of the one-pot labeling of 20 with [99mTcO4]- and Isolink Kit. Top-
down trace: UV-trace of Re-compound 27. 
 
The labeling behaviour of 23, the dimeric form of 18, was also assessed. As seen with 
the monomer 18, the carboxylic acid group in -position to the Cp is close enough to 
serve as an anchoring group towards the metal core, in order to initiate 
complexation of the Cp-ring. In that case, the metal mediated retro Diels-Alder 
reaction, similar to Thiele's Acid, might be possible for dimer 23 as well. Therefore, the 
same set-up as used for the labeling of 18 was applied and 23 was added. Product 
formation was observed. The conversion rate with the dimer was significantly lower 
than with the monomer. After 40 minutes at 90 °C, only 34 % of the starting 
compound was converted. However, using microwave synthesis at temperatures of 
130 °C, 67 % conversion to the 99mTc-complex 28 was observed after 40 minutes. 21 % 
of the 99mTc was oxidized to [99mTcO4]-, and 12 % was still unreacted starting 
compound (Scheme 23). 
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Scheme 23: Bottom-up trace: -trace of the one-pot labeling of 23 with [99mTcO4]- and Isolink Kit. Top-
down trace: UV-trace of Re-compound 24. 
 
With the synthesis of the uncoordinated and protonated HCp-compounds 17 and 19, 
containing methylene groups between the HCp and the carboxylic acid, a new way 
of altering the spacer in a BFC has been introduced; before and after the coupling 
function. Apart from ester hydrolysis, the two compounds are water and air-stable. 17 
undergoes slow Diels-Alder dimerization at room temperature. Keeping 17 at -20 °C, 
beside the dimer 23, the rearrangement product 22 is formed. The dimerization 
behaviour of 19 was not investigated. Derivatisation of the carboxylic acid 18 by 
amide coupling with primary amines leads to rearrangement of the double bonds 
and the formation of a cyclopentene ring, as observed with compounds 21a/b. 
Therefore cyclopentadienyl amides of 18 are not accessible. 
18 and 20 contain a carboxylic acid function in - or in -position, with respect to the 
HCp-ring. Labelling experiments with [99mTc(OH2)3(CO)3]+ proved that these positions 
are still close enough, to allow anchoring of the metal center by the carboxylic acid 
portion. Therefore, bringing the metal in close proximity, 5-coordination of the HCp-
portion is simplified. However, conversion rates of the 99mTc starting compounds were 
very different for the ligand 18 compared to 20, which is in accordance with the 
increasing distance of the anchoring group to the HCp-moiety. Similar to Thiele's 
Acid, the dimer 23 can undergo metal mediated retro Diels-Alder reaction and form 
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the same product as obtained with the monomer 18. The mechanism however is 
unclear.  
Using [(Cp)Re(CO)3], the synthesis of the corresponding Re-complex 24a with 
bromacetic acid failed and the binuclear compound 24b was obtained instead. 
However, 24a was synthesized similar to the 99mTc-compound 28 using ligand 18 with 
[Re(Br)3(CO)3]2- in water. 
Using a Horner-Wardsworth-Emmons olefination, the Re-complex 27 was synthesized. 
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2.3 Biologically Relevant Vectors 
 
The aforementioned functionalities at the Cp-chelator can be derivatized with 
biologically active vectors, to finally form the BFC. These vectors usually consist of a 
certain functional group, which is connected to a spacer, which again can be 
bound to the Cp-derivative. The vector for a target is usually kept constant, while the 
spacer can be altered, in order to explore possible structure activity relationships 
(SARs) and to reach the best possible interaction between the host and the targeting 
molecule. In the following chapter, the synthesis of different targeting functionalities 
with different spacers and for different targets will be discussed. Syntheses included 
the Re-complexes, the free ligands and the 99mTc-complexes (Figure 20). Some of the 
examples were also biologically investigated. 
 
 
Figure 20: The linker is built of different parts, including the Cp-derivative, which can be altered. 
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2.3.1 HDAC-Inhibitors 
 
Histone deacetylases (HDACs) catalyze the removal of acetyl groups of -lysine tails 
on histone proteins, causing condensed chromatin and therefore transcriptional 
silencing. Hence cancer cells escape apoptosis.[93] As HDAC inhibitors can counter 
cancer progression, they contribute to apoptosis and the formation of growth arrest 
proteins.[94, 95] Since these enzymes are highly overexpressed in cancer tissues, they 
are targets for both, cancer diagnosis and therapy. Vectors, which target HDACs 
often incorporate terminal hydroxamic acids. Suberoylanilide hydroxamic acid 
(SAHA, Figure 21) is a clinically approved inhibitor. It is administered for the treatment 
of a number of hematological and solid tumors.[96] While different organometallic 
SAHA-analogues containing ferrocene or cis-platin respectively have been 
investigated for therapeutic application,[97-99] such bioinorganic SAHA-analogues for 
radiopharmaceutical application are still unknown.[93]  
 
 
Figure 21: Lewis structure of Suberoylanilide hydroxamic acid (SAHA) 
 
The Rhenium Complexes. 
[(Cp)Re(CO)3] structurally can be introduced into bioactive substances by replacing 
phenyl rings. Following this strategy, slightly modified organometallic SAHA-analogues 
31, 33 and 36 were synthesized (Figure 22).[93] Compounds 31 and 33 are carboxylic 
acid-conjugates, whereas the native SAHA is an amino-conjugate. Additionally, in 
order to tune interactions with the binding pocket, compound 31 contains one 
methylene spacer more than the lead compound between the amide group and 
the terminal hydroxamic acid portion. In addition to these compounds, 36 was 
synthesized, the exact structural analogue of SAHA. The position of the amide linker 
and the length of the aliphatic spacer correspond to the native SAHA and the only 
difference to the lead structure is the replacement of the phenyl ring with 
[(Cp)Re(CO)3]. 
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Figure 22: Overview: Compounds 31, 33 and 36 differ in the length of the methylene-chain. Moreover, 
31 and 33 are Cp-acid-conjugates, whereas 36 is a Cp-amino-conjugate. 36 is the exact structural 
analogue of SAHA. 
 
[(Cp-COOH)Re(CO)3] (2) was activated with pentafluorophenyl trifluoroacetate 
(PFPTFA) and coupled to the appropriate amine to form complexes 30 and 32. 
Activation of the terminal carboxylic acids with ethyl chloroformate and treatment 
with hydroxylamine gave the final products 31 and 33 (Scheme 24).  
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Scheme 24: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, 8-aminocaprylic acid, DMF, 88 %. 
ii) Pentafluorophenyl trifluoroacetate, 7-aminoheptanoic acid, DMF, 86 %. iii) Ethyl chloroformate, 
NH2OH, THF 80 – 86 %. 
 
The 1H-NMR spectrum of 30 and 32 in DMSO-d6 shows the two aromatic Cp-signals at 
6.26 and at 5.70 ppm respectively. In comparison to 2 (DMSO-d6, 6.21 and 5.74 ppm), 
the signals did not move significantly. The multiplets of the methylene groups can be 
found from 3.13 to 1.25 ppm. However, IR-CO-frequencies (KBr) indicate increased 
C-O bond lengths of the carbonyl ligands (2022 and 1907 cm-1), caused by 
increased electron density on the metal compared to the starting compound 2 
(2032 and 1916 cm-1). 
Upon coupling to hydroxylamine, the chemical shift of the methylene multiplets 
shifted. The metal core and functionalities in close proximity were hardly influenced.  
 
[(Cp-NHCO(CH2)6COOMe)M(CO)3] (34a/b) (a: M = Re, b: M = Mn) was synthesized 
by activation of suberic acid monomethyl ester with isobutyl chloroformate and 
coupling with [(Cp-NH2)M(CO)3] (11). The obtained ester 34a was hydrolyzed with 
aqueous LiOH. Activation of the terminal carboxylic acid with ethyl chloroformate 
and treatment with hydroxylamine gave the final product 36 (Scheme 25). 
Compound 36 corresponds structurally to native SAHA.  
The Mn-complex 34b was synthesized exclusively for crystallographic purposes and 
was not exploited further. Crystals were grown by dissolving in a minimum of CH2Cl2 
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and slow addition of hexane as a precipitant. An Ortep-plot with important bond 
lengths and angles is given in figure 23. 34b crystallized in the monoclinic crystal 
system P21/c and the central manganese is 5-coordinated to the Cp--ligand. The 
geometry around the manganese is distorted octahedral and the amide group is 
almost coplanar with the Cp--ring, showing a torsion angle of -2.5(4)° between O4-
C9-N1-C4. The Mn-C (CO) bond lengths range from 1.776(3) to 1.784(3) and are 
substantially shorter than those found for the Re-complexes discussed above. As a 
consequence of the smaller radius of the metal center, the individual Mn-C bond 
lengths to the Cp ligand are shorter as well in comparison to the Re-complexes 4, 5, 
24a/b and 27. They also reveal variations, from 2.194(2) (Mn1-C4) to 2.102(3) Å (Mn1-
C6), similar to 4 and 5. However in contrast to compounds 4 and 5, the shortest M-C 
bonds (Mn1-C6 and Mn1-C7) are the ones opposite to the derivatized Cp-carbon, 
which forms the longest bond (Mn1-C4). 
 
 
Scheme 25: Synthetic conditions: i) Suberic acid monomethyl ester activated with isobutyl 
chloroformate, THF, 98 %. ii) LiOH, H2O, MeOH, THF, 98 %. iii) Ethyl chloroformate, NH2OH, THF 80 – 86 %. 
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Upon amide coupling of 11 to suberic acid monomethyl ester, the characteristic IR-
CO-bands of 34a were observed at 2019 and at 1913 cm-1 (KBr). Compared to the 
starting compound 11 (1995 and 1874 cm-1), these values indicate a tremendous 
change in the electronic conditions around the metal, caused by the electron 
withdrawing nature of the carbonyl. 
Alterations at the pendent functional group caused shifts of the neighbouring 
methylene multiplets. The metal core and functionalities in close proximity were 
hardly influenced.  
 
 
Figure 23: ORTEP representation of 34b. Relevant bond lengths (Å) and angles (°): Mn(1)-C(1) 1.784(3), 
Mn(1)-C(2) 1.784(3), Mn(1)-C(3) 1.776(3), Mn(1)-C(4) 2.194(2), Mn(1)-C(5) 2.146(2), Mn(1)-C(6) 2.102(3), 
Mn(1)-C(7) 2.105(3), Mn(1)-C(8) 2.133(3), C(1)-O(1) 1.147(4), C(2)-O(2) 1.138(4), C(3)-O(3) 1.143(4), C(4)-
N(1) 1.400(3), C(9)-O(4) 1.212(3), C(16)-O(5) 1.192(3), C(16)-O(6) 1.325(3), C(3)-Mn(1)-C(2) 93.72(15), 
C(3)-Mn(1)-C(1) 92.19(15), C(2)-Mn(1)-C(1) 90.54(14), O(4)-C(9)-N(1) 121.7(3), O(4)-C(9)-C(10) 123.6(3), 
O(5)-C(16)-O(6) 122.9(3), O(5)-C(16)-C(15) 124.8(3), C(16)-O(6)-C(17) 116.0(2).  
 
The Organic SAHA-Analogues  
For the direct comparison of the biological activity of organic and inorganic 
inhibitors, the organic congeners of compounds 31 and 33, namely 38 and 40 were 
prepared. As mentioned before, 36 corresponds to the native SAHA. Syntheses were 
performed analogously to the organometallic compounds, as described above 
(Scheme 26).[93] The inhibitors were purified by silica gel chromatography and 
analysed by NMR, ESI-MS, and CHN-analysis. Characterization will not be discussed 
here. 
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Scheme 26: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, 8-aminocaprylic acid, DMF, 90 %. 
ii) Pentafluorophenyl trifluoroacetate, 7-aminoheptanoic acid, DMF, 89 %. iii) Ethyl chloroformate, 
NH2OH, THF 90-92 %. 
 
The Ligands 
As mentioned in section 2.1.4, the synthesis of an uncoordinated HCp-NH2 molecule 
was not achieved. Therefore, the preparation of the non-coordinated ligand of 
SAHA analogue 36 was not possible. However, as a chemical proof of concept for 
the 99mTc-labeling of HDAC-inhibitors with pendent hydroxamic acids, 42 was 
synthesized, a dimeric form of the protonated ligand of compound 33.[93]  
Thilele's Acid was activated with PFPTFA in DMF in quantitative yield.[63] The obtained 
PFP-ester was isolated and did not hydrolyse during the aqueous work-up, which 
proves, that PFP-esters cause only weak activation of carboxylic acids. However, 
primary amines are nucleophilic enough to form amide bonds with PFP-activated 
Thiele's Acid. The addition of two equivalents of 7-aminoheptanoic acid together 
with an excess of NEt3 led to the formation of compound 41. Activation of the 
terminal carboxylic acids with O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HATU) and treatment with O-(tert-
Butyldimethylsilyl)- hydroxylamine gave hydroxamic acid 42, after aqueous work-up 
(Scheme 27). 
Two triplets at 7.81 and at 7.52 ppm respectively for the NH-protons in the 1H-NMR 
spectrum of 41 (MeOD) indicated the formation of an amide bond. The signal for the 
olefinic protons shifted from 6.86 ppm for Thiele's Acid to 6.63 ppm and from 6.51 to 
6.30 ppm due to increased shielding of the olefinic protons. The same effect of 
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increased electron donation to the Cp upon amide coupling was observed in the IR-
measurement of complexes 30 and 32 (see above). 
After coupling of the two terminal carboxylic acids functions to hydroxylamine, the 
1H-NMR-signals of the methylene groups adjacent to the terminal carbonyl shifted 
clearly from 2.12 to 2.27 ppm but did not have any effect on the HCp-protons.  
 
 
Scheme 27: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, DMF, quantitative. vi) 7-
aminoheptanoic acid, triethylamine, DMF, 54 %. vii) HATU, O-(tert-Butyldimethylsilyl)hydroxylamine, H2O, 
DMF, 70 %. 
 
The Technetium Complexes 
Acording to the theragnostic concept, the Re-HDACIs 31, 33 and 36 could be 
applied in combination with the corresponding 99mTc-labelled compounds; 
macroscopic amounts of Re for therapy and microscopic amounts of the 99mTc-
analogues for diagnosis. Therefore, attempts were made to label 42 with 
[99mTc(OH2)3(CO)3]+. But heating of a millimolar solution of 42 with [99mTc(OH2)3(CO)3]+ 
at 90 °C resulted only in the quantitative formation of [99mTcO4]- (Scheme 28). 
Hydroxamic acids are oxidants towards [99mTc(OH2)3(CO)3]+. The same behavior was 
observed, when [Re(Br)3(CO)3]2- was mixed with 42 or with other hydroxamic acids. 
However, oxidation only occurred, when the metal core contained weakly bound 
and substitution labile ligands, like the water molecules in [99mTc(OH2)3(CO)3]+ or the 
bromides in [Re(Br)3(CO)3]2-. Preliminary formed [(Cp-R)M(CO)3] complexes did not 
show any decomposition under the same conditions. This leads to the assumption, 
that coordination of the hydroxamic acid function to the metal core is a key-step of 
this side reaction. Therefore the hydroxamic acids were protected by acetylation at 
the hydroxyl position. But esters are usually cleaved off under the basic labeling 
conditions, thus the desired labeling product was not obtained.  
Results & Discussion 2013 
 
61 
 
 
Scheme 28: Hydroxamic acids oxidize the metal in [99mTc(OH2)3(CO)3]+ or in [Re(Br)3(CO)3]2- to [TcO4]- or 
[ReO4]- respectively. 
 
However, the one-pot labeling of 41 with [99mTcO4]- in presence of an Isolink Kit 
showed after 80 minutes at 90 °C the expected product 43 in 87 % yield and high 
radio chemical purity (Scheme 29).[93] Two-step procedures, where The 
[99mTc(OH2)3(CO)3]+ precursor is prepared in advance, works equally well. The nature 
of the 99mTc-compound was confirmed by co-injection with the corresponding Re-
complex 32. 
 
 
Scheme 29: Bottom-up trace: -trace of the one-pot labeling of 41 with [99mTcO4]- and Isolink Kit. Top-
down trace: UV-trace of Re-compound 32. 
 
In Vitro Cytotoxicity 
Analyzing the anti-tumor activity of organometallic HDAC-inhibitors 31, 33 and 36, 
cytotoxicity towards five carcinoma cell lines was evaluated.[93] In order to have a 
direct comparison, the corresponding organic congeners SAHA, 38 and 50 were 
tested the same way. The cancer cell lines were exposed to increasing 
concentrations of the different compounds for 72 h and the cellular viability was 
determined by MTT assay. The viability of cells in the presence of the tested 
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compounds was compared to that observed in control cultures and the percentage 
of growth inhibition was calculated. The dose-response curves demonstrate the 
antiproliferative effects of all compounds, exemplified in Figure 24 for human cervical 
carcinoma HeLa and vulva epidermal carcinoma A431 cells. The IC50 (i.e., the 
concentration producing 50 % inhibition of growth) was determined for five cells lines 
and is expressed in micromolar concentration (Table 1). 
 
 
Figure 24: Cytotoxicity on human cervical carcinoma HeLa cells (A) and vulva epidermal carcinoma 
A431 cells (B). 
 
Table 1: Cytotoxicity profile of compounds 31, 33, 36, 38 and 40 and of the reference HDAC inhibitor 
SAHA for 72 h (37 ºC/5 % CO2) continuous treatment of five different tumor cell lines (MCF-7 Human 
breast carcinoma, A431 Human vulva epidermal carcinoma, A375 Human melanoma, B16F1 Murine 
melanoma). 
 
Compound 
IC50 (μM)  
Mean ± SD MCF-7 A431 HeLa A375 B16F1 
31 9.47 13.7 14.4 14.7 9.82 12.4 ± 2.6 
33 15.2 17.1 13.3 23.3 12.6 16.3 ± 4.3 
36 11.4 17.3 8.34 12.5 15.2 12.9 ± 3.4 
38 1.71 2.51 1.65 2.63 3.10 2.32 ± 0.62 
40 7.19 5.22 5.83 4.85 8.88 6.39 ± 1.65 
SAHA 3.74 4.44 4.45 4.58 3.67 4.18 ± 0.43 
 
The analysis of the data presented in table 1 allows to understand how the position 
of the amide linker and the length of the alkyl chain, attached to the [(Cp)Re(CO)3]-
framework, may affect the anti-tumoral capacity of organometallic HDCA inhibitors. 
Moreover, it allows to evidence if the replacement of phenyl rings by [(Cp)Re(CO)3] 
is tolerated in the investigated examples.  
Table 1 shows, that after a drug administration period of 72 h, SAHA displayed a 
broad cytotoxicity across cell lines from different tumor entities with a mean IC50 
value of 4.2 ± 0.4 μM. This value, obtained from the MTT assay, is in agreement with 
 
SAHA
31
33
36
38
40
 
SAHA 
31 
33 
36 
38 
40 
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the antiproliferative activity of SAHA previously reported by using the Alamar Blue cell 
viability assay (IC50 = 3.3 μM, a mean value for several tumor cell lines).[100] 
Among the new compounds reported here, the organic SAHA-analogue 38 showed 
the lowest IC50 values for all tested cell lines. This indicates a superior potency for 
HDCA-inhibition in vitro, even higher than the one described for the native SAHA. In 
fact, the mean IC50 value for compound 38 (2.32 ± 0.62 μM) (38 contains a longer 
aliphatic chain and inverted amide linker as compared to SAHA) was about 2 or 3 
times lower than the one obtained for SAHA or compound 5 respectively (4.2 ± 0.4 
and 6.39 ± 1.65 μM), both containing the shorter hexyl alkyl chain. These results 
suggest that cytotoxicity of HDAC inhibitors of the class of benzamide derivatives 
may depend on the length of the methylene chain attached to the benzamide 
framework. 
The organometallic HDACis 31, 33 and 36, are less active in each case as compared 
to the respective organic congeners SAHA, 38 and 40. The mean IC50 for 31 was 12.4 
μM, compared to 2.3 μM for 38. Re-complex 33 and the corresponding molecule 40 
displayed values of 16.3 μM and 6.4 μM, respectively and while SAHA presented a 
value of 4.2 μM, Re-complex 36 displayed a higher IC50 of 12.9 μM. This slight 
decrease of antiproliferative capacity of the Re-complexes indicates the more bulky 
[(Cp)Re(CO)3] to be disfavored over a simple planar phenyl ring and might be 
caused by reduced ability of cellular penetration. Nevertheless, the Re-complexes 
still retain a high cytotoxic activity, comparable to their organic congeners. No 
significant effect on cytotoxicity was observed by altering the position of the amide 
linker at the Cp. Similar mean values of IC50 were obtained for 33 and 36 (16.3 ± 4.3 vs 
12.9 ± 3.4 μM). All biological experiments were performed by using methanol as co-
solvent (to a final concentration of ≤ 0.1 %). Although this solvent is known to be toxic 
to cells, here due to its low concentration, the cell viability in the control experiments 
was higher than 90 %. 
 
In summary, a series of new organometallic HDAC-inhibitors with pendend 
hydroxamic acids, as well as their organic congeners were synthesized and 
characterized. The preparation of the 99mTc analogues using the uncoordinated 
HCp-dimer failed under standard labeling conditions (millimolar concentration of the 
ligand, [99mTc(OH2)3(CO)3]+, 90-95 °C). Oxidation of [99mTc(OH2)3(CO)3]+ to [99mTcO4]- 
was caused by the hydroxamic acid portion prior to 5 complex formation. However, 
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the same labeling conditions applied to terminal carboxylic acids formed the desired 
product. [(CpR)99mTc(CO)3]-complexes, where R is a HDAC-targeting hydroxamic 
acid, are therefore not accessible via metal mediated retro Diels-Alder reaction.  
Cytotoxic evaluation of the Re-complexes revealed low micromolar IC50-values on 
different tumor cell lines. The values are in the same range as found for SAHA and 
prove the concept of replacing phenyl rings by [(CpR)Re(CO)3] to be applicable in 
the case of organometallic HDAC-inhibitors. Slight alterations in the length of the 
aliphatic spacer as compared to the hexyl alkyl chain in SAHA do affect the activity 
of the HDACis. Increasing the number by one methylene group shows increased 
cytotoxic capacity. No significant effect was observed when the position of the 
amide linker at the Cp-ring was altered. 
 
2.3.2 CA-Inhibitors 
 
Carbonic anhydrases (CAs) are zinc metalloenzymes, found in both, prokaryotes and 
eukaryotes.[101] They catalyze the essential formation of carbonic acid from CO2 and 
water, and are involved in many different physiological and pathological processes. 
In mammals, 16 different isozymes are known, which are either membrane bound, 
expressed in the cytosol or in mitochondria.[101, 102] One feature that attracts interest in 
CAs from a pharmaceutical point of view is the hypoxia induced overexpression of 
hCAIX and hCAXII in many malignancies, including cancer.[101, 103-106] Therefore, CAs 
are a potential target for both cancer diagnosis and therapy and specific inhibitors 
will allow for targeted imaging of cancer tissue or growth inhibition, respectively. 
However, the large number of isozymes combined with the diffuse localization of CAs 
makes selective accumulation of inhibitors difficult.[102] Whereas several fluorescent 
sulfonamide-based CAIs or radio-iodinated monoclonal antibodies are exploited for 
diagnostic application,[107-110] only one report of 99mTc-labeled inhibitors has been 
published.[111] CAs have also been used as host for artificial metalloenzymes. 
Ruthenium based piano-stool complexes with pendent sulfonamide groups 
displayed moderate binding affinities for hCAII.[112] 
 
The Rhenium Complexes 
Meggers et al. recently showed that high selectivity does not only depend on 
intermolecular interactions but also on a directed 3D arrangement of different 
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functionalities as exemplified with organometallic protein kinase inhibitors.[42-44] Inert 
organometallic complexes offer the opportunity to populate biologically relevant 
space. Thus, bioorganometallic complexes are versatile chemical probes.[42, 45-48] 
Retaining the concept of extended three dimensional space population by 
organometallic complexes, new arylsulfonamide, -sulfamide or -sulfamate based 
CAIs containing the small [(Cp-R)M(CO)3]-motif (M = Re or 99mTc) were synthesized.  
The structures of complexes 46 and 51-55 differ in the spacer in terms of length and 
functionality adjacent to the Cp, as well as in the pendent terminal group (Figure 25). 
Compound 46, similar to model compounds 12 and 13, contains an internal 
sulfonamide group, which is coupled at the nitrogen atom to the Cp and via sulfur 
atom to the para-arylsulfamide. 51-53 have an amide group in the spacer, which is 
bound via a carbonyl group to the Cp. The amide-nitrogen in 51 is attached directly 
to the para-arylsulfamate and in 52 to the para-arylsulfonamide. Unlike compound 
53, which contains an additional methylene group between the amide nitrogen and 
the terminal para-arylsulfonamide. Complexes 54 and 55 follow this scaffold and 
contain a methylene group between the amide nitrogen and the terminal para-
arylsulfonamide moiety too. In contrast to 53, 54 and 55 contain also methylene 
spacers between the carbonyl and the Cp-chelator: 54 contains one and 55 
contains two methylene-groups, displacing the metal complex further away from the 
actual targeting vector. 
 
 
Figure 25: Overview: 46 and 51-55 differ in the spacer, as well as in the pendent terminal group. 
 
[(Cp-NH2)Re(CO)3] (11) was coupled to acetamidobenzolsulfonylchloride in refluxing 
CH2Cl2. The resulting product 44 was filtered off and purified by silica gel column 
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chromatography. Acidic hydrolysis of the pendent acetyl group followed by 
sulfamoylation afforded compound 46 (Scheme 30). 
 
 
Scheme 30: Synthetic conditions: i) Acetamidobenzolsulfonyl chloride, CH2Cl2, 80 %. ii)HCl, H2O, EtOH, 98 
%. iii) Sulfamoylchloride, DMA, 68 %. 
 
In the 1H-NMR-spectrum of 44 (MeOD), the four phenyl-protons were observed 
isochronically and show a singlet at 7.82 ppm. Characteristic IR-CO-bands for 
sulfonamide 44 (amino conjugate) were detected at 2020 and at 1915 cm-1 (KBr) 
and are thus similar to amides of the form of 34a (also amino conjugate, 2024 and 
1910 cm-1). Amide substitution of 11 causes therefore a comparable change in the 
electronic environment around the metal as sulfonation. However, inversion of the 
internal sulfonamide group as seen for example in compound 6, decreases electron 
density on the metal and the IR-CO-bands shift towards higher frequencies (2036 
and 1957 cm-1 for 6). 
Upon deacetylation, the isochronicity of the phenyl-protons is lifted in compound 45 
and two multiplets are observed at 7.55 and at 6.72 ppm respectively.  
45 was crystallized from CH2Cl2 by slow addition of hexane as a percipitant. The 
structure was elucidated and an ORTEP-plot is shown in figure 26. The compound 
crystallized in the orthorhombic crystal system Pbcn. The Re-atom shows 5-
coordination by the Cp--ligand. The M-C (CO) bond lengths range from 1.908(3) to 
1.920(3). The C-O bond lengths of the carbonyl ligands of 45 (1.140(4)-1.154(3) Å) are 
longer than those found for compound 4 (1.131(7)-1.144(8) Å), but compare well to 
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those of 24a/b (1.146(5)-1.152(4) Å). Other important bond lengths and angles are 
given in figure 26. 
 
 
Figure 26: ORTEP plot of 45: Important bond lengths (Å) and angles (°): Re(1)-C(1) 1.920(3), Re(1)-C(2) 
1.908(3), Re(1)-C(3) 1.917(3), Re(1)-C(4) 2.319(2), Re(1)-C(5) 2.304(3), Re(1)-C(6) 2.302(3), Re(1)-C(7) 
2.290(3), Re(1)-C(8) 2.319(3), C(1)-O(1) 1.140(4), C(2)-O(2) 1.154(3), C(3)-O(3) 1.144(3), C(9)-S(1) 1.749(2), 
O(4)-S(1) 1.4311(17), O(5)-S(1) 1.4281(18), N(1)-S(1) 1.6337(19), C(2)-Re(1)-C(3) 90.18(12), C(2)-Re(1)-C(1) 
88.32(13), C(3)-Re(1)-C(1) 89.31(13), N(1)-S(1)-C(9) 108.52(11) 
 
For the synthesis of 51, two different strategies were considered. Coupling of 4-
aminophenol to [(Cp-COOH)Re(CO)3] (2), followed by sulfamoylation of the 
pendent hydroxyl group, or sulfamoylation of 4-aminophenol prior to coupling to 2 
would, both lead to the formation of 51. 
However, activation of 2 with PFPTFA and addition of 4-aminophenol lead to the 
mixed formation of 39 % of the amide 47a and 24 % of the ester 47b. Separation of 
the two compounds was achieved by silica gel column chromatography. Only small 
amounts of 51 were obtained upon sulfamoylation of 47a, therefore this strategy was 
not further pursued (Scheme 31).  
 
 
Scheme 31: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, DMF, 80 %. ii)4-aminophenol, 
DMF, 39 % and 24 %. 
 
For a different synthetic approach to 51, 4-aminophenol was boc-protected at the 
nitrogen site and sulfamoylated at the pendend hydroxyl-group to form the 
intermediate 49 in good yields (85 %). Acidic deprotection using TFA in CH2Cl2 formed 
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compound 50, which was then coupled to HATU-activated [(Cp-COOH)Re(CO)3] (2), 
to form 51 in acceptable yields (Scheme 32 and 33). 
 
 
Scheme 32: Synthetic conditions: i) Boc2O, CH2Cl2, 78 %. ii) Sulfamoylchloride, DMA, 85 %. iii) TFA, CH2Cl2, 
98 %. 
 
 
Scheme 33: Synthetic conditions: i) HATU, DMF. ii) 50, DMF, 66 %.  
 
The 1H-NMR of 51 in DMSO-d6 exhibited a shift of the two sets of aromatic Cp--pseudo 
triplets of 0.28 and of 0.07 ppm respectively, compared to unsubstituted carboxylic 
acid 2. The IR-CO-bands were observed at 2030 and at 1941 cm-1 (KBr). Especially 
the asymmetric frequency is shifted towards higher frequencies, compared to the 
starting compound 2 (1916 cm-1). 
Crystals were grown from a concentrated methanol solution of 51 by slow 
evaporation of the solvent. The compound crystallized in the triclinic crystal system P-
1. Similar to complex 34b, the carbonyl group is almost coplanar with the Cp--ring 
and shows a torsion angle between C6-C7-C9-O4 of -4.1(10)°. The geometry around 
the rhenium is distorted octahedral (Figure 27). The M-C (CO) bond lengths range 
from 1.897(13) to 1.949(8). 
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Figure 27: ORTEP plot of 51: Important bond lengths (Å) and angles (°): Re(1)-C(1) 1.926(10), Re(1)-C(2) 
1.949(8), Re(1)-C(3) 1.897(13), Re(1)-C(4) 2.287(7), Re(1)-C(5) 2.297(7), Re(1)-C(6) 2.280(8), Re(1)-C(7) 
2.281(7), Re(1)-C(8) 2.282(8), C(1)-O(1) 1.130(12), C(2)-O(2) 1.115(12), C(3)-O(3) 1.175(15), O(6)-S(1) 
1.425(7), O(7)-S(1) 1.433(6), O(9)-S(1) 1.585(6), N(2)-S(1) 1.565(8), C(3)-Re(1)-C(1) 90.1(4), C(3)-Re(1)-C(2) 
90.4(5), C(1)-Re(1)-C(2) 89.5(4), O(6)-S(1)-O(7) 119.0(4), O(6)-S(1)-N(2) 108.3(4), O(7)-S(1)-N(2) 109.7(4), 
O(6)-S(1)-O(9) 108.7(4), O(7)-S(1)-O(9) 101.8(3), N(2)-S(1)-O(9) 108.9(4) 
 
Activation of [(Cp-COOH)Re(CO)3] (2) with PFPTFA, isobutyl chloroformate or with 
oxalyl chloride followed by the addition of sulfanilamide did not lead to desired 
product formation. Aniline-type of amines like sulfanilamide are not nucleophilic 
enough to form amide bonds using these activation methods with carboxylic acid 2. 
However, the benzotriazole-ester which is formed when carboxylic acids are reacted 
with HATU, is very reactive. Therefore, similar to the synthesis of 51, 2 was activated in 
situ using HATU, where upon the coupling worked smoothly (Scheme 34). Purification 
by silica gel column chromatography gave 52 in 80 % yield. Crystals were obtained 
by slow evaporation of a concentrated methanol solution. 
 
 
Scheme 34: Synthetic conditions: i) HATU, DMF. ii) Sulfanilamide, DMF, 80 %.  
 
Structurally, 52 is very similar to 51 around the metal center. The sulfamate group in 51 
is too far away from the Cp--chelator to cause significant differences in the 
properties of the metal complex. IR-CO-frequencies (KBr) for 52 (2034 and at 1941 
cm-1) are thus similar to 51 (2030 and at 1941 cm-1). Especially the asymmetric 
vibration is energetically higher than found for starting compound 2 (2032 and 1916 
cm-1) and confirms therefore the trend, that amide formation affects predominantly 
the asymmetric vibration frequencies. 
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The 1H-NMR in DMSO-d6 exhibited the typical two sets of pseudo triplets at a 
comparable range (6.51 and at 5.82 ppm) as 51. However, unlike in 51, the Phenyl 
protons in 52 were recorded isochronically at 7.80 ppm.  
52 crystallized in the triclinic system with space group P-1. The amide group is almost 
coplanar with the 5-coordinated Cp--ring (torsion angle C5-C4-C9-O4 of -0.1(4)°), 
whereas the phenyl ring is slightly twisted out of the plane (torsion angle C15-C10-N1-
C9 of 18.1(4)°). The geometry around the rhenium(I) is distorted octahedral (Figure 
28). The M-C (CO) bond lengths are in average shorter than the ones found for 
complexes 24a/b, 27, 45 and 51 and range from 1.900(4) to 1.906(4). 
 
 
Figure 28: ORTEP plot of 52: Important bond lengths (Å) and angles (°): Re(1)-C(1) 1.900(4), Re(1)-C(2) 
1.901(4), Re(1)-C(3) 1.906(4), Re(1)-C(4) 2.291(3), Re(1)-C(5) 2.287(3), Re(1)-C(6) 2.299(3), Re(1)-C(7) 
2.290(3), Re(1)-C(8) 2.293(3), C(1)-O(1) 1.139(4), C(2)-O(2) 1.138(4), C(3)-O(3) 1.148(4), C(13)-S(1) 
1.766(3), N(2)-S(1) 1.605(3), O(5)-S(1) 1.4388(17), O(6)-S(1) 1.430(2), C(1)-Re(1)-C(2) 88.69(15), C(1)-Re(1)-
C(3) 90.29(16), C(2)-Re(1)-C(3) 88.89(16), O(6)-S(1)-O(5) 118.09(11), O(6)-S(1)-N(2) 106.40(13), O(5)-S(1)-
N(2) 107.25(12) 
 
Mafenide, in contrast to sulfanilamide contains a methylene spacer between the 
aromatic moiety and the primary amine. It is not an aniline-type of amine and is 
more nucleophilic and reactive towards activated carboxylic acids. Therefore, the 
activation of 2 as a pentafluoro phenyl-ester, using PFPTFA, was chosen to form a 
mildly activated precursor.[63] Addition of mafenide, in presence of sufficient amount 
of triethylamine, resulted in the quantitative formation of sulfonmide 53, which was 
purified by silica gel column chromatography (Scheme 35). 
 
 
Scheme 35: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, DMF, 80 %. ii) Mafenide, DMF, 78 
%. 
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The more electron donating nature of the methylene spacer in mafenide have an 
impact on the IR-CO-frequencies of 53, when compared to 51 or 52. CO-
frequencies were observed at 2025 and at 1918 cm-1 (KBr), in contrast to 51 (2030 
and 1941 cm-1) or 52 (2034 and 1941 cm-1). The same effect is observed in the 1H-
NMR (DMSO-d6). The Cp--pseudo triplets of 53 were detected at 6.34 and at 5.75 
ppm. This corresponds to a shift of 0.15 or 0.06 ppm (compared to 51) and of 0.17 or 
0.07 ppm (compared to 52) towards higher field. In contrast to 52, phenyl protons 
were not recorded isochronically.  
 
In contrast to the CAIs discussed above, where the coupling function is directly 
bound to the Cp, a new way of altering the spacer in a BFC is introduced, when the 
building blocks 24a or 27 respectively are used. With methylene groups between the 
Cp and the amide, variations before and after the coupling function are generated. 
This variation represents a new factor for interesting structure activity relationships 
(SARs).  
54 and 55 both were synthesized along an analogous procedure to the preparation 
of 53 (Scheme 36). Product 54 was worked up by aqueous extraction and did not 
require further purification. Arylsulfonamide 55 needed additional purification by 
silica gel column chromatography. Both complexes were analysed by IR (KBr), NMR, 
ESI-MS and elemental analysis. 
 
 
Scheme 36: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, DMF, 70-80 %. ii) Mafenide, DMF, 
66-78 %. 
 
  
Results & Discussion 2013 
 
72 
 
Upon amide coupling, the asymmetric IR-CO-band of 54 (1930 cm-1) shifted 
towards higher frequencies, whereas the symmetric number did not change (2020 
cm-1), when compared to starting compound 24a (2020 and 1911 cm-1). In 55, the 
distance between the metal center and the position of the amide coupling is larger 
than in 54. Therefore, IR-CO-frequencies do not shift substantially (2017 and 1911 
cm-1 for 55 compared to 2023 and 1912 cm-1 for 27).  
 
The Ligands 
As described above, the synthesis of a free HCp-NH2 molecule was not achieved in 
the course of this thesis. Therefore, the synthesis of the uncoordinated ligand of 46 
was not possible. However, the protonated dimers of the free ligands of the 
synthesized CAIs 51-53 were prepared. Depending on whether the nucleophile was 
an aniline-type of amine or not, Thiele's Acid was activated with oxalyl chloride (for 
56 and 58) or with PFPTFA (for 59) (Scheme 37-39). In presence of triethylamine, the 
appropriate amine was added and the reaction progress was monitored by HPLC. 
56 was purified by silica gel column chromatography. After treatment with 
sulfamoylchloride, 57 was isolated. 58 percipitated from the reaction mixture and 
was washed on a filter with fresh THF and a small portion of MeOH.  
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Scheme 37: Synthetic conditions: i) Oxalylchloride, CH2Cl2. ii) 4-Aminophenol, THF, 63 %. iii) 
Sulfamoylchloride, CH2Cl2, 89 %. iv) Sulfanilamide, THF, 43 %. v) Pentafluorophenyl trifluoroacetate, DMF, 
88 %. vi) Mafenide, DMF, 90 %. 
 
The Technetium Complexes 
Surprisingly, 57 did not give the desired product, when reacted with 
[99mTc(OH2)3(CO)3]+ under our labeling conditions. The arylsulfamate-function is 
unstable under these reaction conditions, which leads to the degradation of the 
ligand. However, labeling with precursor 56 formed the corresponding product 60 in 
72 % yield (Scheme 38).  
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Scheme 38: Bottom-up trace: -trace of the one-pot labeling of 56 with [99mTcO4]- and Isolink Kit. Top-
down trace: UV-trace of Re-compound 47a. 27 % of the activity was observed as unreacted 
[Tc(CO)3(OH2)3]+ and 1 % as [TcO4]-. 
 
In contrast to the arylsulfamate-functionality, the arylsulfonamide-group was stable 
under labeling conditions. The 99mTc analogues of 52 and 53, namely 61 and 62 were 
prepared. No degradation was observed. The authenticity of the products was 
assessed by comparing the HPLC retention times of 52 with 61 and 53 with 62 
(Scheme 39 and 40).  
The one-pot reactions with [99mTcO4]- gave nearly quantitative yields at 90 °C after 
60-90 minutes. Two-step procedures, where The [99mTc(OH2)3(CO)3]+ precursor is 
prepared in advance, works equally well. Ligands 58 and 59 were present in 
millimolar concentrations. No sideproducts were observed during the labeling 
procedure. 
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Scheme 39: Bottom-up trace: -trace of the one-pot labeling of 58 with [99mTcO4]- and Isolink Kit. Top-
down trace: UV-trace of Re-compound 52. 
 
 
Scheme 40: Bottom-up trace: -trace of the one-pot labeling of 59 with [99mTcO4]- and Isolink Kit. Top-
down trace: UV-trace of Re-compound 53. 
 
In Vitro Binding Affinities 
Binding studies of complexes 46 and 51-55 with 12 CA isozymes showed inhibition 
constants in the low nanomolar range for some of the isoforms (Table 2).  
Such low Ki values are uncommon for bioorganometallic compounds or 
radiopharmaceuticals.[113] The hCA II, VI, VII, IX, XII and XIII are considered as 
sulfonamide- and sulfamate-avid isoforms[101] which is consistent with the observed 
values for inhibitors 46 and 51-55. It should be noted that the Ki values reported here 
for the various isoforms compare well to those of the AZA standard and are for some 
isoforms even better. In addition, distinct selectivity for hCA IX, XII and XIV over the 
other isoforms was observed. The Ki ratios (hCA II/hCA IX) of 4.0 (for 53) or 7.0, 
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respectively (for 51 and 52), indicate a clear preference for hCA IX, overexpressed in 
certain tumors, over the physiologically dominant hCA II. In contrast, 54 and 55 do 
not show a preference of hCA IX over hCA II. Compound 46 showed the most 
pronounced selectivity pattern (solid line in Figure 29) and strongly favors hCA II, IX, 
XIV. Compounds 51-53 all behave similarly, Ki values of the standard acetazolamide 
(AZA) do not show such a distinct preference pattern for any of the isoforms. It has 
only a slightly higher affinity for hCA II over hCA IX (hCA II/hCA IX = 0.5). 
Inhibition constants found for 46 and 51-53 are, thus, in the same range as found for 
organic inhibitors[101] but much better than those reported for the aforementioned 
two organometallic CA inhibitors,[111, 112] indicating smaller and more compact [(Cp-
R)M(CO)3] (M = Re or 99mTc) to be favored over more bulky metal complexes.  
 
Table 2: Inhibition data of complexes 46 and 51-53 against selected CA isozymes in comparison with 
acetazolamide (AZA). [a] Data was determined by the CA-catalyzed hydration of CO2.  
 
Ki (nM)[a] 
Compound 46 51 52 53 
 
54 
 
55 AZA 
CAI 39 2570 4590 2775 288 246 250 
CAII 15.1 27.4 35.5 25.3 4.5 6.2 12 
CAIV 467 32.9 41.1 33.8   74 
CAVA 481 113 124 109   63 
CAVB 305 105 104 102   54 
CAVI 497 10.6 22.1 14.5   11 
CAVII 360 7.6 21.3 10.1   2.5 
CAIX 43 3.7 5.2 7 3.8 4.7 25 
CAXII 6.7 4.5 6.9 4.4 42.7 59.8 5.7 
CAXIII 482 62.1 78.5 56.8   17 
CAXIV 20.1 4.1 7.9 5.4   41 
CAXV 313 28.4 36.8 12.5   72 
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Figure 29: Graphical representation of Ki values of compounds 46 and 51-53 for selected isozymes of 
hCAs. 
 
In Vitro pH-Studies 
CAs are amongst the most effective catalysts known in biological systems (kcat/KM > 
108 M-1).[102] Due to increased carbonic acid formation, the high activity of hypoxia-
induced, overexpressed CAs leads to a remarkable extracellular pH drop in tumor 
tissue (to  6 as compared to 7.4 in normal tissues).[101, 111, 114, 115] Consequently, strong 
CA inhibition will reduce acidification. To confirm this hypothesis, hCA IX-induced 
extracellular acidification was quantified before and after exposure to the inhibitors 
52 and 53. The three different human carcinoma cell models cervical 
adenocarcinoma HeLa, breast adenocarcinoma MDA MB 231 and colon 
adenocarcinoma HT29 were studied. This panel of cell lines was assessed by western 
blot for the levels of hCA IX expression under normoxic and hypoxic conditions 
(Figure 30). The HeLa and HT29 carcinoma cells showed elevated levels of hCA IX 
under hypoxic conditions while MDA MB 231 did not. Only HT29 cells expressed hCA 
IX under normoxic conditions, albeit at a lower amount than under reduced oxygen 
levels. This basal expression in HT29 cells is not surprising, and might be caused by the 
cluster shaped growth of these cells. 
In order to minimize potential cytotoxicity of the complexes, extracellular 
acidification experiments were performed at a 0.5 mM concentration of the Re 
complexes 52 and 53. Hypoxic incubation of HeLa and HT29 cells led to the 
expected extracellular acidification by about 0.5 to 0.7 pH units, caused by 
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overexpression of hCA IX. Under normoxic conditions, a pH drop of only about 0.1 for 
HeLa (no overexpression) and 0.2 for HT29 (slight expression) was found. 
 
 
Figure 30: Western blot analysis of hCA IX expression in normoxic N (21 % O2, 24 h) and hypoxic H (1 % 
O2, 24 h) MDA MB 231, HeLa and HT29 carcinoma cells using a polyclonal hCA IX antibody. Actin was 
used as loading control.  
 
The presence of the reference inhibitors mafenide and sulfanilamide under hypoxia 
caused a significant reduction of extracellular acidification; more pronounced for 
HeLa than for HT29 cells (Figure 31A compare with 31C). The Re complexes 52 and 53 
showed a distinct reduction of extracellular acidification, in hypoxia comparable or 
even better than the organic compounds, confirming CA IX inhibition. The normoxic 
extracellular pH was not significantly affected by incubation with either compound, 
indicating a specific interaction with hCA IX. In agreement with the lack of hCA IX 
expression, MDA MB 231 cells did not show a pH difference for cells grown under 
normoxic or hypoxic conditions. 
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Figure 31: Effect of the reference sulfonamides and compounds 52 and 53 on the reduction of 
extracellular acidification in HeLa and HT29 cell lines. Cells were incubated for 24h. Data show the 
mean ± S.D. of 4 replicates and are plotted as difference between pHe values (delta pH = pHafter incubation 
− pHbefore incubation) measured in absence (control) or in presence of the sulfonamides. 
 
Protein Crystallization 
In order to assess the binding mode of the Re-based CAIs with proteins, crystals of 
hCA II were grown by "hanging drop" vapor diffusion. The crystals were then soaked 
with the respective inhibitor and gave diffraction data until 1.2 Å resolutions. The 
electron density of the complete complex 53 could be traced, confirming its 
localization in the binding pocket of hCA II. An electron density map of the binding 
pocket is shown in Figure 32A. The binding mode is reminiscent to the arrangement 
as seen in other hCA II structures.[116, 117] Avvaru et al. defined two binding pockets I 
and II for elongate hCA II inhibitors.[118] Complex 53 binds in the hydrophobic pocket 
II (SI). The deprotonated nitrogen of the arylsulfonamide terminus coordinates to the 
Zn-atom of the active site (Figure 32B). The major conformation of the [(Cp)Re(CO)3] 
unit, including the amide linker, does not interact with either the protein or water 
molecules. However, there is a hydrophobic interaction between the [(Cp)Re(CO)3]-
moiety and the hydrophobic part of Phe131, Leu198 and Pro202. Further details are 
given in the supporting material. 
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Figure 32: A: Crystal structure of 53 bound to hCA II (only major conformation of 53 shown) A: Electron 
density map of 53, superimposed with the stick-model of the inhibitor bound to the active site of hCA II. 
Hydrophobic interactions can be observed between the [(Cp)Re(CO)3]-moiety and Phe131, Leu198, 
and Pro202. B: Detail of the binding cavity of hCA II with 53. The Zn atom is shown as a green sphere. 
 
In Vivo Biodistribution 
In vivo accumulation of 61 and 62 in HT-29 tumors was evaluated at 1h and 4h post 
injection (Table 3 and 4). 
 
 
Figure 33: A) Balb/C nude mouse bearing HT-29 colorectal tumor after 14 days of inoculation. Animals 
were previously s.c inoculated with 107 HT-29 colon carcinoma cells ressuspended in 50 % Matrigel. B) 
HT29 tumor removed from mouse of image A). 
 
Table 3: Biodistribution of 61 in BaLb/C nude mice with human HT-29 colon carcinoma (n = 3). 
 
Tissue/organ 
 % ID/g ± SD 
1h 4h 
Tumor 0,70 0,12 0,36  0,12 
Blood 25,54  12,05 7,39  6,82 
Liver 23,59  3,19 55,84  4,92  
Intestine 3,08  0,25 10,39 6,17 
Spleen 9,51  2,69  7,03  5,63 
Heart 9,02  4,54 0,99  0,74 
A B 
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Lung 6,36 2,67  3,11  2,55 
Kidney 13,13  0,90 5,57  4,19  
Muscle 1,23  0,10 0,50  0,41 
Bone 2,06  0,13 1,26  0,88 
Stomach 5,18  1,99 6,51  2,92 
Pancreas 1,71 0,00  0,97  0,79 
Total excretion 
( %) 
4,9  0,1 
 
3,5  1,0  
 
Table 4: Biodistribution of 62 in BaLb/C nude mice with human HT-29 colon carcinoma (n = 3). 
 
Tissue/organ 
 % ID/g ± SD 
1h 4h 
Tumor 0,47 0,02 0,12  0,04 
Blood 2,29  0,01 0,24  0,01 
Liver 44,1  1,5 35,5  6,4  
Intestine 9,6  0,3 12,6  1,0 
Spleen 2,77  0,20  0,11  0,02 
Heart 0,75  0,27 0,07  0,01 
Lung 0,93 0,21  0,14  0,04 
Kidney 1,81  0,06 0,54  0,04  
Muscle 0,50  0,06 0,05  0,01 
Bone 0,55  0,01 0,06  0,01 
Stomach 1,83  0,49 1,34  0,39 
Pancreas 0,37 0,13  0,07  0,00 
Total excretion 
( %) 
0,47  0,99 
 
18,0  2,4  
 
The compound 62 was moderately cleared from the bloodstream and major organs 
(0.24±0.01 %IA/g, 4h p.i.), except the excretory organs. The slow overall excretion 
(only 18 % after 4h p.i.) and the very high levels of activity in liver and intestine (about 
78 % of the activity at 4h p.i) indicate the hepatobiliar route as the principal path for 
the elimination of 62. This is in accordance with the lypophilic character of the 
radioconjugate (log Po/w=1.7). More unfavorable pharmacokinetic profile was 
observed for the radioconjugate 61. The blood clearance and whole-body excretion 
of 61 was very slow with a negligible fraction of the radioactivity excreted via renal 
(urinary) route at 4h p.i. (about 4 %). The accumulation of 61 in the hepatobiliary 
tract was again very high, indicating the importance of this path for the elimination 
of these radioconjugates and again correlating well with the log Po/w value of 2.3. A 
significant non-specific accumulation was also observed for other non-excretory 
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organs such as spleen, stomach and lungs. The stomach uptake could be an 
indication for some in vivo oxidation of the complex to [99mTcO4]-. 
Tumor uptake was minimal (negligible) for both complexes. However, tumor-to-blood 
ratios slightly increased as a function of time (61: 0.2 and 0.5; 62: 0.03 and 0.05, at 1h 
and 4h p.i., respectively). Western blotting analysis was performed to confirm the 
expression levels of CAIX in the tumors.  
 
CAIX Expression in Tumor Xenografts of Human Carcinoma Cell Lines 
While HT29 cells showed intermediate expression levels of CAIX under normoxia, 
tumors showed elevated levels of expression indicating hypoxia conditions (Figure 
34).  
Considering the encouraging results obtained during the in vitro affinity studies using 
Re-complexes 52 and 53 for CAIX (Ki: 5.2 and 7 nM, respectively), the negligible 
uptake of the respective 99mTc-labeled compounds in CAIX-expressing HT-29 tumors 
was unexpected. The low accumulation of 61 and 62 in tumors could be due to low 
expression levels of the active form of CAIX in the tumor. It has been shown, that for 
efficient binding of sulfonamides to CAIX not only its expression but also its activation 
is required.[119] Furthermore, tumor biology in vivo with its complexity of 
microenvironments and with dynamic changes of oxygen gradients at variable 
episodes resulting in an imbalance in hypoxia, can differ from the in vitro conditions. 
In summary, these results show the increasing but low uptake of 99mTc-complexes 61 
and 62 in the tumor, despite of the remarkably low Ki values and significant 
expression of CAIX in HT29 tumors. 
 
 
Figure 34: Western blot analysis of CA IX expression in tumor xenografts of HT29 carcinoma cells using a 
polyclonal CA IX antibody. Actin was used as loading control. 
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In conclusion, six new piano-stool Re-complexes with pendent arylsulfonamides, -
sulfamides or –sulfamates were synthesized. They inhibit CAs with nanomolar affinities. 
Particularly strong inhibition was found for the pharmaceutically relevant isozymes 
hCA IX and hCA XII. Compound 46 exhibited superior CA isoform selectivity than the 
AZA standard. Enhanced receptor selectivity due to better 3-D space occupation is 
one crucial preponderance of bioorganometallic compounds. For molecular 
imaging purposes, the 99mTc homologues of 52 and 53 were synthesized. Inert 
bioorganometallic 99mTc and Re compounds behave biologically identical, thus, 
these potent CAIs can be applied in combination with each other, macroscopic 
amounts of Re for therapy and microscopic amounts of the 99mTc analogues for 
diagnosis, according to the theragnostic concept. 
In order to assess the binding mode of the Re-based CAIs with proteins, crystals of 
hCA II were grown and soaked with inhibitor 53. The electron density of the complete 
complex 53 could be traced, confirming its localization in the binding pocket of hCA 
II and showing hydrophobic interaction between the [(Cp)Re(CO)3]-moiety and the 
hydrophobic part of Phe131, Leu198 and Pro202. 
In vivo accumulation of the 99mTc-compounds 61 and 62 in BaLb/C nude mice with 
human HT-29 colon carcinoma was evaluated at 1h and 4h post injection. Slow 
overall excretion and high levels of activity in liver and intestine indicate the 
hepatobiliar route as the principal path for the elimination of the two CAIs. This is in 
accordance with the lypophilic character of the radioconjugates (log Po/w=1.7 for 62 
or 2.3 for 61 respectively). Tumor uptake was negligible for both complexes. 
However, tumor-to-blood ratios slightly increased as a function of time (61: 0.2 and 
0.5; 62: 0.03 and 0.05, at 1h and 4h p.i., respectively).  
The stomach uptake could be an indication for some in vivo oxidation of the 
complex to [99mTcO4]-. Apart from this, the compounds were found intact in the urine 
and in the blood, pointing out the stability of the complexes.  
The high lipophilicity of the compounds caused a relatively high uptake of the 
compounds into red blood cells. Designing the inhibitors more hydrophilically might 
therefore improve tumor uptake.[111] 
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2.3.3 Organometallic Antibiotics 
 
Besides the carbonic anhydrase inhibitors, sulfonamides are an important class of 
agents, which have pioneered the antimicrobial therapy. Nowadays, these 
compounds are often applied in combination with other antibiotics, in order to 
decrease the development of resistance and in order to increase the potency of 
therapies.[120] Their mechanism of action is related to the inhibition of the bacterial 
dihydropteroate synthase, catalysing the folic acid synthesis.[121] Structurally, many of 
these molecules are based on a p-amino-benzol-sulfonamide scaffold, which can 
contain different substituents bound to the sulfonamide moiety (Figure 35). 
Organometallic analogs of known antibiotics might cause decreased resistance 
development properties in bacteria. The corresponding 99mTc-complexes could serve 
as imaging agents for bacterial infections. 
 
 
Figure 35: Lewis structures of selected commercialized antibiotics. A) Sulfacetamide, B) Sulfadiazine, C) 
Sulfamethoxazol, D) Sulfalen. 
 
The Rhenium Complexes I 
Depending on the position where the metal complex is introduced, two different 
approaches were followed for the investigation of organometallic antibiotics with 
internal sulfonamide moiety. Starting from the sulfonyl-Cp-complex 4, the 
replacement of the p-amino-benzene-moiety in sulfadiazine and in sulfamethoxazol 
by the organometallic [(Cp)Re(CO)3]-complex was intended (Figure 36). 
As shown with a few examples in figure 35, for sulfonamide antibiotics numberous 
derivatives can be introduced while keeping the p-amino-benzol-sulfonamide 
scaffold intact. Therefore, another possibility to incorporate the Re-complex is to 
replace this substituent which is bound opposite to the p-amino-benzol-sulfonamide. 
Following the later strategy, intermediate 45, which was described in section 2.2.2, 
was investigated for this purpose (Figure 36).  
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Figure 36: Lewis structure of possible organometallic antibiotics with internal sulfonamide moiety. Either 
the p-amino-benzene-moiety or the R group can be replaced by the metal complex.  
 
A THF-solution of 5 was mixed with 3-amino-5-methylisoxazole or with 2-
aminopyrimidine respectively. The mixture was gently heated to 40 °C over night. The 
main products were purified by silica gel column chromatography to form colourless 
solids. They were analysed by 1H-NMR, IR (KBr) and crystal structure determination. 
Crystals were grown by slow diffusion of hexane into a solution of the corresponding 
compound dissolved in a minimum of CH2Cl2. Unfortunately, the condensation of 3-
amino-5-methylisoxazole or of 2-aminopyrimidine, with the sulfonyl chloride 5 did not 
lead to the anticipated products (Scheme 41 and 42). During the reaction the 5-Cp-
complex is degraded and complexes 63 or 65 respectively are formed. Interestingly, 
as a side product, the free HCp-ligand 64 was also isolated after silica gel column 
chromatography.  
 
 
Scheme 41: Decomplexation of 5 upon treatment with 3-amino-5-methylisoxazole. The ligand with the 
sulfonamide group on the HCp was isolated as a dimer. 
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The crystallization solution of 63 contained a small amount of DMSO, therefore one 
DMSO molecule was found in the asymmetric unit. 63 crystallized as colourless plates 
and in the triclinic crystal system with space group P-1. The geometry around the 
metal center is slightly distorted octahedral, with angles between neighbouring 
ligands close to 90°. The M-C (CO) bond lengths range from 1.908(3) to 1.920(3). The 
C-O bond distances of the carbonyl ligands of 63 (1.147(3)-1.155(3) Å) compare very 
well to those found for the 5-Cp-complexes discussed in other sections of this thesis. 
The bond length between the central rhenium to the coordinating nitrogen of the 3-
amino-5-methylisoxazole is 2.1758(17) Å in average and to the chloride 2.5060(6) Å. 
 
 
Figure 37: ORTEP plot of 63: Important bond lengths (Å) and angles (°): Re(1)-C(1) 1.899(2), Re(1)-C(3) 
1.913(2), Re(1)-C(2) 1.915(2), Re(1)-N(1) 2.1696(17), Re(1)-N(3) 2.1820(18), Re(1)-Cl(1) 2.5060(6), C(1)-O(1) 
1.155(3), C(2)-O(2) 1.147(3), C(3)-O(3) 1.150(3), C(1)-Re(1)-C(3) 87.45(10), C(1)-Re(1)-C(2) 87.96(10), C(3)-
Re(1)-C(2) 86.80(10), C(1)-Re(1)-N(1) 95.36(8), C(3)-Re(1)-N(1) 176.67(8), C(2)-Re(1)-N(1) 95.06(9), C(1)-
Re(1)-N(3) 93.81(8), C(3)-Re(1)-N(3) 91.34(8), C(2)-Re(1)-N(3) 177.37(8), N(1)-Re(1)-N(3) 86.71(7), C(1)-
Re(1)-Cl(1) 178.16(7), C(3)-Re(1)-Cl(1) 93.76(7), C(2)-Re(1)-Cl(1) 90.72(8), N(1)-Re(1)-Cl(1) 83.47(5), N(3)-
Re(1)-Cl(1) 87.55(5). 
 
 
Scheme 42: Decomplexation of 5 upon treatment with 2-aminopyrimidine. The corresponding ligand 
was not isolated in this case. 
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64 crystallized as orange plates and in the monoclinic crystal system P21/c. The 
geometry around the metal center is distorted octahedral, with angles between 
neighbouring ligands close to 90°. The chloride Cl1 is disordered with the carbonyl 
ligand C3B-O3B. The M-C (CO) bond lengths are almost identical to those in 
compound 63 and range from 1.902(3) to 1.920(6). The C-O bond distances of the 
carbonyl ligands of 64 are within 1.132(6) and 1.150(4) Å. The bond length between 
the central rhenium to the coordinating nitrogen of the 2-aminopyrimidine is 2.232(2) 
Å in average and to the chloride 2.4747(16) Å. 
 
 
Figure 38: ORTEP plot of 65: Important bond lengths (Å) and angles (°): Re(1)-C(2) 1.902(3), Re(1)-C(1) 
1.918(3), Re(1)-C(3) 1.920(6), Re(1)-C(3B) 1.926(19), Re(1)-N(1) 2.228(2), Re(1)-N(2) 2.235(2), Re(1)-Cl(1B) 
2.372(10), Re(1)-Cl(1) 2.4747(16), C(3)-O(3) 1.132(6), O(3B)-C(3B) 1.23(3), C(1)-O(1) 1.144(4), C(2)-O(2) 
1.150(4), C(2)-Re(1)-C(1) 84.98(13), C(2)-Re(1)-C(3) 88.97(18), C(1)-Re(1)-C(3) 87.59(18), C(2)-Re(1)-C(3B) 
89.3(15), C(1)-Re(1)-C(3B) 91.1(14), C(3)-Re(1)-C(3B) 177.9(15), C(2)-Re(1)-N(1) 97.26(11), C(1)-Re(1)-N(1) 
177.30(11), C(3)-Re(1)-N(1) 93.94(15), C(3B)-Re(1)-N(1) 87.4(14), C(2)-Re(1)-N(2) 177.30(11), C(1)-Re(1)-
N(2) 92.35(11), C(3)-Re(1)-N(2) 90.57(16), C(3B)-Re(1)-N(2) 91.1(15), N(1)-Re(1)-N(2) 85.43(9), C(2)-Re(1)-
Cl(1B) 94.0(3), C(1)-Re(1)-Cl(1B) 88.5(3), C(3)-Re(1)-Cl(1B) 5.0(3), C(3B)-Re(1)-Cl(1B) 176.7(15), N(1)-Re(1)-
Cl(1B) 92.9(2), N(2)-Re(1)-Cl(1B) 85.6(2), C(2)-Re(1)-Cl(1) 90.10(11), C(1)-Re(1)-Cl(1) 93.63(11), C(3)-Re(1)-
Cl(1) 178.40(14), C(3B)-Re(1)-Cl(1) 2.6(14), N(1)-Re(1)-Cl(1) 84.88(7), N(2)-Re(1)-Cl(1) 90.42(7), Cl(1B)-
Re(1)-Cl(1) 175.6(2). 
 
Even though the homologous ligand from the degradation with 2-aminopyrimidine 
was not isolated, it was concluded from this observation, that in both reactions the 
desired product might have been formed in a first step. 3-Amino-5-methylisoxazole 
and 2-aminopyrimidine both contain a tertiary nitrogen atom in the hetero cycle, 
which is placed in -position relative to the Cp-ring, after the condensation reaction 
(Figure 39). From this position, its lone pairs can interact with the large orbitals of the 
rhenium metal and compete therefore with the Cp- as a donor and finally lead to 
decomplexation (Figure 39). The sulfone, as an electron withdrawing group, supports 
this decomplexation by destabilizing the complex. The naked fac-{Re(CO)3} core is 
then rapidly trapped by free donors like 3-Amino-5-methylisoxazole or 2-
aminopyrimidine respectively. This assumption is supported by the fact that the 
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chlorine was substituted from the sulfone during the reaction and is found 
coordinated to the Re-center. 
 
 
Figure 39: Decomplexation of the sulfonyl-Cp-complexes. 
 
The two complexes showed the IR-CO-frequencies at 2023 and 1915 cm-1 (for 63) or 
at 2025 and 1916 cm-1 (for 65) respectively. Comparing with [Re(Br)3(CO)3] (1999 and 
1868 cm-1), these values indicate much shorter C-O bond lengths. This can be 
expected, as [Re(Br)3(CO)3] has three negatively charged ligands in the 
coordination sphere. The bromides can transfer more electron density to the metal 
and stimulate -backbonding to the carbonyls, whereas 63 and 65 both have only 
one Cl- coordinated. The two heterocycles complete the coordination sphere in 
each complex. 
The 1H-NMR of 63 (DMSO) shows a singlet at 6.30 ppm for the isochrone amine 
protons. Another singlet at 5.85 ppm indicates the olefinic protons. The methyl groups 
are detected as a singlet at 2.27 ppm. In the 1H-NMR of 65 (DMSO) the aromatic 
protons are observed in three sets of a doublet times doublet patterns at 8.17 ppm, 
at 6.84 ppm and at 6.71 ppm respectively. It can be assumed from the pattern of the 
1H-NMR, that both heterocycles in both compounds are equivalent. 
The isolated ligand 64 revealed in the 1H-NMR (CD3CN) olefinic multiplets at 6.42 
ppm, at 6.18 ppm, 6.05 ppm, 6.04 – 6.02 ppm and at 5.71 ppm respectively, clearly 
indicating the presence of an isomeric mixture. 
 
The synthesis of compound 45 was discussed in section 2.2.2. This compound was 
assessed in a simple test for antibiotic activity on escheria coli bacteria. For this 
purpose, agar solutions were prepared in presence of 0, 50, 100 or 250 g/ml of 
complex 45 and filled into petri dishes. The plates were charged with escheria coli 
bacteria, incubated at 37 °C for 24 to 48 h, and the number of colonies per plate 
was counted. The results clearly show a decreasing number of colonies with 
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increasing concentration of the compound 45 and indicate therefore a moderate 
antibiotic activity (Figure 40). No reference compounds were used for comparison 
with these results. 
 
 
Figure 40: Antibiotic effect of compound 45 on escheria coli. 
 
Another class of well-known antibiotics are penicillins, which are derivatives of the 6-
aminopenicillanic acid (6-APA).[120] Their mechanism of action is referred to the 
inhibition of the bacterial transpeptidase. Structurally, penicillins usually differ in the 
substituents at the amino group of 6-APA, which influences their antibiotic effects by 
swaying their receptor binding affinity or cell membrane penetration ability. 
Penicillin-G for example contains a methylene spacer between the phenyl ring and 
the carbonyl, which is coupled via amide bond to 6'-aminopenicillanic acid (Figure 
41). 
 
 
Figure 41: General structure of penicillins. Depending on R, different groups of penicillins are 
differentiated: benzyl- or phenoxypenicillins, aminopenicillins, acylaminopenicillins, isoxazolylpenicillins. 
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Organometallic ferrocene-containing analogues have been studied for therapeutic 
applications.[122-125] Using the three different Cp-moieties that were introduced in 
section 2.1, carboxylic acids 2, 24a and 27 were coupled to the ethyl ester of 6-APA. 
Therefore, the compounds 66-68 differ in the methylene spacers between the Cp--
chelator and the carbonyl group. With one methylene spacer, 67 represents the 
exact structural analog of penicillin-G. 
 
The Rhenium Complexes II 
The three penicillins were prepared by activation of the carboxylic acid with oxalyl 
chloride and coupling to the previously prepared ethyl ester of 6-APA (Scheme 
43).[126] The esterification of the 6-aminopenicillanic acid was necessary, because of 
solubility issues. Attempts, to use the unprotected 6-APA in aqueous acetone failed, 
due to the low solubility of the rhenium complexes. Owing to the insolubility of 6-APA 
in other solvents like CH2Cl2 or THF, the ester of 6-APA was used. However, harsh basic 
or acidic conditions, which are needed for ester hydrolysis, lead to decomposition of 
the -lactam ring of the amino penicillanic acid derivative. Therefore, the 
deprotection of the pharmacologically inactive compounds 66-68 to form the active 
species was not achieved. 
Compounds 66-68 were characterized by ESI-MS and NMR. All three compounds 
revealed in their ESI-MS spectrum (MeOD) the [M+H3O]+ and the [M+OH]-. The shift of 
the -proton of the penicillanic acid next to the amide nitrogen and also the Cp--
signals in the 1H-NMR (MeOD) are indicative for the compounds. The -proton of 6-
APA-OEt shifted upon binding to the carboxylic acid for all compounds by 
approximately 0.5 ppm towards lower field. The Cp--signals were observed as 
multiplets, instead of the often found pseudo triplets due to the adjacent stereo 
center at the derivative.  
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Scheme 43: Synthetic conditions: i) oxalyl chloride, CH2Cl2. ii) 6-aminopenicillanic acid ethyl ester, THF, 
66-71 %. 
 
The Ligands 
In order to prepare the homologous 99mTc-compounds, the uncoordinated ligand of 
68, namely 69 was synthesized. Starting from acid 20, the analogous synthetic 
procedure to the Re-compounds lead to the formation of 69 (Scheme 44).  
The compound was analysed by ESI-MS (CH3OH) and NMR. Similar to the Re-
complexes, the [M+H3O]+-adduct was detected in the ESI-MS. In the 1H-NMR, also 
similar to the Re-complexes, the signal for the -proton of 6-APA-OEt shifted upon 
binding to the carboxylic acid by approximately 0.5 ppm towards lower field and 
can be found at 4.55 ppm. 
 
 
Scheme 44: Synthetic conditions: i) oxalyl chloride, CH2Cl2. ii) 6-aminopenicillanic acid ethyl ester, THF, 
64 %. 
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The Technetium Complexes 
As mentioned above, harsh basic or acidic conditions lead to decomposition of the 
-lactam ring of the amino penicillanic acid derivative. The same was observed 
when standard labeling conditions were applied with 69. The high temperatures lead 
to the formation of a multitude of products. The desired 99mTc-analog of 68 was 
therefore not obtained. 
 
Recapitulatory, the synthesis of organometallic antibiotics with an internal 
sulfonamide group, as a structural analogue of Sulfadiazine or of Sulfamethoxazol 
respectively, failed. Mechanistically, a degradation of the Re-complex during the 
coupling reaction is supposed (Figure 39). However, complex 45 was described in 
section 2.2.2 and contains the p-amino-benzol-sulfonamide scaffold, which is 
generally found in this class of antibiotics. 45 was assessed in a simple test for 
antibiotic activity and shows moderate activity against escheria coli. 
Furthermore, three different organometallic derivatives of 6-APA-ethyl ester were 
prepared. Decomposition of the -lactam ring occurred during ester hydrolysis, 
therefore the active antibiotics were not isolated. For the same reasons, the 
corresponding 99mTc-complexes were not obtained. 
 
2.3.4 Catecholamines 
 
Epinephrine (adrenaline), dopamine and norepinephrine (noradrenaline) structurally 
belong to the class of catecholamines (Figure 42). Physiologically they have several 
functions. Binding to adrenergic receptors, they have an impact on the 
cardiovascular system or act as hormones and as neurotransmitters.[127] 
Dopamine-like receptors or noradrenaline transporters on presynaptic terminals have 
been used as targets for PET-imaging.[128] Using 99mTc-labeled derivatives of 
catecholes, the imaging of adrenergic receptors in brain and in the cardiovascular 
system using SPECT (Single Photon Emission Computed Tomography) is aimed. 
 
Results & Discussion 2013 
 
93 
 
 
Figure 42: Different catecholamines. A) Epinephrine. B) Norepinephrine. C) Dopamine. 
 
The Rhenium Complexes I 
A number of lipid-soluble molecules can diffuse though the BBB and enter the brain 
in a passive manner.[129] As a very lipophilic and small fragment, the [(Cp)Re(CO)3] is 
therefore a promising candidate to cross the BBB. Therefore, 2 was derivatized with 
norepinephrine to form compound 70. Coupling was performed by activation of 2 
with PFPTFA,[63] followed by addition of L-epinephrine in DMF (Scheme 47). 
 
 
Scheme 45: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, DMF, 88 %. ii) L-noradrenaline, 
NEt3, DMF, 76 %. 
 
Similar to 66-68, the aromatic Cp--signals in the 1H-NMR (DMSO) were observed as 
multiplets from 6.34 to 5.64 ppm, due to the stereo center in close proximity at the 
derivative. The amide proton was detected as a triplet at 8.29 ppm and the phenyl 
signals as a multiplet from 6.75 to 6.52 ppm.  
 
The Ligands 
Thilele's Acid was activated with PFPTFA in DMF in quantitative yield.[63] The addition 
of two equivalents of L-noradrenaline together with an excess of NEt3 led to the 
formation of compound 71 (Scheme 46). 
Two multiplets from 6.65 – 6.60 and from 6.36 – 6.33 ppm respectively for the olefinic 
protons in the 1H-NMR spectrum of 71 (MeOD) indicated the formation of the 
product. Like the Re-compound above, the signals show a complicated multiplet 
pattern, due to the stereocenter, which is introduced next to the olefinic protons.  
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Scheme 46: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, DMF, 88 %. ii) L-noradrenaline, 
NEt3, DMF, 21 %. 
 
The Technetium Complexes 
As shown in section 2.2.1 with pendent hydroxamic acids, chemically labile 
functional groups, that are able to coordinate to the fac-{99mTc(CO)3}-core compete 
with Thiele's Acid derivatives for complex formation. They represent therefore 
limitations to this synthetic approach. Comprising an aromatic diol-moiety, the 
labeling of 71 with [99mTc(OH2)3(CO)3], therefore lead to the formation of a multitude 
of undefined products. Similar to the hydroxamic acids, coordination to the 99mTc-
core and formation of a polymeric structure or metal oxidations is assumed. 
 
In summary, catecholamine derivative 70 was synthesized as a model compound for 
adrenergic receptor targeting molecules. The corresponding Thiele's Acid derivative 
71 was prepared analogously. 99mTc-labeling was not successful due to competing 
coordination via the pendend diol of the catechol. 
Further investigations on this topic should therefore include the protection of the 
pendent diol group before 99mTc-labeling and the biological investigation of the 
corresponding Re-compound. 
 
2.3.5 Asymmetric Thiele's Acid-Derivatives  
 
Labeling of bioactive functionalized ligands with the fac-{99mTc(CO)3}+-core was 
significantly simplified with the introduction of the Isolink Kit, allowing the fast 
formation of the [99mTc(OH2)3(CO)3]+ precursor.[27, 28] [(Cp-R)99mTc(CO)3]-type 
complexes are accessible via metal mediated retro Diels-Alder reaction from amide 
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coupled Thiele’s Acid derivatives and [99mTc(OH2)3(CO)3]+ or [99mTcO4]- in water.[61, 63] 
This reaction allowed to transfer the biological advantages of these complexes to 
99mTc-labelled compounds and therefore paved the way for diagnostic applications. 
Introducing suitable biologically active residues R, this approach can be regarded as 
an applicable easy-to-use protocol for routine applications in nuclear medicine.[5, 46, 
64] 
So far, HCp-R-dimers always contained two identical substituents R, which led to the 
generation of one imaging agent [(Cp-R)99mTc(CO)3]. Mechanistically, it was 
supposed the carbonyl oxygens to serve as a preliminary anchoring group for the 
metal core, which is followed by a retro Diels-Alder reaction, deprotonation and 5-
coordination of the Cp-ring (see also section 2.1.1).[61] If this mechanism is true, either 
the bridged or the non-bridged Cp of the dimer could in principle be preferred for 
metal coordination, unless both parts are considered as equivalent, in the transition 
state.[93] To gain deeper insights into the mechanism of the metal mediated retro 
Diels-Alder reaction, the asymmetric derivatives of Thiele’s Acid 73-75 were 
synthesized and adapted to the usual labeling conditions for type of compounds.[93] 
 
The Ligands 
Compounds 73-75 were prepared from one single isomer of Thiele’s Acid (Scheme 
47). [93] Products were obtained after activation of both carboxylic acids with PFPTFA 
and coupling to the appropriate amines. Depending on the amount of amine that 
was used and if a base was present or not, single- or di-substituted products were 
obtained. Mono substituted derivatives were mainly observed as their 
pentafluorophenyl-esters (PFP) at the bridged side of the HCp-dimer which could be 
isolated by silica gel column chromatography (72). Side products that were formed 
during the synthesis were not isolated or characterized. However, HPLC-analysis 
during the reaction showed the formation of two minor products, which were 
assumed to be the double substituted and as the inverted mono substituted 
derivative. This observation indicated that the unbridged side of the PFP-ester of 
Thiele's Acid reacts faster with primary alkyl-amines than the bridged side. This effect 
was exclusively observed with the PFP-activated Acid. Stronger activation methods 
did not show this differentiated reaction pattern. Subsequent addition of the second 
substituent along with triethylamine led to the final products 73-75 (Scheme 47). 
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Scheme 47: Synthetic conditions: i) Pentafluorophenyl trifluoroacetate, DMF. ii) 7-aminoheptanoic acid, 
DMF, 34 %. iii) 8-aminocaprylic acid, triethylamine, DMF, 32 %. iv) benzyl alcohol, triethylamine, DMF, 9 %. 
v) 4-Aminomethylbenzensulfonamide, triethylamine, DMF, 80 %. 
 
The signals for the olefinic protons in the 1H-NMR spectrum of 72 (MeOD) were 
observed at 7.35 and at 6.38 ppm. Comparing these values with the ones for starting 
compound Thiele's Acid (6.86 and 6.51 ppm) or with other derivatives, the signal for 
the proton next to the electron withdrawing PFP-ester is strongly shifted towards lower 
field. 
 
The Technetium Complexes.  
In extension to the labeling strategy of symmetric HCp-R-dimers, the asymmetric 
derivatives of Thiele’s Acid, 73-75 were treated accordingly.[93] All compounds 
showed the formation of two main peaks in the HPLC trace when reacted with 
[99mTc(OH2)3(CO)3]+. Proving, that no site preference for metal coordination of the Cp 
fragments in HCp-R-dimer is present, the [(Cp-R)99mTc(CO)3]-products were formed 
nearly in a 50:50 ratio. Demonstrating the versatile possibilities of these kind of 
complexes for medicinal inorganic chemistry and extending the labeling strategy of 
metal mediated retro Diels-Alder reaction, this observation allows now for the 
synthesis of two different imaging agents with one single substrate and in one pot. 
Again, the ligand concentrations were millimolar and reactions were performed at 
90 °C in aqueous saline. Besides the two main products 43 and 62, the labeling of 73 
generated a small portion (7 %) of [99mTcO4]- (Scheme 48). Compounds 43 and 62 
gave a product ratio of 45:55 (62:43), indicating no clear preference of complex 
formation concerning localization of the derivatives at the unbridged or at the 
bridged side of the HCp-dimer. Coinjection of the Re-congeners 32 and 53 
respectively clearly confirmed the nature of the products. 
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Scheme 48: Bottom-up trace: -trace of the two-step labeling of 73 with [99mTc(OH2)3(CO)3]+. Top-down 
trace: the UV-trace of Re-compounds 32 and 53. 
 
A very similar result was observed with 74, containing two different aliphatic chain 
lengths but the same conjugation to Cp (Scheme 49). Two products in a similar ratio 
of 45:55 (43:76) were obtained as before, confirming the lack of preference for one 
of the sides in the Thiele's acid dimers. 
 
 
Scheme 49: Bottom-up trace: -trace of the one-pot labeling of 74 with [99mTcO4]-. Top-down trace: the 
UV-trace of Re-compounds 30 and 32. 
 
Compound 75 contains an amide bound substituent on one side and an ester group 
on the other. Even though the labeling of 75, similar to 73 and 74, revealed two 
products, the benzyl ester [(Cp-COOCH2C6H5)99mTc(CO)3] was not obtained but 
hydrolyzed during the process. One of the products was identified as the acid 
[(CpCOOH)99mTc(CO)3] 3.[70] The second peak proved to be 43, the 99mTc-analogue 
32. The product ratio was nearly 50:50 (Scheme 50). 
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Scheme 50: Top-down trace: -trace of the one-pot labeling of 75 with [99mTcO4]-. Bottom-up trace: the 
UV-trace of Re-compounds 2 and 32. 
 
Reactivities of the carboxylic acid groups in Thiele's Acid are not equivalent at the 
bridged and at the unbridged side. By activation with PFPTFA and addition of 
aliphatic primary amines like 7-aminoheptanoic acid, the monosubstituted product 
72 can be isolated, when no base is used during the reaction. Mono substituted 
derivatives are mainly observed as their pentafluorophenyl-esters (PFP) at the 
bridged side of the HCp-dimer. This observation indicates that the unbridged side of 
the PFP-ester of Thiele's Acid reacts faster with primary alkyl-amines than the bridged 
side. Subsequent addition of the second substituent along with triethylamine led to 
asymmetrically derivatized Thiele’s Acid.  
Using these derivatives, two different imaging agents of [(Cp-R)99mTc(CO)3] (R = 
potential targeting vector) can be generated in one-pot and from one substrate. 
Introducing appropriate vectors, combined imaging of two targets from one 
substrate is now possible. 
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2.4 Conclusions & Outlook  
 
Structurally, a bifunctional chelator (BFC) can be regarded as consisting of three 
building blocks:  
 a chelator is the part that binds to the metal core, the actual ligand. 
 a linker, which consists of a functional group, that enables the coupling of a 
spacer.  
 a targeting vector, which is bound to the spacer and contains a biologically 
active function. 
In the course of the present thesis, the linker, the spacer and the targeting vector 
were varied and investigated chemically as well as biologically. 
 
Carboxylic acid derived Cp-compounds have been described in literature in the 
form of the uncoordinated ligand and as 5-coordinated Re- or 99mTc tricarbonyl 
complexes (1, 2 and 3).[61, 70, 72-74] The compounds allow a wide range of synthetic 
manipulations at the carboxylic acid portion, even in aqueous solvents.  
A variety of organic and inorganic amide coupled derivatives like arylsulfonamides, -
sulfamides and -sulfamates for the targeting of human carbonic anhydrase IX, 
hydroxamic acids acting as HDAC-inhibitors, organometallic antibiotics or catechol 
amine derivatives have been prepared.  
 
The sulfonic acid of the [CpRe(CO)3]-complex and some limited derivatives are 
available according to literature procedure.[71, 80] The protonated uncoordinated 
HCp-sulfonic acid, which was also described in literature,[80] was not obtained. 
Therefore, the corresponding 99mTc complexes were also not synthesized in the 
course of this thesis.  
The aryl-sulfone-dimer 8 was prepared and its labeling behaviour with 99mTc was 
studied. Product formation was only observed in a microwave synthesis at 130 °C. 
However, the authenticity of the product must still be confirmed by comparison with 
the corresponding rhenium complex.  
No biological active derivatives of the form Cp-SO2-R have been prepared and will 
be part of further investigations. 
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The nitro-derivatized Cp-compound 10 was prepared along literature procedure and 
is readily soluble and stable in water.[65, 73] However, the complexation of 10 with the 
99mTc-core was not observed and needs further improvement. 
 
The organometallic aniline analogue [(CpNH2)Re(CO)3] (11) was prepared 
according to literature.[69] Synthetically, it can be treated like aniline and nucleophilic 
coupling reactions are suitable methods for derivatization. Coupling to suitable 
targeting vectors, organometallic antibiotics, HDAC-inhibitors or carbonic anhydrase 
inhibitors were prepared.  
In situ derivatized HCp-amines in their dimeric form were prepared from Thiele's Acid 
applying the Curtius Rearrangement. The reaction progress was investigated by time 
resolved IR-measurement and by 1H-NMR. The 99mTc-labeling behaviour of 16a-b is 
subject of ongoing investigations. 
 
With the synthesis of the uncoordinated and protonated HCp-compounds 17 and 19, 
containing methylene groups between the HCp and the carboxylic acid, a new way 
of altering the spacer in a BFC has been introduced; before and after the coupling 
function. 17 undergoes slow Diels-Alder dimerization at room temperature. Keeping 
17 at -20 °C, beside the dimer 23, the rearrangement product 22 is formed. The 
dimerization behaviour of 19 was not investigated. Derivatisation of the carboxylic 
acid 18 by amide coupling with primary amines leads to rearrangement of the 
double bonds and the formation of a cyclopentene ring, as observed with 
comounds 21a/b. Therefore cyclopentadienyl amides of 18 were not accessible. 
Labelling experiments of 18 and 20 with [99mTc(H2O)3(CO)3]+ proved that the 
carboxylic acid function in - or in -position, with respect to the HCp-ring are still 
close enough, to allow anchoring of the metal center by the carboxylic acid portion. 
Therefore, bringing the metal in close proximity, 5-coordination of the HCp-portion is 
simplified. However, conversion rates of the 99mTc starting compounds were very 
different for the ligand 18 compared to 20, which is in accordance with the 
increasing distance of the anchoring group to the HCp-moiety. Similar to Thiele's 
Acid, the dimer 23 can undergo metal mediated retro Diels-Alder reaction and form 
the same product as obtained with the monomer 18. The mechanism however is 
unclear.  
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24a was synthesized similar to the 99mTc-compound 28 using ligand 18 with 
[Re(Br)3(CO)3]2- in water. The Re-complex 27 was synthesized along Horner-
Wardsworth-Emmons olefination. 
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3. Experimental 
 
3.1 General Remarks 
 
Reactions were carried out in dried glassware under nitrogen atmosphere. Solvents 
were dried using standard techniques and stored over molecular sieves. Human 
Carbonic Anhydrase II (hCAII) and all chemicals were obtained from commercial 
sources and used without further purification. 2,[70] 11,[69] sulfamoyl chloride,[130] 4, 5, 
6,[71] 7 and 8[68] were prepared according to literature procedures. 10,[65] 18[66] and 
20[67] were prepared according to literature procedures with slight modifications. 1H-
NMR and 13C-NMR spectra were recorded on a Bruker Advance 400 MHz or 500 MHz 
spectrometer. Mass spectra were measured on a Bruker Esquire HCT (ESI) instrument. 
IR spectra were recorded as KBr pellets on a Perkin-Elmer BX II IR spectrometer. RP-
HPLC was performed on a Merck Hitachi LaChrom L7200 tunable UV detector and a 
radiodetector, separated by a Teflon tube, which causes about a 0.4 – 1.0 min delay 
compared to UV/vis detection. UV/vis detection was performed at 250 nm. The 
detection of radioactive 99mTc complexes was performed with a Berthold LB 507 
radiodetector equipped with a NaI(Tl) scintillation detector. The traces shown in this 
section are crude and unpurified samples directly taken from the reaction mixture. 
Analytical separations were performed on a Nucleosil C-18 column (100 Å, 5 m, 
250×4 mm) and were eluted with a flow rate of 0.5 ml min−1 using 0.1 % TFA in H2O 
(solvent A) and methanol (solvent B) as eluents with a variable gradient (0–3 min, 100 
% A; 3–3.1 min, 0 to 25 % B; 3.1–9 min, 25 % B; 9–9.1 min, 25 % B to 34 % B; 9.1–20 min, 
34 % B to 100 % B; 20–25 min, 100 % B; 25–25.1 min 100 % B to 100 % A; 25.1–30 min 100 
% A).  
For carbonic anhydrase inhibitors, absorbance of the DMSO solution of formazan in 
the cytotoxicity study was determined using a plate spectrophotometer (Power 
Wave Xs; Bio-Tek). Statistical analysis of the pH-studies were performed with Graph 
Pad Prism version 5.01 for windows (Graph pad software 2007, CA, USA). For all tests, 
P < 0.05 was considered significant. Antibodies for western blot were purchased from 
Novus Biologicals for CA IX, Sigma for actin and, secondary antibodies from Biorad. 
Membranes were developed using the SuperSignal WetsPico Substrate kit from 
Pierce, Rockford according to the manufacturer’s instructions. 
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For biological studies of the HDAC inhibitors, Dulbecco’s Modified Eagle Medium 
(DMEM) with GlutaMax-I, fetal bovine serum (FBS), penicillin/streptomycin antibiotic 
solution, phosphate-buffered saline (PBS), and trypsin were purchased from Gibco 
Invitrogen Co. (Alfagene, Portugal). Methanol, DMSO, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), and trypan blue were bought from 
SigmaChemical Co. (Sigma, Portugal). Suberoylanilide hydroxamic acid (SAHA) was 
purchased from Cayman Corporation. For the determination of the IC50-values, 
absorbance at 570 nm was measured using a microplate spectrophotometer 
(PowerWave Xs, Bio-Tek Instruments, Winooski, VT, USA). 
Crystallographic data were collected at 183(2) K with Mo Kα radiation (λ = 0.7107 Å) 
that was graphite-monochromated on a Stoe IPDS diffractometer or an Oxford 
Diffraction CCD Xcalibur system with a Ruby detector respectively. Suitable crystals 
were covered with oil (Infineum V8512, formerly known as Paratone N), mounted on 
top of a glass fibre or a CryoLoop™ (Hampton Research) and immediately 
transferred to the diffractometer. In the case of the IPDS, a maximum of eight 
thousand reflections distributed over the whole limiting sphere were selected by the 
program SELECT and used for unit cell parameter refinement with the program 
CELL.[131] Data were corrected for Lorentz and polarisation effects as well as for 
absorption (numerical). In case of the Oxford system, the program suite CrysAlisPro 
was used for data collection, multi-scan absorption correction and data 
reduction.[132] Structures were solved with direct methods using SIR97[133] and were 
refined by full-matrix least-squares methods on F2 with SHELXL-97.[134] The hydrogen 
atoms of the NH2 units were localized and their positions freely refined. All other 
hydrogen atoms were placed on calculated positions. The structures were checked 
for higher symmetry with help of the program Platon.[135] 
 
3.2 Biological Evaluation 
 
3.2.1 Carbonic Anhydrase Inhibitors 
 
In vitro: cells and culture conditions 
The human cervical adenocarcinoma HeLa and human breast adenocarcinoma 
MDA MB 231 cell lines were maintained in DMEM (Invitrogen) supplemented with 10 
% fetal calf serum (FBS) in a humidified atmosphere of 5 % CO2 at 37 ºC. The human 
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colon adenocarcinoma cell line HT29 was maintained in McCoy´s (Invitrogen) 
supplemented with 10 % FBS in a humidified atmosphere of 5 % CO2 at 37 ºC. 
 
In vitro: cytotoxicity assays  
Cytotoxicity of rhenium complexes 52 and 53 was evaluated using a colorimetric 
method based on the tetrazolium salt MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), which was reduced by viable cells to yield purple 
formazan crystals. Cells were seeded in 96-well plates at a density of 15 to 50 x 104 
cells per well, were allowed to attach overnight and then incubated for 24 h in the 
presence of various concentrations of the complexes. At the end of the incubation 
period the media was removed and the cells were incubated with MTT (0.5 mg/mL) 
for 3h at 37 ºC and 5 % CO2. The purple formazan crystals formed inside the cells 
were then dissolved in DMSO by thorough shaking, and the absorbance was 
measured at 570 nm. Each test was performed with at least six replicates and 
repeated at least 2 times. The result was expressed as percentage of the surviving 
cells in relation with the control. 
 
In vitro: pH studies 
Cells were platted in 24 well plates at a density of 1 x 105 cells per well, one day 
before the start of the experiment. Cells were then incubated 24 h at 37ºC with 1mM 
and 500 M of the sulfonamides or metal complexes under normoxia (air with 5 % 
CO2) or hypoxia (1 % O2, 5 % CO2 and residual N2 in a sealed hypoxic culture 
chamber). 
The extracellular acidification of cell lines was measured by inserting a pH probe into 
the culture medium, at the beginning and at the end of each experiment. Each test 
was performed with 4 replicates and repeated at least 2 times.  
 
In vitro: western blot  
Western blot experiments were performed to evaluate the levels of expression of CA 
IX. Hela, HT29 and MDA MB231 cells were lysed in Laemmli sample buffer (1.5 % SDS, 
10 % glycerol, 0.5 mM dithiothreitol, 31.25 mM Tris, pH 6.8 and 0.001 % bromophenol 
blue). The total protein content was determined by using the RCDC Protein Assay Kit 
(Biorad) and aliquots of protein (50 μg) from each sample were analysed using 
standard western blot procedures. Briefly, protein extracts were subjected to 
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electrophoresis on a 10 % SDS-polyacrylamide gel and transferred electrophoretically 
onto nitrocellulose membranes. The blots were blocked with PBS-T containing 5 % 
nonfat dry milk for 1 h. Then, the blotting membranes were incubated with primary 
antibodies against CA IX (1:2000, rabbit polyclonal, Novus Biologicals) and actin 
(1:8000, mouse monoclonal, Sigma) overnight. Membranes were washed with PBS-T 
and incubated for 1 h with secondary antibodies (goat anti-mouse and goat anti-
rabbit IgG-HRP, Biorad) diluted 1:3000. Finally, membranes were developed using the 
SuperSignal WetsPico Substrate kit (Pierce, Rockford, IL) according to the 
manufacturer’s instructions. 
 
In vitro: hCA inhibition 
An Applied Photophysics stopped-flow instrument was used for assaying the CA 
catalysed CO2 hydration activity.15 Phenol red (0.2 mM) was used as indicator, 
working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.4) and 20 
mM NaBF4 (in order to keep the ionic strength constant), following the initial rates of 
the CA-catalyzed CO2 hydration reaction for a period of 10-100 s. The CO2 
concentrations ranged from 1.7 to 17 mM for the determination of the kinetic 
parameters and inhibition constants. For each inhibitor, at least six traces of the initial 
5-10 % of the reaction have been used for determining the initial velocity. The 
uncatalyzed rates were determined in the same manner and subtracted from the 
total observed rates. Stock solutions of inhibitor (10 mM) were prepared in distilled-
deionized water and dilutions up to 0.01 nM were done thereafter with distilled-
deionized water. Inhibitor and enzyme solutions were preincubated together for 15 
min at room temperature prior to assay, in order to allow formation of the E-I 
complex. The inhibition constants were obtained by non-linear least-squares methods 
using PRISM 3, whereas the kinetic parameters for the uninhibited enzymes were 
obtained from Lineweaver-Burk plots and represent the mean from at least three 
different determinations. All CAs were recombinant proteins obtained as reported 
earlier by these groups.[136-141] 
 
In vivo: cell culture, animals and tumor model 
Biodistribution of the radiolabeled compounds 61 and 62 at 1h and 4h p.i. was 
evaluated in HT-29 xenograft mice bearing CAIX-expressing tumors.  
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Exponentially growing colorectal HT-29 adenocarcinoma cells were cultured in 
McCoy´s medium (Invitrogen) supplemented with 10 % fetal bovine serum as 
described above.[5]  
Animal experiments were performed using adult BaLB/c (nu/nu) female mice with an 
average body weight of 30 g (6-8 weeks). The animal facilities and experiments were 
in accordance with Portuguese and European regulations. The animals were housed 
in a temperature- and humidity-controlled room with a 12h light/12h dark schedule. 
HT-29 cells were resuspended with 50 % Basement Membrane Matrix (Matrigel™ BD 
Biosciences, ref 356234) in PBS and were subcutaneously injected into the lateral 
flank of the animal (107 cells per animal).  
 
When tumors reached an average volume of 500 mm3 (9 and 14 days after 
inoculation for 1h and 4h biodistribution of 61 and 62, respectively), the isoflurane-
anesthetised animals were intravenously injected with purified 99mTc-labelled 
compounds (61 or 62) into their retro-orbital sinus. 
Mice were killed by cervical dislocation at 1 and 4h respectively after injection. The 
injected activity and the activity in the killed animals were measured using a dose 
calibrator (Curiemeter IGC-3, Aloka, Tokyo, Japan). The difference between the 
injected radioactivity and the activity that was measured in the killed animals was 
assumed to be excretied by the mice. Tumors and normal tissues of interest were 
dissected, rinsed to remove excess blood, weighed, and their radioactivity was 
measured using a -counter (LB2111, Berthold, Germany). The uptake in the tumor 
and in healthy tissues of interest was calculated and expressed as a percentage of 
the injected activity per gram of tissue ( %IA/g). For blood, bone, muscle, and skin, 
total activity was estimated assuming that these organs constitute 6, 10, 40, and 15 % 
of the total body weight, respectively.  
 
In vivo: stability 
The stability of the complexes was assessed by urine, and murine serum RP-HPLC 
analysis. The samples were taken 1 h post injection. The urine collected at the time of 
sacrifice was filtered through a Millex GV filter (0.22 m) before RP-HPLC analysis. 
Blood collected from mice was centrifuged at 3000 rpm for 15 min at 4 ºC, and the 
serum was separated. The serum was treated with ethanol in a 2:1 (v/v) ratio to 
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precipitate the proteins. After centrifugation at 3000 rpm for 15 min at 4 ºC, the 
supernatant was collected and analysed by RP-HPLC. 
 
In vivo: western blot analysis of tumor samples 
Quantification of CAIX expression in BaLB/c nude mice bearing HT-29 tumors was also 
carried by western blot experiments. Tumors were excised, rinsed in PBS and 
homogenized with ice cold Cell Lytic-MT Extraction reagent (Sigma) supplemented 
with Complete protease inhibitor cocktail tablets (Roche Applied Science) using a 
Dounce glass apparatus. Lysates were transferred to microcentrifuge tubes and 
centrifuged at 14000g for 10 min at 4 °C to pellet the cellular debris and the 
supernatants removed for further use. 
The total protein concentration was determined by the DC Protein Assay Kit (BioRad) 
with bovine serum albumin as standard. Aliquots of protein (50 μg) from each sample 
were analysed using standard western blot procedures.[5] Protein extracts were 
subjected to electrophoresis on a 10 % SDS-polyacrylamide gel and transferred 
electrophoretically onto nitrocellulose membranes. The blots were blocked with PBS-T 
containing 5 % nonfat dry milk for 1 h. Then, the blotting membranes were incubated 
with primary antibodies against CA IX (1:2000, rabbit polyclonal, Novus Biologicals) 
and actin (1:8000, mouse monoclonal, Sigma) overnight. Membranes were washed 
with PBS-T and incubated for 1 h with secondary antibodies (goat antimouse and 
goat anti-rabbit IgG-HRP, Biorad) diluted 1:3000. Finally, membranes were developed 
using the SuperSignal West Pico Substrate kit (Pierce, Rockford, IL) according to the 
manufacturer’s instructions. 
 
3.2.2 HDAC Inhibitors 
 
Tumor cell lines 
The human breast carcinoma MCF-7, prostate carcinoma PC3, cervical carcinoma 
HeLa, vulva epidermal carcinoma A43 and melanoma A375 cell lines as well as the 
murine melanoma B16F1cell line used in this study were grown in Dulbecco’s 
Modified Eagle Medium (DMEM) containing GlutaMax-I supplemented with 10 % 
heat-inactivated foetal bovine serum (FBS) and 1 % penicillin/streptomycin antibiotic 
solution (all from Gibco, Alfagene, Lisbon). Cells were cultured in a humidified 
atmosphere of 95 % air and 5 % CO2 at 37 °C (Heraeus, Germany), with the medium 
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changed every other day. The cells were adherent in monolayers and, when 
confluent, were harvested from the cell culture flasks with trypsin EDTA (Gibco, 
Alfagene, Lisbon) and seeded farther apart. 
 
Cytotoxic activity 
The antiproliferative activity on tumor cells was evaluated using a colorimetric 
method based on the tetrazolium salt MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide]), which is reduced in viable cells to yield purple 
formazan crystals. The optimal plating density of each cell line, which ensures 
exponential growth throughout all of the experimental period, was first optimized. 
MCF-7 (15× 103 cells), HeLa (9 × 103 cells), A431 (7.5 × 103 cells), A375 (7 × 103 cells), 
PC3 (6 × 103 cells) and B16F1 (6 × 103 cells) cells were plated in 96-well sterile plates in 
150 μL of culture medium per well and incubated for 24 h at 37 ºC/5 % CO2 for 
seeding. Then the cells were incubated with various concentrations of the 
compounds 31, 33, 36, 38, 40 and SAHA for 72 h at 37 °C/5 % CO2, dissolved in 
methanol and diluted in the culture medium (methanol final concentration 0.025 % 
and 0.1 % respectively). The effect of the vehicle solvent (methanol) on the growth of 
these cell lines was evaluated in all experiments by exposing untreated control cells 
to both concentrations of methanol used (0.025 % and 0.1 %). 
At the end of the incubation period, the compounds were removed and cells were 
washed with 200 μL of PBS. Cell viability was then determined by incubating cells with 
200 μL of MTT solution (0.5 mg mL−1 in PBS). After 3 h at 37 °C/5 % CO2, the solution 
was removed and the purple formazan crystals formed inside the cells were 
dissolved in 200 μL DMSO by thorough shaking. For each test compound and for 
each cell line, a dose−response curve was obtained. The cytotoxic effects of ligands 
and Re-complexes were quantified by calculating the compound concentration 
inhibiting tumor cell growth by 50 % (IC50), based on non-linear regression analysis of 
dose–response data (GraphPad Prisma 5 software). For comparison suberoylanilide 
hydroxamic acid (SAHA), was evaluated under the same experimental conditions. 
All compounds were tested in at least two independent studies with eight replicates 
for each concentration. 
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3.3 hCAII Crystallization 
 
Applying similar conditions as Behnke et al,[142] crystals were grown with the hanging 
drop vapor diffusion method. 1 l of protein solution and 1 l of precipitant (2.4 M 
(NH4)2SO4, 0.1 M Tris-HCl at pH 7.5, 1 mM 4-(hydroxymercuri) benzoic acid sodium salt 
and 5.1 % vol. DMSO) were mixed. The protein solution consisted of hCA II dissolved in 
unbuffered water at 20 mg/ml. Good crystals were obtained after four weeks at 298 
K, two weeks at 277 K then again four weeks at 298 K. The obtained crystals were 
soaked for four weeks at 298 K with 0.25 mg of solid inhibitor. 
One crystal was covered with oil (Infineum V8512, formerly known as Paratone N) 
and the mother liquid was removed as gently as possible by moving the crystal 
through the oil. The crystal was frozen by dropping into liquid nitrogen. Single crystal 
diffraction data till 1.2 Å resolution were recorded at 100 K at the Swiss Light Source 
(Paul Scherrer Institute, Villigen, Switzerland) using the X06DA beamline (λ = 1 Å) 
equipped with a mar225 mosaic CCD detector. The data sets were indexed and 
integrated with XDS.[143] The structure was solved by molecular replacement with 
Phaser[144] using the GUI of CCP4i[145] and pdb entry 3IQK.[146] Refinement of the 
structure was done with SHELXL[134] and inspection of the model and electron 
densities with COOT.[147] The restraints for the rhenium complexes were taken from the 
corresponding small molecule structures. Atomic coordinates and diffraction data 
have been deposited in the RCSB Protein Data Bank under accession code 3RJ7. 
Pictures were drawn with the help of ccp4mg [148] and Pymol.[149] 
The electron density of complex 53 could be traced till the terminal carbonyl units. 
Additionally, two high residual electron densities were found nearby and assigned to 
minor disordered rhenium positions. The ratio of the three conformations was refined 
as 6:2:2, summing up to full occupancy. The benzyl-sulfonamide part of the complex 
is not disordered. One of the minor conformations is near PHE131 with a closest 
distance of the found rhenium position to PHE131, CZ, of 1.21 Å. For this conformation 
of the complex, the phenyl ring of PHE131 must be oriented away from the complex. 
For both minor conformations, it was impossible to locate the electron density of the 
light elements. 
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Figure 43: Ribbon presentation of hCAII with bound 53 to the zinc center (zinc in magenta). The minor 
conformations of 53 with their found two disordered Rhenium centers (in grey, 20 % probability each) 
and the side chain group of PHE131 are also shown. 
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3.4 The Re-complexes 
 
3.4.1 [Re(CO)3Cp-NHSO2R] 
 
(12) 
[(Cp-NH2)Re(CO)3] (50 mg, 0.142 mmol) was dissolved in 10 ml of dry CH2Cl2 
containing pyridine (11.5 l, 0.142 mmol). Benzenesulfonyl chloride (23.8 l, 0.186 
mmol) was added and the solution was stirred for 10h at room temperature. Water 
was added and the mixture was extracted three times with fresh CH2Cl2. The 
combined organic layers were dried over Na2SO4 and evaporated under reduced 
pressure to give 12 (95 %). No further purification was necessary. 
Calc. for Mr (C14H10NO5ReS) 490.5; ESI-MS [m/z] (CH3OH): 489.9 [M-H]-; 1H NMR (500 
MHz, CDCl3, in ppm): 7.78 (m, 2H, Ar), 7.58 (m, 2H, Ar), 6.17 (s, 1H, NH), 5.23 (m, 2H, 
Cp), 5.03 (m, 2H, Cp). 
 
(13) 
[(Cp-NH2)Re(CO)3] (50 mg, 0.142 mmol) was dissolved in 10 ml of dry CH2Cl2 
containing pyridine (11.5 l, 0.142 mmol). p-Toluenesulfonyl chloride (35.4 mg, 0.1855 
mmol) was added and the solution was refluxed for 10h. After cooling to room 
temperature, water was added and the mixture was extracted three times with fresh 
CH2Cl2. The combined organic layers were dried over Na2SO4 and evaporated under 
reduced pressure. Recrystallization from CH2Cl2/Hexane afforded coloreless needles 
of 13 (95 %). Crystals suitable for X-Ray analyses were grown from CH2Cl2/hexane. 
Calc. for Mr (C15H12NO5ReS) 504.5; ESI-MS [m/z] (CH3OH): 506.0 [M+H]+; 1H NMR (500 
MHz, CDCl3, in ppm): 7.75 (m, 2H, Ar), 7.37 (m, 2H, Ar), 6.28 (s, 1H, NH), 5.32 (m, 2H, 
Cp), 5.11 (m, 2H, Cp), 2.47 (s, 3H, CH3). 
 
(44) 
[(Cp-NH2)Re(CO)3] (200 mg, 0.57 mmol) was dissolved in 10 ml of dry CH2Cl2 
containing pyridine (46.1 l, 0.57 mmol). 4-Acetylsulfanilyl chloride (133.3 mg, 0.57 
mmol) was added and the suspension was refluxed for 8 h. After cooling to r.t., the 
colorless precipitate was filtered off and washed with a small portion of CH2Cl2. Silica 
gel column chromatography using EtOAc/Hexane 1:1 afforded 44 in 80 % yield. 
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IR (cm-1 KBr): 2020, 1915, 1678, 1594, 1492, 1399, 1325, 1157; Calc. for Mr 
(C16H13N2O6ReS) 547.6; ESI-MS [m/z] (CH3OH): 546.8 [M-H]-; 1H NMR (400 MHz, MeOD, 
in ppm): 7.82 (s, 4H, Ar), 5.43 (m, 2H, Cp), 5.27 (m, 2H, Cp), 2.19 (s, 3H, CH3). 13C NMR 
(125 MHz, DMSO-d6, in ppm): 194.8 (CO), 169.2 (COCH3), 143.8 (Ar1), 131.0 (Ar4), 
128.5 (Ar2), 118.6 (Ar3), 117.6 (Cp1), 81.3 (Cp2), 73.1 (Cp3), 24.2 (CH3); Calc. C, 35.10; 
H, 2.39; N, 5.12; Found. C, 35.21; H, 2.46; N, 5.08. 
 
(45) 
44 (50 mg, 0.091 mmol) was dissolved in 10 ml of absolute EtOH. Conc. HCl (1 ml) was 
added and the solution was refluxed at 90 °C for 1 h. After cooling to room 
temperature, the mixture was neutralized with conc. NaHCO3. The solvent was 
removed under reduced pressure to give 45 in quantitative yield. Crystals suitable for 
X-Ray analysis were grown from Hexane/CH2Cl2. 
IR (cm-1 KBr): 2021, 1914, 1595, 1494, 1316, 1157, 1093; Calc. for Mr. (C14H11N2O5ReS) 
505.5; ESI-MS [m/z] (CH3OH): 505.0 [M-H]-; 1H NMR (400 MHz, MeOD, in ppm): 7.55 
(m, 2H, Ar), 6.72 (m, 2H, Ar), 5.37 (m, 2H, Cp), 5.25 (m, 2H, Cp), 13C NMR (125 MHz, 
DMSO-d6, in ppm): 195.02 (CO), 153.45 (Ar1), 129.3 (Ar4), 122.2 (Ar2), 119.3 (Cp1), 
112.7 (Ar3), 81.0 (Cp2), 72.3 (Cp3); Calc. C, 33.26; H, 2.19; N, 5.54; Found C, 33.01; H, 
2.28; N, 5.35. 
 
(46) 
45 (100 mg, 0.2 mmol) was dissolved in 3 ml of dry DMA and freshly prepared 
sulfamoyl chloride was added dropwise until no more starting material was observed 
(TLC monitoring). The reaction mixture was quenched with H2O and extracted with 
EtOAc (3 x 15 ml). The combined organic layers were washed with brine (3 x 15 ml) 
and H2O (3 x 15 ml), dried over Na2SO4, filtered and concentrated in vacuo to give a 
yellow oil. Silica gel column chromatography eluting with 10 % MeOH in CH2Cl2 
followed by recrystallization from H2O/EtOH afforded the desired product as a yellow 
solid in 68 % yield.  
IR (cm-1 KBr): 2014, 1934, 1915, 1593, 1490, 1342, 1313, 1149; Calc. for Mr. 
(C14H12N3O7ReS2) 584.6; ESI-MS [m/z] (CH3OH): 584.1 [M-H]-; 1H NMR (400 MHz, DMSO-
d6, in ppm): 10.44 (s, 1H, Ar-NH), 10.28 (s, 1H, Cp-NH), 7.75 (m, 2H, Ar), 7.43 (s, 2H, 
SO2-NH2), 7.31 (m, 2H, Ar), 5.46 (m, 2H, Cp), 5.42 (m, 2H, Cp); 13C NMR (100 MHz, 
DMSO-d6, in ppm): 195.7 (CO), 145.0 (Ar1), 130.9 (Ar4), 129.4 (Ar2), 119.0 (Ar3), 117.5 
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(Cp1), 82.3 (Cp2), 74.1 (Cp3); Calc. C, 28.76; H, 2.07; N, 7.19; Found. C, 28.91; H, 2.04; 
N, 7.07. 
 
3.4.2 [Re(CO)3Cp-CONHR] 
 
(47a/b) 
[(Cp-COOH)Re(CO)3] was activated with pentafluorophenyl trifluoroacetate 
according to literature procedure.[63] p-Aminophenol (11.2 mg, 0.10 mmol) was 
dissolved in 5 ml of THF and the activated acid (56 mg, 0.10 mmol) was added. The 
mixture was heated at 60 °C for 16 h, then the solvent was evaporated and the 
residue was extracted with CH2Cl2 and 0.1 M HCl. The combined organic fractions 
were dried over Na2SO4, evaporated to dryness and purified by silica gel 
chromatography using a gradient from pure CH2Cl2 to EtOAc/Hex 1:1. Two fractions 
were isolated, revealing the amide bound product 47a as a coloreless oil (39 %) and 
the ester 47b as a yellow powder (24 %). 
47a: Calc. for Mr. (C15H10NO5Re) 470.5; ESI-MS [m/z] (CH3OH): 470.8 [M+H]-, 506.1 
[M+H3O2]-; 1H NMR (400 MHz, DMSO-d6, in ppm): 9,69 (s, 1H, Ar-NH), 9.31 (s, 1H, Ar-
OH), 7.37 (m, 2H, Ar), 6.74 (m, 2H, Ar), 6.44 (m, 2H, Cp), 5.79 (m, 2H, Cp). 
47b: 1H NMR (400 MHz, DMSO-d6, in ppm): 6.78 (m, 2H, Ar), 6.59 (m, 2H, Ar), 6.48 (m, 
2H, Cp), 5.87 (m, 2H, Cp), 5.12 (s, 2H, NH2). 
 
(48) 
NaHCO3 (167 mg, 2 mmol) was dissolved in 5 ml of Water and added to a suspension 
of 4-Aminophenol (218.3 mg, 2 mmol) in 10 ml of CH2Cl2. Boc2O (433.7 mg, 2 mmol) 
was added and the mixture was strirred under reflux for 3 h and for another 12 h at 
room temperature. The organic layer was separated and washed with brine (3 x 10 
ml) and H2O (3 x 10 ml), dried over Na2SO4, filtered and concentrated in vacuo to 
give a slightly yellow oil which was not further purified (78 %). 
Calc. for Mr. (C11H15NO3) 209.2; ESI-MS [m/z] (CH3OH): 232.1 [M+Na]+; 1H NMR (400 
MHz, DMSO-d6, in ppm): 9,00 (s, 1H, Ar-NH), 8.95 (s, 1H, Ar-OH), 7.20 (m, 2H, Ar), 6.63 
(m, 2H, Ar), 1.45 (s, 9H, tBu). 
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(49) 
48 (1 g, 4.8 mmol) was dissolved in 5 ml of dry DMA and freshly prepared 
sulfamoylchloride was added drop-wise until no more starting material was observed 
(HPLC monitoring). The reaction mixture was quenched with H2O and extracted with 
ethyl acetate (3 x 15 ml). The combined organic layers were washed with brine (3 x 
15 ml) and H2O (3 x 15 ml), dried over Na2SO4, filtered and concentrated in vacuo to 
give a brown oil, which was used without further purification (85 %). 
Calc. for Mr. (C11H16N2O5S) 288.3; ESI-MS [m/z] (CH3OH): 287.4 [M-H]-, 311.3 [M+Na]+; 1H 
NMR (400 MHz, DMSO-d6, in ppm): 9,43 (s, 1H, Ar-NH), 7.86 (s, 2H, SO2-NH2), 7.48 (m, 
2H, Ar), 7.16 (m, 2H, Ar), 1.47 (s, 9H, tBu). 
 
(50) 
49 (450 mg, 1.6 mmol) was dissolved in 10 ml of CH2Cl2 and 1 ml of trifluoroacetic 
acid was added dropwise. The mixture was stirred for 3 h at room temperature and 
then concentrated in vacuo to give a brown oil. The product was not further purified.  
Calc. for Mr. (C6H8N2O3S) 188.2; ESI-MS [m/z] (CH3OH): 189.8 [M+H]+; 1H NMR (400 MHz, 
DMSO-d6, in ppm): 7.97 (s, 2H, SO2-NH2), 7.23 (m, 2H, Ar), 7.13 (m, 2H, Ar). 
 
(51) 
[(Cp-COOH)Re(CO)3] (30 mg, 0.08 mmol) was dissolved in 1 ml of dry DMF. N-
Methylmorpholine (13.2 l, 0.12 mmol) and O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (45.6 mg, 0.12 mmol) was added. After 30 
min of strirring 50 (30 mg, 0.16 mmol) was added and the mixture was stirred for 15 h 
at room temperature. The solvent was evaporated in vacuo and the residue was 
purified by silica gel column chromatography using EtOAc/Hexane 1:1, which 
afforded 51 in 66 % yield. Crystals were grown from a concentrated methanol 
solution of 51 by slow evaporation while standing in the air. 
IR (cm-1 KBr): 2030, 1941, 1907, 1655, 1605, 1527, 1502, 1381, 1314, 1161; Calc. for Mr 
(C15H11N2O7ReS) 549.5; ESI-MS [m/z] (CH3OH): 573.5 [M+Na]+; 1H NMR (400 MHz, 
DMSO-d6, in ppm): 9.97 (s, 1H, Ar-NH), 7.94 (s, 2H, SO2N-H2), 7.68 (m, 2H, Ar), 7.26 (m, 
2H, Ar), 6.49 (m, 2H, Cp), 5.81 (m, 2H, Cp); 13C NMR (125 MHz, DMSO-d6, in ppm): 
193.9 (CO), 160.4 (CONH), 146.0 (Ar1), 136.7 (Ar4), 122.7 (Ar2), 121.5 (Ar3), 95.2 (Cp1), 
88.0 (Cp2), 86.7 (Cp3); Calc. C, 32.78; H, 2.02; N, 5.10; Found. C, 32.97; H, 2.11; N, 5.01 
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(52) 
Using 1.5 eq. of 4-Aminobenzensulfonamide, 52 was obtained in an analogueous 
procedure to 51. The reaction time was 6 h and the crude product was purified by 
silica column chromatography eluting with CH2Cl2/Hexane/EtOAc (3:2:3) yielding a 
pale yellow solid (80 %). Crystals were grown from a concentrated methanol solution 
of 52 by slow evaporation while standing in the air. 
IR (cm-1 KBr): 2034, 1941, 1914, 1667, 1594, 1535, 1327, 1153; Calc. for Mr 
(C15H11N2O6ReS) 533.5; ESI-MS [m/z] (CH3OH): 557.0 [M+Na]+; 1H NMR (400 MHz, 
DMSO-d6, in ppm): 10.14 (s, 1H, Ar-NH), 7.80 (s, 4H, Ar), 7.27 (s, 2H, SO2N-H2), 6.51 (m, 
2H, Cp), 5.82 (m, 2H, Cp); 13C NMR (125 MHz, DMSO-d6, in ppm): 193.8 (CO), 160.8 
(CONH), 141.3 (Ar1), 130.1 (Ar4), 126.7 (Ar2), 120.0 (Ar3), 94.7 (Cp1), 88.2 (Cp2), 86.8 
(Cp3); Calc. C, 33.77; H, 2.08; N, 5.25; Found. C, 33.57; H, 2.00; N, 5.19. 
 
(53) 
[(Cp-COOH)Re(CO)3] was activated with pentafluorophenyl trifluoroacetate 
according to literature procedure.[63] 4-(Aminomethyl)benzene-sulfonamid 
hydrochloride (81.7 mg, 0.37 mmol) was suspended in 1 ml of DMF. Triethylamine 
(51.2 l, 0.37 mmol) was added and the mixture was stirred for 10 min before it was 
added to a solution of [(Cp-COOPFP)Re(CO)3] (100 mg, 0.18 mmol) in 1 ml DMF. 
After stirring for 4 h at room temperature, the solvent was evaporated in vacuo. The 
crude product was dissolved in EtOAc and washed with brine (3 x 10 ml) and H2O (3 
x 10 ml), dried over Na2SO4, filtered and concentrated in vacuo. Silica gel 
chromatography using EtOAc/Hex 3:1 yielded 53 in 78 % as a colorless powder. 
IR (cm-1 KBr): 2025, 1918, 1642, 1542, 1325, 1158; Calc. for Mr (C16H13N2O6ReS) 547.6; 
ESI-MS [m/z] (CH3OH): 571.0 [M+Na]+; 1H NMR (400 MHz, DMSO-d6, in ppm): 8.88 (t, 
J=5.90 Hz, 1H, CH2-NH), 7.76 (m, 2H, Ar), 7.41 (m, 2H, Ar), 7.31 (s, 2H, SO2N-H2), 6.34 (m, 
2H, Cp), 5.75 (m, 2H, Cp), 4.45 (d, J=5.8 Hz, 2H, CH2); 13C NMR (125 MHz, DMSO-d6, in 
ppm): 194.1 (CO), 161.1 (CONH), 143.4 (Ar1), 142.7 (Ar4), 127.2 (Ar2), 125.7 (Ar3), 94.9 
(Cp1), 87.9 (Cp2), 86.4 (Cp3), 41.8 (CH2); Calc. C, 35.10; H, 2.39; N, 5.12; Found. C, 
34.89; H, 2.45; N, 5.09. 
 
(30) 
[(Cp-COOH)Re(CO)3] was activated with pentafluorophenyl trifluoroacetate 
according to literature procedure.[63] PFP-activated acid (360.4 mg, 0.53 mmol) was 
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dissolved in 5 ml DMF and cooled to 0 °C. A solution of 8-aminocaprylic acid (100 
mg, 0.63 mmol) and NaHCO3 (53 mg, 0.63 mmol) in 5 ml H2O was slowly added. A 
thick cream colored precipitate formed instantly. The mixture was allowed to reach 
room temperature and was stirred for 18 h whereon the precipitate was consumed. 
Removal of the solvent under reduced pressure and silica gel chromatography using 
CH2Cl2/MeOH/AcOH 100:1:1 afforded 30 in 88 % yield. 
IR (cm-1 KBr): 2022, 1907, 1706, 1621, 1551; Calc. for Mr (C16H13N2O6ReS) 547.6; ESI-MS 
[m/z] (CH3OH): 519.8 [M-H]-; 1H-NMR (400 MHz, DMSO-d6, in ppm): 8.16 (t, J=5.7 Hz, 
1H, NH), 6.26 (m, 2H, Cp), 5.70 (m, 2H, Cp), 3.13 (m, 2H, CH2), 2.17 (m, 2H, CH2), 1.45 
(m, 4H, CH2), 1.25 (m, 6H, CH2); 13C-NMR (125 MHz, DMSO-d6, in ppm): 194.2 (CO), 
174.5 (COOH), 161.2 (NHCO), 96.0 (Cp1), 87.2 (Cp2), 86.2 (Cp3), 38.7 (CH2), 33.7 
(CH2), 29.0 (CH2), 28.6 (CH2), 28.5 (CH2), 26.2 (CH2), 24.5 (CH2); Calc. C, 39.07 H, 4.24; 
N, 2.68; Found: C, 38.19; H, 3.97; N, 2.86. 
 
(32) 
32 was prepared as described for 30 using 7-aminoheptanoic acid. Silica gel 
chromatography using CH2Cl2/MeOH/AcOH 100:1:1 afforded 32 in 86 % yield. 
IR (cm-1 KBr): 2022, 1909, 1705, 1623, 1551; Calc. for Mr (C16H18NO6Re) 506.5; ESI-MS 
[m/z] (CH3OH): 508.0 [M+H]+, 530.0 [M+Na]+, 505.7 [M-H]-; 1H-NMR (400 MHz, DMSO-d6, 
in ppm): 8.17 (t, J=5.7 Hz, 1H, NH), 6.26 (m, 2H, Cp), 5.70 (m, 2H, Cp), 3.13 (m, 2H, 
CH2), 2.18 (m, 2H, CH2), 1.30 (m, 4H, CH2), 1.26 (m, 4H, CH2); 13C-NMR (125 MHz, DMSO-
d6, in ppm): 194.2 (CO), 174.5 (COOH), 161.2 (CONH), 96.0 (Cp1), 87.2 (Cp2), 86.2 
(Cp3), 38.6 (CH2), 33.6 (CH2), 28.9 (CH2), 28.3 (CH2), 26.1 (CH2), 24.5 (CH2); Calc. C, 
37.94; H, 3.58; N, 2.77; Found: C, 37.74; H, 3.61; N, 2.60. 
 
(31) 
To a solution of 31 (318 mg, 0.61 mmol) in 5 ml dry THF, NEt3 (123 l, 0.88 mmol) and 
ClCOOEt (78 l, 1.0 mmol) were added. After stirring the mixture for 1h at room 
temperature, a solution of NH2OH*HCl (141 mg, 2.03 mmol) and NaOMe (30 % in 
MeOH, 381 l, 2.03 mmol) in 2 ml MeOH was added and the mixture was stirred at 
room temperature for 18h. Solvents were evaporated at reduced pressure and the 
residue was redissolved in THF, filtered and evaporated to dryness. Silica gel 
chromatography using a gradient from CH2Cl2/AcOH 100:5 to CH2Cl2/MeOH 100:5 
afforded 31 (80 %). 
Experimental 2013 
 
117 
 
IR (cm-1 KBr): 2020, 1905, 1633, 1548, 1367, 1303, 1036; Calc. for Mr (C16H13N2O6ReS) 
535.5; ESI-MS [m/z] (CH3OH): 559.1 [M+Na]+, 537.2 [M+H]+; 1H-NMR (500 MHz, MeOD, 
in ppm): 8.19 (t, J=5.6 Hz, 2H, NHCH2), 6.15 (m, 2H, Cp), 5.56 (m, 2H, Cp), 3.26 (m, 2H, 
CH2), 2.08 (m, 2H, CH2), 1.60 (m, 4H, CH2), 1.35 (m, 6H, CH2); 13C-NMR (125 MHz, 
MeOD, in ppm): 194.3 (CO), 173.2 (CONHOH), 164.9 (CONH), 96.2 (Cp1), 87.9 
(Cp2), 86.6 (Cp3), 40.7 (CH2), 33.9 (CH2), 30.5 (CH2), 30.2 (CH2), 30.1 (CH2), 27.9 (CH2), 
26.8 (CH2). 
 
(33) 
33 was prepared as described for 31 using 32. Silica gel chromatography using a 
gradient from CH2Cl2/AcOH 100:5 to CH2Cl2/MeOH 100:5 afforded 16 (83 %). 
IR (cm-1 KBr): 2020, 1907, 1633, 1549, 1368, 1303, 1036; Calc. for Mr (C16H19N2O6Re) 
521.5; ESI-MS [m/z] (CH3OH): 545.1 [M+Na]+; 1H-NMR(400 MHz, DMSO-d6, in ppm): 
10.32 (s, 1H, OH), 8.63 (s, 1H, NHOH), 8.20 (t, J=5.6 Hz, 2H, NHCH2), 6.27 (m, 2H, Cp), 
5.70 (m, 2H, Cp), 3.13 (m, 2H, CH2), 1.92 (m, 2H, CH2), 1.45 (m, 4H, CH2), 1.25 (m, 4H, 
CH2); 13C-NMR (125 MHz, DMSO-d6, in ppm): 194.2 (CO), 169.1 (CONHOH), 161.2 
(CONH), 96.1 (Cp1), 87.3 (Cp2), 86.2 (Cp3), 38.7 (CH2), 32.3 (CH2), 29.0 (CH2), 28.4 
(CH2), 26.1 (CH2), 25.1 (CH2). 
 
(34a/b) 
Suberic acid monomethyl ester (309 l, 1.72 mmol) was dissolved in 10 ml dry THF. 
Addition of N-methylmorpholine (190 l, 1.72 mmol) and isobutyl chloroformate (225.5 
l, 1.72 mmol) resulted in formation of a coloreless precipitate. After stirring the 
suspension for 10 minutes, [(Cp-NH2)M(CO)3] (a: M = Re, b: M = Mn) [69] (0.86 mmol) 
was added and the mixture was stirred for another 17 h at room temperature. The 
solvent was removed at reduced pressure. 30 ml H2O was added and the residue 
was extracted three times with 50 ml EtOAc. The combined organic fractions were 
dried over Na2SO4 and evaporated under reduced pressure. Silica gel 
chromatography with hexane/EtOAc 2:1 afforded 34a/b in quantitative yield. 
Crystals of 34b were grown from CH2Cl2/Hexane. 
a: IR (cm-1 KBr): 2024, 1910, 1719, 1703, 1541, 1487, 1235, 1163; Calc. for Mr 
(C17H20NO6Re) 520.6; ESI-MS [m/z] (CH3OH): 544.0 [M+Na]+; 1H-NMR (400 MHz, DMSO-
d6, in ppm): 10.02 (s, 1H, NH), 5.78 (m, 2H, Cp), 5.48 (m, 2H, Cp), 3.57 (s, 3H, CH3), 
2.27 (m, 2H, CH2), 2.14 (m, 2H, CH2), 1.25 (m, 4H, CH2), 1.23 (m, 4H, CH2); 13C-NMR (125 
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MHz, DMSO-d6, in ppm): 195.5 (CO), 173.3 (COCH3), 171.3 (NHCO), 118.7 (Cp1), 81.4 
(Cp2), 72.5 (Cp3), 51.2 (COCH3), 35.6 (CH2), 33.2 (CH2), 28.1 (CH2), 28.0 (CH2), 24.7 
(CH2), 24.2 (CH2); Calc. C, 39.02; H, 4.09; N, 2.84; Found: C, 38.91; H, 3.95; N, 2.76. 
b: ESI-MS [m/z] (CH3OH): 412.0 [M+Na]+ 
 
(35) 
34a (342 mg, 0.66 mmol) was dissolved in a mixture of 2 ml THF and 4 ml MeOH. LiOH 
(138 mg, 3.28 mmol) in 2 ml H2O was added and the mixture was stirred at room 
temperature for 2h. Solvents were evaporated at reduced pressure to roughly 2 ml 
and the mixture was acidified with HCl (conc.) to pH 1. Extraction of the aqueous 
layer with EtOAc afforded 310 mg of 18 (92 %). 
Calc. for Mr (C16H18NO6Re) 506.5; ESI-MS [m/z] (CH3OH): 530.0 [M+Na]+, 506.0 [M-H]-; 
1H-NMR (400 MHz, DMSO-d6, in ppm): 10.02 (s, 1H, NH), 5.78 (m, 2H, Cp), 5.48 (m, 2H, 
Cp), 2.17 (m, 4H, CH2), 1.47 (m, 4H, CH2), 1.24 (m, 4H, CH2). 
 
(36) 
36 was prepared as described for 31 using 35. Silica gel chromatography using a 
gradient from CH2Cl2/AcOH 100:5 to CH2Cl2/MeOH 100:5 afforded 36 (86 %). 
IR (cm-1 KBr): 2019, 1913, 1640, 1558, 1487, 1385; Calc. for Mr (C16H19N2O6Re) 521.5; ESI-
MS [m/z] (CH3OH): 545.1 [M+Na]+; 1H-NMR (400 MHz, DMSO-d6, in ppm): 10.30 (s, 1H, 
OH), 10.02 (s, 1H, NH), 8.63 (s, 1H, NHOH), 5.78 (m, 2H, Cp), 5.48 (m, 2H, Cp), 2.14 (m, 
2H, CH2), 1.92 (m, 2H, CH2), 1.47 (m, 4H, CH2), 1.22 (m, 4H, CH2); 13C-NMR (125 MHz, 
DMSO-d6, in ppm): 195.5 (CO), 171.3 (NHCO), 169.0 (CONHOH), 118.7 (Cp1), 81.4 
(Cp2), 72.5 (Cp3), 35.7 (CH2), 32.2 (CH2), 28.3 (CH2), 28.2 (CH2), 25.0 (CH2), 24.8 (CH2); 
Calc. C, 39.02; H, 4.09; N, 2.84; Found: C, 38.91; H, 3.95; N, 2.76. 
 
(37) 
Benzoic acid (250 mg, 2.05 mmol) was dissolved in 5 ml dry DMF. Pyridine (180.6 l, 
2.24 mmol) and pentafluorophenyl trifluoracetate (386.8 l, 2.24 mmol) were added 
and the solution was stirred for 3 h at room temperature. DMF was evaporated at 
reduced pressure. EtOAc was added and the residue was extracted three times with 
0.1 M HCl and three times with 5 % NaHCO3. The organic fraction was washed with 
fresh H2O, dried over Na2SO4 and evaporated to dryness. The activated acid (151.3 
mg, 0.53 mmol) was dissolved in 5 ml DMF and cooled to 0 °C. A solution of 8-
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aminocaprylic acid (100 mg, 0.63 mmol) and NaHCO3 (53 mg, 0.63 mmol) in 1 ml 
H2O was slowly added. A thick cream colored precipitate formed instantly. The 
mixture was allowed to reach room temperature and was stirred for 18 h. Silica gel 
chromatography using EtOAc/Hexane 1:1 afforded 37 (90 %). 
Calc. for Mr (C15H21NO3) 263.3; ESI-MS [m/z] (CH3OH): 286.1 [M+Na]+, 264.0 [M+H]+, 
262.0 [M-H]-; 1H-NMR (400 MHz, DMSO-d6, in ppm): 8.41 (t, J=5.4 Hz, 1H, NH), 7.81 (m, 
2H, Ar), 7.46 (m, 3H, Ar), 3.24 (m, 2H, CH2), 2.19 (m, 2H, CH2), 1.50 (m, 4H, CH2), 1.29 
(m, 6H, CH2); 13C-NMR (125 MHz, MeOD, in ppm): 177.9 (COOH), 170.4 (CONH), 
136.0 (Ar1), 132.7 (Ar2), 129.7 (Ar3), 128.4 (Ar4), 41.1 (CH2), 35.1 (CH2), 30.6 (CH2), 30.3 
(CH2), 30.2 (CH2), 28.1 (CH2), 26.2 (CH2); Calc. C, 68.42; H, 8.04; N, 5.32; Found: C, 
67.99; H, 7.76; N, 5.26. 
 
(39) 
39 was prepared as described for 37 using 7-aminoheptanoic acid. Silica gel 
chromatography using EtOAc/Hexane 1:1 afforded 39 (89 %). 
Calc. for Mr (C15H19NO3) 249.3; ESI-MS [m/z] (CH3OH): 250.0 [M+H]+, 272.0 [M+Na]+, 
247.9 [M-H]-; 1H-NMR (400 MHz, DMSO-d6, in ppm): 8.41 (t, J=5.3 Hz, 1H, NH), 7.81 (m, 
2H, Ar), 7.46 (m, 3H, Ar), 3.24 (m, 2H, CH2), 2.19 (m, 2H, CH2), 1.50 (m, 4H, CH2), 1.30 
(m, 4H, CH2); 13C-NMR (125 MHz, MeOD, in ppm): 177.9 (COOH), 170.5 (CONH), 
136.1 (Ar1), 132.7 (Ar2), 129.7 (Ar3), 128.4 (Ar4), 41.1 (CH2), 35.1 (CH2), 30.5 (CH2), 30.1 
(CH2), 27.9 (CH2), 26.2 (CH2); Calc. C, 67.45; H, 7.68; N, 5.62; Found: C, 67.25; H, 7.48; 
N, 5.46. 
 
(38) 
38 was prepared as described for 31 using 37. Silica gel chromatography using a 
gradient from CH2Cl2/AcOH 100:5 to CH2Cl2/MeOH 100:5 afforded 22 (90 %). 
Calc. for Mr (C15H22N2O3) 278.4; ESI-MS [m/z] (CH3OH): 279.1 [M+H]+, 301.1 [M+Na]+, 
277.1 [M-H]-; 1H-NMR (400 MHz, DMSO-d6, in ppm): 10.33 (s, 1H, OH), 8.62 (s, 1H, 
NHOH), 8.41 (t, J=5.5 Hz, 1H, NH), 7.81 (m, 2H, Ar), 7.46 (m, 3H, Ar), 3.24 (m, 2H, CH2), 
1.93 (m, 2H, CH2), 1.50 (m, 4H, CH2), 1.15 (m, 6H, CH2); 13C-NMR (125 MHz, MeOD, in 
ppm): 173.2 (CONHOH), 170.4 (CONH), 136.0 (Ar1), 132.7 (Ar2), 129.7 (Ar3), 128.4 
(Ar4), 48.0 (CH2), 41.1 (CH2), 33.9 (CH2), 30.6 (CH2), 30.2 (CH2), 28.0 (CH2), 26.8 (CH2); 
Calc. C, 64.73; H, 7.97; N, 10.06; Found: C, 64.32; H, 7.88; N, 9.91. 
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(40) 
40 was prepared as described for 31 using 39. Silica gel chromatography using a 
gradient from CH2Cl2/AcOH 100:5 to CH2Cl2/MeOH 100:5 afforded 23 (92 %). 
Calc. for Mr (C14H20N2O3) 264.3; ESI-MS [m/z] (CH3OH): 265.2 [M+H]+, 263.2 [M-H]-; 1H-
NMR (400 MHz, DMSO-d6, in ppm): 10.33 (s, 1H, OH), 8.64 (s, 1H, NHOH), 8.42 (t, J=5.5 
Hz, 1H, NH), 7.83 (m, 2H, Ar), 7.46 (m, 3H, Ar), 3.24 (m, 2H, CH2), 1.93 (m, 2H, CH2), 1.50 
(m, 4H, CH2), 1.15 (m, 4H, CH2); Calc. (for 23 + 0.5 H2O) C, 61.52; H, 7.74; N, 10.25; 
Found: C, 61.14; H, 7.67; N, 9.89. 
 
(66) 
[(Cp-COOH)Re(CO)3] (135 mg, 0.36 mmol) was dissolved in 5 ml dry CH2Cl2. 
Oxalylchloride (91.5 l, 1.07 mmol) and a catalytic amount of DMF was added. The 
suspension was stirred at 0 °C for 1h and for 4h at room temperature. The solvent was 
evaporated and the residue was redissolved in dry THF. 
In a separate flask 6-aminopenicillanic acid (84.7 mg, 0.39 mmol) was suspended in 1 
ml EtOH. Trimethylsilyl chloride (87.3 l, 0.69 mmol) was added, whereas the mixture 
turned clear instandly and was stirred for 2h. Solvents and excess of trimethylsilyl 
chloride were removed under reduced pressure. The colourless residue was 
redissolved in dry THF and triethylamine (150 l, 1.08 mmol) was added. 
Both solutions were slowly mixed together at 0 °C and stirred for 1h, then the mixture 
was allowed to reach room temperature and was stirred for another 3h. THF was 
evaporated and the residue was purified by silica gel column chromatography using 
CH2Cl2/MeOH/AcOH 100:2:1 (70 %). 
Calc. for Mr (C19H19N2O7ReS) 605.5; ESI-MS [m/z] (CH3OH): 625.0 [M+H3O]+, 622.9 
[M+OH]-; 1H NMR (400 MHz, MeOD, in ppm): 6.27 – 6.21 (m, 2H, Cp), 5.66 – 5.55 (m, 
2H, Cp), 5.05 (d, J=8.3 Hz, 1H, CH), 4.62 (d, J=8.3 Hz, 1H, CH), 4.21 (q, J=3x7.0, 2H, CH2 
ester), 3.75 (s, 1H, CHCOOEt), 1.64 (s, 3H, CH3), 1.30 (t, J=2x7.2, 3H, CH3 ester), 1.30 (s, 
3H, CH3); 13C NMR (125 MHz, CDCl3, in ppm): 194.1 (3xCO), 172.3 (CO), 171.4 (CO), 
165.1 (CO), 94.8 (Cp1), 89.1 (Cp2), 88.2 (Cp3), 87.0 (Cp4), 86.2 (Cp5), 73.7 (CHCO), 
66.9 (CHS), 62.8 (tert. C), 59.8 (CH2 ester), 59.2 (CHNH), 28.3 (CH3), 27.6 (CH3), 14.6 
(CH3). 
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(70) 
[(Cp-COOH)Re(CO)3] was activated with pentafluorophenyl trifluoroacetate 
according to literature procedure.[63] PFP-activated acid (100.0 mg, 0.18 mmol) was 
dissolved in 1 ml DMF. L-Noradrenaline (34.2 mg, 0.20 mmol) and triethylamine (28.0 
l, 0.20 mmol) were slowly added. The mixture was stirred for 5 h. Removal of the 
solvent under reduced pressure and silica gel chromatography using 
CH2Cl2/MeOH/AcOH 100:5:1 afforded 70 in 76 % yield. 
Calc. for Mr (C17H14NO7Re) 530.5; ESI-MS [m/z] (CH3OH): 530.0 [M-H]-; 1H-NMR (400 
MHz, DMSO-d6, in ppm): 8.28 (t, J=5.8 Hz, 1H, NH), 6.79 – 6.5 (m, 3H, Ar), 6.34 – 6.21 
(m, 2H, Cp), 5.73 – 5.64 (m, 2H, Cp), 4.50 – 4.42 (m, 1H, CH). 
 
3.4.3 [Re(CO)3Cp-SO2R] 
 
(4)  
[CpRe(CO)3] (1 g, 2.98 mmol) was suspended in 2 ml of acetic anhydride. Over the 
course of 1h H2SO4 (95-97 %, 329 l) was added, while keeping the temperature 
between 25 and 30 °C. The dark solution was stirred for another hour and was then 
refluxed for 1 h at 60 °C. The mixture was chilled to room temperature and was 
poured over ice and was allowed to stand for 1h. After filtration, the aqueous layer 
was separated. p-Toluidine (555 mg, 5.13 mmol), dissolved in 2 ml of water containing 
0.5 ml conc HCl, was added under vigorous stirring, whereas a cream colored thick 
precipitate formed instantly. The suspension was stirred for another 30min, then 
filtered and washed with toluene to give 4 (90 % yield). 
IR (cm-1 KBr): 2032, 1939, 1920, 1515, 1198; Calc. for Mr (C8H4O6ReS-) 414.9; ESI-MS 
[m/z] (CH3OH): 414.9 [M-H]-; 1H NMR (400 MHz, MeOD, in ppm): 7.35 (m, 2H, Ar), 7.27 
(m, 2H, Ar), 5.91 (m, 2H, Cp), 5.43 (m, 2H, Cp), 2.30 (s, 3H, CH3); Calc. C, 34.48; H, 2.70; 
N, 2.68; Found C, 34.29; H, 2.76; N, 2.59. 
 
(5)  
A mixture of 28 (250 mg, 0.478 mmol) and phosphorus pentachloride (197 mg, 0.959 
mmol) was stirred vigorously for 20min at room temperature until a melt was formed. 
The mixture was then heated at 45 °C for 1h. After cooling to room temperature, 
toluene was added. The mixture was stirred well, poured over ice, allowed to stand 
for 1h and was then filtered. The organic layer was separated, dried over Na2SO4, 
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treated with activated charcoal and evaporated under reduced pressure. The 
residue was dissolved in a minimum of CH2Cl2 and hexane was added. The pale 
yellow precipitate was collected to afford 5 (70 %). Crystals suitable for X-Ray analysis 
were grown from CH2Cl2/hexane. 
IR (cm-1 KBr): 2038, 1949, 1508, 1378, 1214; Calc. for Mr (C8H4ClO5ReS) 433.9; ESI-MS 
[m/z] (CH3OH): 433.1 [M-H]-. 1H NMR (500 MHz, CD3CN, in ppm): 6.35 (m, 2H, Cp), 
5.71 (m, 2H, Cp). Calc. C, 22.15; H, 0.93; Found C, 22.09; H, 0.98 
 
(6)  
5 (50 mg, 0.115 mmol) and p-Toluidine (37 mg, 0.345 mmol) were dissolved in 10 ml of 
absolute EtOH. The solution was refluxed at 90 °C for 5h. After cooling to room 
temperature, the solvent was evaporated under reduced pressure and the residue 
was purified by column chromatography using EtOAc/Hexane 2:1 to afford a light 
brown powder (49 %).  
IR (cm-1 KBr): 2036, 1957, 1943, 1510, 1334, 1138; Calc. for Mr (C15H12NO5ReS) 505.0; ESI-
MS [m/z] (CH3OH, formic acid): 503.7 [M-H]-. 1H NMR (500 MHz, MeOD, in ppm): 7.12 
(m, 2H, Ar), 7.06 (m, 2H, Ar), 5.83 (m, 2H, Cp), 5.48 (m, 2H, Cp), 2.30 (s, 3H, CH3).  
 
(63/64)  
5 (50 mg, 0.115 mmol) and 3-amino-5-methylisoxazole (33.8 mg, 0.345 mmol) were 
dissolved in 5 ml of dry THF. The solution was heated under stirring at 40 °C for 10h. 
After cooling to room temperature, the solvent was evaporated under reduced 
pressure. The dark residue was purified by silica gel column chromatography using 
EtOAc/hexane 1:1, to give a coloreless powder (69 %). Crystals suitable for X-Ray 
analysis were grown from CH2Cl2/hexane containing a small amount of DMSO. 
NMR analysis and crystal structure showed the unexpected formation of complex 63 
instead of the desired sulfonamide. Compound 64 was isolated as a second product 
of the decomplexation. 
63: IR (cm-1 KBr): 2023, 1915, 1883, 1626, 1534, 1473; 1H NMR (400 MHz, DMSO, in 
ppm): 6.30 (s, 4H, NH2); 5.85 (s, 2H, CH); 2.27 (s, 6H, CH3).  
64: Calc. for Mr (C18H20N4O6S2) 452.5; ESI-MS [m/z] (CH3OH): 451.3 [M-H]-. 1H NMR (500 
MHz, CD3CN, in ppm): 6.42 (m, 1H), 6.18 (s, 1H), 6.05 (s, 1H), 6.04 – 6.02 (m, 1H), 5.71 
(d, J=5.7 Hz, 1H), 3.90 – 3.87 (m, 1H), 3.27 – 3.22 (m, 1H), 3.09 (s, 1H), 1.84-1.72 (m, 2H).  
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(65)  
5 (50 mg, 0.115 mmol) and 2-aminopyrimidine (32.1 mg, 0.345 mmol) were dissolved 
in 5 ml of dry THF. The solution was heated under stirring at 40 °C for 12h. After cooling 
to room temperature, the solvent was evaporated under reduced pressure. Crystals 
were grown from methanol. 
Similar to 63, the crystal structure shows the formation of complex 65 instead of the 
desired sulfonamide. 
IR (cm-1 KBr): 2025, 1916, 1890, 1867, 1638, 1555; 1H NMR (400 MHz, DMSO, in ppm): 
8.17 (dd, J=6.0, 4.5 Hz, 2H, Ar); 6.84 (dd, J=5.8, 4.7 Hz, 2H, Ar); 6.71 (dd, J=6.0, 4.5 Hz, 
2H, Ar) 
 
3.4.4 [Re(CO)3Cp-CH2COR] 
 
(24a)  
(NEt4)2[Re(Br)3(CO)3] (100 mg, 0.13 mmol), 18 (16.1 mg, 0.13 mmol) and Borax (70 mg) 
were suspended in 10 ml distilled water. The mixture was stirred at 90 °C for 16 h and 
then concentrated to dryness under reduced pressure. The crude product was 
purified by silica gel column chromatography using CH2Cl2/Hexane 1:2 containing 
1.6 % AcOH (20 %). 
IR (cm-1 KBr): 2020, 1911, 1579, 1394, 1024; Calc. for Mr (C10H7O5Re) 393.4; ESI-MS [m/z] 
(CH3OH): 348.8 [M-CO2]-, 321.0 [M-C2O3]-; 1H NMR (400 MHz, CDCl3, in ppm): 5.46 (m, 
2H, Cp), 5.31 (m, 2H, Cp), 3.5 (s, 2H, CH2). 13C NMR (125 MHz, CDCl3, in ppm): 194.0 
(CO), 175.9 (COOH), 99.7 (Cp1), 85.5 (Cp2), 84.2 (Cp3), 34.90 (CH2); Calc. C, 30.53; H, 
1.79; Found. C, 30.18; H, 1.94. 
 
(24b)  
[(Cp)Re(CO)3] (150 mg, 0.40 mmol) was dissolved in 5 ml dry THF. The Solution was 
cooled to -78 °C and nBuLi (2 M, 246 l, 0.492 mmol) was added tropwise. After 
stirring for 1h, bromoacetic acid methylester (83.6 l, 0.88 mmol) was dropped to the 
mixture was stirred for 3h at room temperature. The solvent was removed under 
reduced pressure, CH2Cl2 was added and the residue was extracted with brine. The 
product was purified by silica gel column chromatography using CH2Cl2/Hexane 2:3. 
Crystals were grown from CH2Cl2/Hexane. X-Ray and NMR analysis revealed the 
unexpected formation of compound 24b instead of 24a (50 % yield).  
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IR (cm-1 KBr): 2018, 1921, 1904, 1639; 1H NMR (400 MHz, CDCl3, in ppm): 5.71 (m, 2H, 
Cp), 5.56 (m, 2H, Cp), 5.30 (m, 4H, Cp), 3.72 (s, 2H, CH2), 2.41 (s, 1H, OH).  
 
(67)  
24a (50 mg, 0.13 mmol) was dissolved in 2 ml dry CH2Cl2. Oxalylchloride (33.6 l, 0.39 
mmol) and a catalytic amount of DMF was added. The suspension was stirred at 0 °C 
for 1h and for 4h at room temperature. The solvent was evaporated and the residue 
was redissolved in dry THF. 
In a separate flask 6-aminopenicillanic acid (32.6 mg, 0.13 mmol) was suspended in 1 
ml EtOH. Trimethylsilyl chloride (29 l, 0.33 mmol) was added, whereas the mixture 
turned clear instandly and was stirred for 2h. Solvents and excess of trimethylsilyl 
chloride were removed under reduced pressure. The colourless residue was 
redissolved in dry THF and triethylamine (70 l, 0.504 mmol) was added. 
Both solutions were slowly mixed together at 0 °C and stirred for 1h, then the mixture 
was allowed to reach room temperature and was stirred for another 3h. THF was 
evaporated and the residue was purified by silica gel column chromatography using 
CH2Cl2/MeOH/AcOH 100:2:1 (66 %). 
Calc. for Mr (C20H21N2O7ReS) 619.1; ESI-MS [m/z] (CH3OH): 639.0 [M+H3O]+, 637.0 
[M+OH]-; 1H NMR (400 MHz, MeOD, in ppm): 5.68 – 5.60 (m, 2H, Cp), 5.45 – 5.41 (m, 
2H, Cp), 5.00 (d, J=7.2 Hz, 1H, CH), 4.53 (d, J=7.2 Hz, 1H, CH), 4.20 (q, J=3x7.2, 2H, CH2 
ester), 3.75 (s, 1H, CHCOOEt), 3.42 (s, 1H, CH2), 3.40 (s, 1H, CH2), 1.62 (s, 3H, CH3), 1.29 
(t, J=2x7.2, 3H, CH3 ester), 1.28 (s, 3H, CH3); 13C NMR (125 MHz, CDCl3, in ppm): 195.7 
(CO), 172.6 (CO), 172.3 (CO), 171.5 (CO), 104.2 (Cp1), 86.8 (2xCp), 85.3 (2xCp), 73.8 
(CHCO), 67.4 (CHS), 62.7 (tert. C), 60.1 (CH2 ester), 59.4 (CHNH), 36.2 (CH2), 28.1 
(CH3), 27.5 (CH3), 14.6 (CH3). 
 
(54)  
24a (50 mg, 0.13 mmol) was activated with pentafluorophenyl trifluoroacetate in an 
analogous procedure to the literature procedure for [(CpCOOH)Re(CO)3].[63] 
4-(Aminomethyl)benzene-sulfonamid hydrochloride (57.6 mg, 0.25 mmol) was 
suspended in 1 ml of DMF. Triethylamine (36.1 l, 0.25 mmol) was added and the 
mixture was stirred for 10 min before it was added to a solution of [(Cp-
CH2COOPFP)Re(CO)3] (72.7 mg, 0.13 mmol) in 1 ml DMF. After stirring for 16 h at room 
temperature, the solvent was evaporated in vacuo. The crude product was 
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dissolved in CH2Cl2 and extracted first three times with 0.1 M HCl and then three times 
with 5 % NaHCO3. The Organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo (66 %).  
IR (cm-1 KBr): 2020, 1930, 1899, 1618, 1552; Calc. for Mr (C17H15N2O6ReS) 561.6; ESI-MS 
[m/z] (CH3OH): 1144.8 [2M+Na]+; 1H NMR (400 MHz, CDCl3, in ppm): 7.89 (m, 2H, Ar), 
7.43 (m, 2H, Ar), 5.46 (m, 2H, Cp), 5.31 (m, 2H, Cp), 4.52 (d, J=5.8 Hz, 2H, CH2), 3.39, (s, 
2H, CH2); 13C NMR (125 MHz, MeOD, in ppm): 172.7 (CO), 144.6 (Ar1), 144.1 (Ar2), 
129.2 (Ar3), 127.6 (Ar4), 104.3 (Cp1), 86.7 (Cp2), 85.3 (Cp3), 44.0 (CH2), 36.3 (CH2); 
Calc. C, 36.36; H, 2.69; N, 4.99; Found. C, 36.49; H, 2.74; N, 5.06. 
 
3.4.5 [Re(CO)3Cp-CH2CH2COR] 
 
(25)  
Sodium metal (25.7 mg, 1.11 mmol) was dissolved in 5 ml of MeOH. When the sodium 
was consumed, [(CpCOH)Re(CO)3] (271 mg, 0.746 mmol) in 2 ml MeOH and triethyl 
phosphonoacetate (167.2 mg, 0.746 mmol) in 2 ml MeOH were added dropwise at 0 
°C. The mixture was allowed to reach room temperature and was stirred for 2h. The 
solvent was removed in vacuo and the residue was purified by silica gel column 
chromatography using Hexane/EtOAc 10:1 (80 %). 
IR (cm-1 KBr): 2023, 1934, 1909, 1714, 1642, 1428, 1307, 1205; Calc. for Mr (C12H9O5Re) 
420.0; ESI-MS [m/z] (CH3OH): 443.0 [M+Na]+; 1H NMR (400 MHz, CDCl3, in ppm): 7.30 
(d, J=15.8 Hz, 1H, CH), 6.12 (d, J=15.8 Hz, 1H, CH), 5.68 (m, 2H, Cp), 5.37 (m, 2H, Cp), 
3.77 (s, 3H, CH3); 13C NMR (125 MHz, CDCl3, in ppm): 193.0 (CO), 166.6 (COCH3), 
136.6 (CH), 118.7 (CH), 97.6 (Cp1), 85.5 (Cp2), 85.0 (Cp3), 52.1 (CH3); Calc. C, 34.37; 
H, 2.16; Found. C, 33.81; H, 2.35. 
 
(26-27)  
25 (100 mg, 0.231 mmol) and palladium adsorbed on charcoal (10 %, 20 mg) were 
dispersed in 10 ml EtOAc. The mixture was first saturated with N2, then with H2 and 
was then stirred for 48h under an atmosphere of H2 at ambient pressure. Filtration 
and evaporation of the solvent afforded the reduced product quantitatively (26). 
Calc. for Mr (C12H11O5Re) 421.4; ESI-MS [m/z] (CH3OH): 445.0 [M+Na]+; 1H NMR (400 
MHz, CDCl3, in ppm): 5.29 (m, 2H, Cp), 5.24 (m, 2H, Cp), 3.70 (s, 3H, CH3), 2.78 (t, 
J=7.4 Hz, 2H, CH2), 2.53 (t, J=7.4 Hz, 2H, CH2); 13C NMR (125 MHz, CDCl3, in ppm): 
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194.4 (CO), 172.8 (COCH3), 109.0 (Cp1), 83.8 (Cp2,3), 52.1 (CH3), 36.1 (CH2), 23.48 
(CH2). 
 
Hydrolysis of the ester function was performed with LiOH (5 eq.) in a mixture of 
H2O/MeOH/THF (1:2:2). The solution was stirred for 2h at 0 °C and for another 5h at 
room temperature. Concentration under reduced pressure and acidification with 1M 
HCl to pH 3 produced a colourless precipitate. Et2O was added and the aqueous 
phase was extracted three times. The combined organic fractions were dried with 
Na2SO4 and evaporated under reduced pressure. 27 was obtained as a pale yellow 
solid (78 %). 
IR (cm-1 KBr): 2023, 1912, 1697; Calc. for Mr (C11H9O5Re) 408.4; ESI-MS [m/z] (CH3OH): 
407.0 [M-H]-; 1H NMR (500 MHz, CDCl3, in ppm): 5.31 (m, 2H, Cp), 5.26 (m, 2H, Cp), 
2.77 (t, J=7.3 Hz, 2H, CH2), 2.59 (t, J=7.3 Hz, 2H, CH2); 13C NMR (125 MHz, CDCl3, in 
ppm): 194.3 (CO), 177.1 (COCH3), 108.55 (Cp1), 83.9 (Cp2), 83.8 (Cp3), 35.8 (CH2), 
23.2 (CH2); Calc. C, 32.43; H, 2.23; Found. C, 32.15; H, 2.42. 
 
(68)  
27 (53 mg, 0.13 mmol) was dissolved in 2 ml dry CH2Cl2. Oxalylchloride (33.6 l, 0.39 
mmol) and a catalytic amount of DMF was added. The suspension was stirred at 0 °C 
for 1h and for 4h at room temperature. The solvent was evaporated and the residue 
was redissolved in dry THF. 
In a separate flask 6-aminopenicillanic acid (32.6 mg, 0.13 mmol) was suspended in 1 
ml EtOH. Trimethylsilyl chloride (29 l, 0.33 mmol) was added, whereas the mixture 
turned clear instandly and was stirred for 2h. Solvents and excess of trimethylsilyl 
chloride were removed under reduced pressure. The colourless residue was 
redissolved in dry THF and triethylamine (70 l, 0.504 mmol) was added. 
Both solutions were slowly mixed together at 0 °C and stirred for 1h, then the mixture 
was allowed to reach room temperature and was stirred for another 3h. THF was 
evaporated and the residue was purified by silica gel column chromatography using 
CH2Cl2/MeOH/AcOH 100:2:1 (71 %). 
Calc. for Mr (C21H23N2O7ReS) 633.7; ESI-MS [m/z] (CH3OH): 653.1 [M+H3O]+, 650.9 
[M+OH]-; 1H NMR (400 MHz, MeOD, in ppm): 5.55 – 5.52 (m, 1H, Cp), 5.50 – 5.45 (m, 
1H, Cp), 5.41 – 5.38 (m, 1H, Cp), 5.38 – 5.34 (m, 1H, Cp), 4.96 (d, J=7.8 Hz, 1H, CH), 4.57 
(d, J=7.8 Hz, 1H, CH), 4.18 (q, J=3x7.0, 2H, CH2 ester), 3.75 (s, 1H, CHCOOEt), 2.85 – 
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2.66 (m, 2H, CH2), 2.49 (t, J=7.2 Hz, 2H, CH2), 1.61 (s, 3H, CH3), 1.27 (t, J=2x7.0, 3H, CH3 
ester), 1.27 (s, 3H, CH3); 13C NMR (125 MHz, CDCl3, in ppm): 196.0 (CO), 174.4 (CO), 
172.4 (CO), 171.6 (CO), 111.2 (Cp1), 85.4 (Cp2), 85.3 (Cp3), 85.2 (Cp4), 85.0 (Cp5), 
73.8 (CHCO), 67.5 (CHS), 62.7 (tert. C), 60.1 (CH2 ester), 59.2 (CHNH), 38.6 (CH2), 28.3 
(CH3), 27.6 (CH3), 25.1 (CH2), 14.6 (CH3). 
 
(55)  
27 (153 mg, 0.38 mmol) was activated with pentafluorophenyl trifluoroacetate in an 
analogous procedure to the literature description for [(CpCOOH)Re(CO)3].[63] 
4-(Aminomethyl)benzene-sulfonamid hydrochloride (100.4 mg, 0.45 mmol) was 
suspended in 1 ml of DMF. Triethylamine (62.5 l, 0.45 mmol) was added and the 
mixture was stirred for 10 min before it was added to a solution of [(Cp-CH2 
CH2COOPFP)Re(CO)3] (217.5 mg, 0.38 mmol) in 1 ml DMF. After stirring for 16 h at 
room temperature, the solvent was evaporated in vacuo. The crude product was 
purified by silica gel column chromatography using a gradient from pure CH2Cl2 to a 
mixture of CH2Cl2/MeOH/AcOH 14:1:0.2 (78 %).  
IR (cm-1 KBr): 2017, 1911, 1636, 1548, 1323; Calc. for Mr (C18H17N2O6ReS) 575.6; ESI-MS 
[m/z] (CH3OH): 689.3 [M-H]-; 1H NMR (400 MHz, MeOD, in ppm): 7.85 (m, 2H, Ar), 7.42 
(m, 2H, Ar), 5.42 (m, 2H, Cp), 5.38 (m, 2H, Cp), 4.43 (s, 2H, CH2), 2.75 (t, J=7.3 Hz, 2H, 
CH2), 2.48 (t, J=7.3 Hz, 2H, CH2); 13C NMR (125 MHz, MeOD, in ppm): 195.9 (CO), 
174.4 (CONH), 144.8 (Ar1), 144.0 (Ar2), 129.2 (Ar3), 127.5 (Ar4), 110.9 (Cp1), 85.2 (Cp2), 
43.8 (CH2), 39.0 (CH2), 25.3 (CH2); Calc. C, 37.56; H, 2.98; N, 4.97; Found. C, 37.89; H, 
3.01; N, 4.82. 
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3.5 Organic Syntheses 
 
3.5.1 Cp-CONHR 
 
(56) 
3a,4,7,7a-Tetrahydro-1H-4,7-methanoindene-2,6-dicarboxylic acid (Thiele’s acid) 
(85.4 mg, 0.39 mmol) were suspended in 5 ml of CH2Cl2. Oxalyl chloride (100.0 l, 1.16 
mmol) and a catalytic amount of DMF was added. The mixture was stirred until all 
reactants were dissolved. The solvent was removed in vacuo and the activated 
Thiele’s acid was redissolved in 10 ml of THF. 4-aminophenol (85 mg, 0.78 mmol) and 
triethylamine (110.0 l, 0.79 mmol) were added and the mixture was stirred for 2 h. 
Filtration and silica gel column chromatography using THF/Hexane 1:1 afforded pure 
56 (63 %). 
1H NMR (400 MHz, MeOD, in ppm): 7.36-7.20 (m, 4H, Ar), 6.87 (s, 1H, CH), 6.78 – 6.56 
(m, 4H, Ar), 6.51 (s, 1H, CH), 3.65-3.55 (m, 1H, CH), 3.54-3.45 (m, 1H, CH), 3.25-3.16 (m, 
1H, CH), 3.11 – 3.00 (m, 1H, CH), 2.65-2.53 (m 1H, CH), 2.31-2.20 (m, 1H, CH), 1.76 – 
1.67 (m, 1H, CH), 1.55 – 1.46 (m, 1H, CH). 
 
(57) 
56 (120 mg, 0.30 mmol) was dissolved in 1 ml of dry DMA at 0 °C and freshly prepared 
sulfamoylchloride was added drop-wise until no more starting material was observed 
(HPLC monitoring). The reaction mixture was quenched with H2O and extracted with 
ethyl acetate (3 x 15 ml). The combined organic layers were washed with brine (3 x 
15 ml) and H2O (3 x 15 ml), dried over Na2SO4, filtered and concentrated in vacuo to 
give a brown oil, which was not further purified (89 %). 
1H NMR (400 MHz, MeOD, in ppm): 7.59-7.47 (m, 4H, Ar), 7.05 – 6.99 (m, 4H, Ar), 6.91 – 
6.88 (m, 1H, CH), 6.55 – 6.50 (m, 1H, CH), 3.65-3.55 (m, 1H, CH), 3.54-3.49 (m, 1H, CH), 
3.27-3.19 (m, 1H, CH), 3.11 – 3.00 (m, 1H, CH), 2.67-2.54 (m 1H, CH), 2.34-2.23 (m, 1H, 
CH), 1.77 – 1.70 (m, 1H, CH), 1.56 – 1.48 (m, 1H, CH). 
 
(58) 
3a,4,7,7a-Tetrahydro-1H-4,7-methanoindene-2,6-dicarboxylic acid (Thiele’s acid) (100 
mg, 0.46 mmol) were suspended in 5 ml of CH2Cl2. Oxalyl chloride (98 l, 1.35 mmol) 
and a catalytic amount of DMF was added. The mixture was stirred until all reactants 
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were dissolved. The solvent was removed in vacuo and the activated Thiele’s acid 
was redissolved in 10 ml of THF. 4-aminobenzensulfonamide (172 mg, 0.99 mmol) and 
triethylamine (138.5 l, 0.99 mmol) were added and the mixture was stirred for 15 h. 
Filtration and washing with fresh THF and a small portion of MeOH yielded the 
product as yellow solid (43 %). 
Calc. for Mr (C24H24N4O6S2) 528.6; ESI-MS [m/z] (CH3OH): 529.5 [M+H]+; 1H NMR (400 
MHz, DMSO-d6, in ppm): 9.88 (s, 1H, Ar-NH), 9.77 (s, 1H, Ar-NH), 7.92-7.67 (m, 8H, Ar), 
7.20 (s, 4H, SO2N-H2), 6.95 (d, J=3.26 Hz, 1H, CH), 6.59 (d, J=2.01 Hz, 1H, CH), 3.62-3.53 
(m, 1H, CH), 3.48-3.40 (m, 1H, CH), 3.26-3.20 (m, 1H, CH), 3.02-2.90 (m, 1H, CH), 2.71-
2.63 (m 1H, CH), 2.46-2.43 (m, 1H, CH), 2.22-2.12 (m, 1H, CH), 1.65-1.58 (m, 1H, CH), 
1.48-1.40 (m, 1H, CH); Calc. C, 54.53; H, 4.58; N, 10.60; Found. C, 54.19; H, 4.71; N, 
10.60. 
 
(59)  
Thiele’s acid was activated with pentafluorophenyl trifluoroacetate as described 
earlier.[63] 4-(Aminomethyl)benzene-sulfonamide hydrochloride (151.6 mg, 0.68 mmol) 
was suspended in 1 ml of DMF. Triethylamine (190 l, 1.36 mmol) was added and the 
mixture was stirred for 10 minutes The activated Thiele’s acid (188 mg, 0.34 mmol) 
was added and the reaction mixture was stirred for 15 h. The solvent was 
evaporated in vacuo and the residue was extracted with EtOAc and H2O (3 x 10 ml), 
dried over Na2SO4, filtered and concentrated in vacuo. Silica gel chromatography 
using 10 % MeOH in EtOAc yielded 59 as a cream colored powder (90 %). 
Calc. for Mr (C26H28N4O6S2) 556.7; ESI-MS [m/z] (CH3OH): 555.1 [M-H]-; 1H NMR (400 
MHz, MeOD, in ppm): 8.51 (t, J=6.02 Hz, 1H, CH2-NH), 8.23 (t, J=6.02 Hz, 1H, CH2-NH), 
7.88-7.79 (m, 4H, Ar), 7.47-7.36 (m, 4H, Ar), 6.78 (d, J=3.01 Hz, 1H, CH), 6.42 (d, J=1.00 
Hz, 1H, CH), 4.57-4.40 (m, 4H, CH2), 3.63-3.54 (m, 1H, CH), 3.46-3.40 (m, 1H, CH), 3.23-
3.16 (m, 1H, CH), 3.09-2.99 (m, 1H, CH), 2.62-2.49 (m, 1H, CH), 2.23-2.11 (m, 1H, CH), 
1.74-1.65 (m, 1H, CH), 1.54 -1.45 (m, 1H, CH); Calc. C, 56.10; H, 5.07; N, 10.06; Found. 
C, 55.94; H, 5.18; N, 9.73. 
 
(71) 
Thiele’s acid was activated with pentafluorophenyl trifluoroacetate as described 
earlier.[63] L-Noradrenaline (745.0 mg, 4.4 mmol) and triethylamine (1.16 ml, 8.8 mmol) 
were suspended in 1 ml DMF. The activated acid (200 mg, 0.36 mmol) was added in 
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one portion and the dark reaction mixture was stirred for 48 h at room temperature. 
The solvent was evaporated in vacuo and the residue was purified by flash silica gel 
chromatography using a gradient from pure CH2Cl2 to CH2Cl2/MeOH/AcOH 7:1:0.01 
(21 %). 
Calc. for Mr (C28H30N2O8) 522.2; ESI-MS [m/z] (CH3OH): 521.1 [M-H]-, 545.2 [M+Na]+; 1H-
NMR (400 MHz, MeOD, in ppm): 6.88 – 6.65 (m, 6H, Ar), 6.65 – 6.60 (m, 1H, CH), 6.36 – 
6.33 (m, 1H, CH), 4.70 – 4.58 (m, 2H, CHOH), 3.56 – 3.48 (m, 1H, CH), 3.17 – 3.09 (m, 1H, 
CH), 3.06 – 2.93 (m, 1H, CH), 2.53 – 2.41 (m, 1H, CH), 2.21 – 2.11 (m, 1H, CH), 1.70 – 1.63 
(m, 1H, CH), 1.49 – 1.43 (m, 1H, CH). 
 
(72) 
Thiele’s acid was activated with pentafluorophenyl trifluoroacetate as described 
earlier.[63] 7-aminoheptanoic acid (1.2 eq, 60.3 mg, 0.42 mmol) was dissolved in 1 ml 
of DMF. The activated acid (191 mg, 0.34 mmol) was added in one portion and the 
reaction mixture was stirred for 20 h at room temperature. The solvent was 
evaporated in vacuo and the residue was purified by silica gel chromatography 
using CH2Cl2/MeOH/AcOH 100:1:1 (34 %). 
Calc. for Mr (C25H24F5NO5) 513.5; ESI-MS [m/z] (CH3OH): 536.1 [M+Na]+; 1H-NMR (400 
MHz, MeOD, in ppm): 7.67 (t, J=5.5 Hz, 1H, NH), 7.35 (m, 1H, CH), 6.38 (m, 1H, CH), 
3.67 (m, 1H, CH), 3.47 (m, 1H, CH), 3.22 (m, 3H, CH2 superimposed with CH), 3.11 (m, 
1H, CH), 2.58 (m, 1H, CH), 2.29 (t, J=7.4 Hz, 2H, CH2), 2.08 (m, 1H, CH), 1.81 (m, 1H, 
CH), 1.57 (m, 5H, CH2 superimposed with CH), 1.35 (m, 4H, CH2). 
 
(73) 
4-(Aminomethyl)benzene-sulfonamide hydrochloride (1.2 eq, 92.4 mg, 0.42 mmol) 
was dissolved in 1 ml DMF. Triethylamine (5 eq, 235.6 l, 1.7 mmol) and 72 (174.6 mg, 
0.34 mmol) was added. The reaction progress was monitored by HPLC. When the 
starting compound was consumed, the solvent was evaporated in vacuo and the 
residue was purified by silica gel chromatography using CH2Cl2/MeOH/AcOH 100:5:5 
(80 %). 
Calc. for Mr (C26H33N3O6S) 515.6; ESI-MS [m/z] (CH3OH): 514.1 [M-H]-, 538.2 [M+Na]+; 
1H-NMR (400 MHz, MeOD, in ppm): 7.86 (m, 2H, Ar), 7.61 (t, J=5.9 Hz, 1H, NH), 7.41 
(m, 2H, Ar), 6.77 (m, 1H, CH), 6.35 (m, 1H, CH), 3.56 (m, 1H, CH), 4.52 (m, 2H, CH2) 3.41 
(m, 1H, CH), 3.22 (m, 3H, CH2 superimposed with CH), 3.03 (m, 1H, CH), 2.51 (m, 1H, 
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CH), 2.27 (t, J=7.4 Hz, 2H, CH2), 2.11 (m, 1H, CH), 1.69 (m, 1H, CH), 1.56 (m, 5H, CH2 
superimposed with CH), 1.35 (m, 4H, CH2). 
 
(74) 
74 was synthesized as described for 73 using 8-aminocaprylic acid. The crude 
product was purified by flash chromatography on silica gel (eluent gradient from 
CH2Cl2 to CH2Cl2/MeOH/AcOH 20 : 1 : 1), from which the pure product were 
obtained (32 %).  
Calc. for Mr (C27H40N2O6) 488.3; ESI-MS [m/z] (CH3OH): 527.3 [M+K]+, 511.3 [M+Na]+, 
489.3 [M+H]+; 1H-NMR (500 MHz, MeOD, in ppm): 7.83 (t, J=5.7 Hz, 1H, NH), 7.54 (t, 
J=5.7 Hz, 1H, NH), 6.66 (m, 1H, CH), 6.33 (m, 1H, CH), 3.52 (m, 1H, CH), 3.37 (m, 1H, 
CH), 3.17 (m, 4H, CH2), 3.13 (m, 1H, CH), 3.01 (m, 1H, CH), 2.48 (m, 1H, CH), 2.30 (m, 
4H, CH2), 2.06 (m, 1H, CH), 1.65 (m, 5H, CH2 superimposed with CH), 1.51 (m, 5H, CH2 
superimposed with CH), 1.35 (m, 10H, CH2). 
 
(75) 
To a solution of 72 (934.5 mg, 1.82 mmol) in 3 ml DMF benzyl alcohol (4 eq, 754 l, 7.28 
mmol) and triethylamine (4 eq, 1.01 ml, 7.28 mmol) were added, and the mixture was 
stirred at room temperature under nitrogen. Reaction control by NMR still showed 
incomplete coupling after seven days. Hence, more benzyl alcohol (4 eq, 754 l, 7.28 
mmol) and triethylamine (2 eq, 500 l, 3.64 mmol) were added, and the mixture was 
stirred during additional 24 hours at 50 °C. The solvent was evaporated at reduced 
pressure. The residue was suspended in 4 ml saturated NaHCO3 solution diluted 
20fold by water and extracted with 100 ml EtOAc. The aqueous phase was then 
acidified by 1 M HCl to pH 1, and extracted three times with 100 ml EtOAc. The 
combined organic phases were dried with Na2SO4, and the solvent was removed in 
vacuo, yielding 700 mg crude product. The crude product was purified by flash 
chromatography on silica gel (eluent gradient from CH2Cl2 to CH2Cl2/MeOH 9 : 1), 
from which 70 mg (9 %) pure product were obtained. 
Calc. for Mr (C26H31NO5) 473.2; ESI-MS [m/z] (CH3OH): 460.1 [M+Na]+, 438.1 [M+H]+, 
436.1 [M-H]-; 1H-NMR (500 MHz, MeOD, in ppm): 7.64 (t, J=5.5 Hz, 1H, NH) 7.35 (m, 5H, 
Ar), 6.95 (m, 1H, CH), 6.32 (m, 1H, CH), 3.55 (m, 1H, CH), 3.36 (m, 1H, CH), 3.20 (m, 3H, 
CH2 superimposed with CH), 3.01 (m, 1H, CH), 2.49 (m, 1H, CH), 2.28 (t, J=7.4 Hz, 2H, 
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CH2), 2.02 (m, 1H, CH), 1.67 (m, 1H, CH), 1.60 (m, 1H, CH), 1.48 (m, 4H, CH2), 1.33 (m, 
4H, CH2). 
 
(41) 
Thiele’s acid was activated with pentafluorophenyl trifluoroacetate as described 
earlier.[63] 7-aminoheptanoic acid (2.2 eq, 115.7 mg, 0.80 mmol) was dissolved in 1 ml 
of DMF and triethylamine (4.4 eq, 220.8 l, 1.59 mmol) was added. The activated 
acid (200 mg, 0.36 mmol) was added in one portion and the reaction mixture was 
stirred for 20 h at room temperature. The solvent was evaporated in vacuo and the 
residue was purified by silica gel chromatography using CH2Cl2/MeOH/AcOH 
100:0.5:0.1 (54 %). 
Calc. for Mr (C26H38N2O6) 474.6; ESI-MS [m/z] (CH3OH): 497.2 [M+Na]+, 475.3 [M+H]+; 
1H-NMR (400 MHz, MeOD, in ppm): 7.81 (t, J=5.7 Hz, 1H, NH), 7.52 (t, J=5.7 Hz, 1H, 
NH), 6.63 (m, 1H, CH), 6.30 (m, 1H, CH), 3.48 (m, 1H, CH), 3.34 (m, 1H, CH), 3.18 (m, 4H, 
CH2), 3.10 (m, 1H, CH), 2.97 (m, 1H, CH), 2.45 (m, 1H, CH), 2.27 (m, 4H, CH2), 2.00 (m, 
1H, CH), 1.60 (m, 5H, CH2 superimposed with CH), 1.47 (m, 5H, CH2 superimposed with 
CH), 1.33 (m, 8H, CH2). 
 
(42) 
42 (50 mg, 0.11 mmol) was dissolved in 1 ml DMF and N-methylmorpholine (3 eq, 35.1 
l, 0.32 mmol) and O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (3 eq, 121.1 mg, 0.32 mmol) was added. The solution was 
stirred for 30 minutes at room temperature. O-(tert-Butyldimethylsilyl)hydroxylamine (3 
eq, 47 mg, 0.32 mmol) dissolved in 1 ml DMF was added and the reaction mixture 
was stirred for 5 h at room temperature. The solvent was evaporated in vacuo. The 
residue was suspended in distilled water and extracted three times with 20 ml EtOAc. 
The aqueous phase was evaporated and the residue was purified by silica gel 
chromatography using CH2Cl2/MeOH/AcOH 10:1:0.1 (70 %). 
Calc. for Mr (C26H40N4O6) 504.6; ESI-MS [m/z] (CH3OH): 527.3 [M+Na]+; 1H-NMR (400 
MHz, MeOD, in ppm): 7.86 (t, J=5.7 Hz, 1H, NH), 7.59 (t, J=5.6 Hz, 1H, NH), 6.68 (m, 1H, 
CH), 6.33 (m, 1H, CH), 3.53 (m, 1H, CH), 3.38 (m, 1H, CH), 3.21 (m, 5H, CH2 
superimposed with CH), 3.02 (m, 1H, CH), 2.49 (m, 1H, CH), 2.12 (m, 4H, CH2), 2.06 (m, 
1H, CH), 1.65 (m, 5H, CH2 superimposed with CH), 1.51 (m, 5H, CH2 superimposed with 
CH), 1.36 (m, 8H, CH2). 
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3.5.2 Cp-SO2R 
 
(7)  
Bis-phenylsulfonyl-methane (296.0 mg, 1.0 mmol) was dissolved in 15 ml toluene. 50 % 
aqueous NaOH (3 ml), a catalytic amound of TBAF (1 mol %) and cis-1,4-dichloro-2-
butene (162.5 mg, 1.3 mmol) were added. The mixture was stirred vigorously for 24h 
at room temperature. The two layers were separated and the aqueous layer was 
extracted with MTBE. The combined organic layers were washed with brine, dried 
over Na2SO4 and evaporated under reduced pressure. The residue was recrystallized 
from CH2Cl2/hexane to yield 7 (90 %). 
Calc. for Mr (C17H16O4S2) 348.4; ESI-MS [m/z] (CH3OH): 387.0 [M+K]+. 1H NMR (500 MHz, 
CDCl3, in ppm): 8.06 – 7.60 (m, 10H, Ar), 5.43 (s, 2H, CH), 3.39 (s, 4H, CH2). Calc. C, 
58.60; H, 4.63; Found C, 58.39; H, 4.74. 
 
3.5.3 Cp-NO2 
 
(9)  
Phenylsulfonyl-nitromethane (100 mg, 0.5 mmol) was dissolved in 6 ml DMF. The 
solution was cooled to 0 °C and NaH (60 %, 50 mg, 1.25 mmol) was added. After 1.5h 
cis-1,4-dichloro-2-butene (60.5 l, 0.575 mmol) was added and the mixture was stirred 
at room temperature for 5 days. The reaction was quenched with aqueous NH4Cl. 
The aqueous layer was removed and the organic layer was diluted with CH2Cl2 and 
extracted two times with water and two times with brine. After drying over Na2SO4, 
solvents were removed under reduced pressure and the residue was purified by silica 
gel column chromatography using CH2Cl2/hexane 1:1 to yield 9 as a coloreless 
powder (80 %). Crystals suitable for X-Ray analysis were grown from CH2Cl2/hexane. 
Calc. for Mr. (C11H11NO4S) 253.3; ESI-MS [m/z] (CH3OH): 276.1 [M+Na]+. 1H NMR (500 
MHz, CDCl3, in ppm): 7.80 – 7.50 (m, 5H, Ar), 5.63 (s, 2H, CH), 3.43 (s, 4H, CH2). Calc. 
C, 52.16; H, 4.38; N, 5.53; Found C, 52.29; H, 4.43; N, 5.60. 
 
(8)  
7 or 9 was dissolved in 5 ml THF and cooled to -78 °C. Saturated KtBuO (1 ml) in THF 
was added and the mixture was stirred for 1h, before it was allowed to reach -20 °C 
and after 30min 0 °C. At this point, the reaction was quenched by adding a 
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saturated aqueous solution of NH4Cl. The product was extracted two times with 
CH2Cl2 and brine and dried. Concentration under reduced pressure and column 
chromatography with CH2Cl2 with EtOAc gradient afforded dimer 8 (65-70 %). 
Calc. for Mr. (C22H20O4S2) 412.08; ESI-MS [m/z] (CH3OH): Dimer: 435.1 [M+Na]+; 
Monomer: 229.1 [M+Na]+. 1H NMR (500 MHz, CDCl3, in ppm): 7.83 – 7.43 (m, 8H, Ar), 
6.45 (d, 1H, CH), 5.90 – 5.79 (m, 2H, CH), 3.86 – 3.83 (m, 1H, CH), 3.04 – 2.99 (m, 2H, 
CH), 2.89 (s, 1H, CH), 2.40 – 2.34 (m, 1H, CH), 1.81 – 1.76 (m, 2H, CH2). Calc. C, 52.16; 
H, 4.38; N, 5.53; Found C, 52.29; H, 4.43; N, 5.60. 
 
(10)  
Sodium (1g, cutt in small pieces) was dissolved in 20 ml of EtOH and cooled to 0 °C. 
Freshly distilled cyclopentadiene (2.91 g, 44 mmol) and isopropyl nitrate (4.46 ml, 0.44 
mmol) were added and the mixture was stirred for one hour and was then allowed 
to warm to room temperature. After stirring for another two hours, the orange 
precipitate was collected by filtration and was washed with toluene on the filter (15 
% yield). 
1H NMR (400 MHz, D2O, in ppm): 6.49 – 6.47 (m, 2H, Cp), 6.23 – 6.21 (m, 2H, Cp). 
 
3.5.4 Cp-NHR 
 
(14) 
Thiele's Acid (50 mg, 0.22 mmol) was suspended in Toluene (1 ml). Triethylamine (72.3 
l, 0.48 mmol) and diphenylphosphoryl azide (107.8 l, 0.50 mmol) were added. The 
mixture was stirred until the solution became clear and then one more hour. The 
solvent was evaporated under reduced pressure and the residue was purified by 
silica gel column chromatography, using CH2Cl2/hexane 2:3 (80 %). 
IR (cm-1 KBr): 2030, 1681, 1618, 1487, 1175; Calc. for Mr (C12H10N6O2) 270.3; ESI-MS [m/z] 
(CH3OH): 269.3 [M-H]-; 1H NMR (400 MHz, CDCl3, in ppm): 6.96 – 6.93 (m, 1H, CH), 
6.62 – 6.59 (m, 1H, CH), 3.60 – 3.53 (m, 1H, CH), 3.45 – 3.41 (m, 1H, CH), 3.23 - 3.18 (m, 
1H, CH), 3.05 - 2.96 (m, 1H, CH), 2.56 - 2.47 (m, 1H, CH), 2.06 - 1.98 (m, 1H, CH), 1.74 - 
1.69 (m, 1H, CH), 1.49 - 1.44 (m, 1H, CH). 
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(15-16a/b) 
14 (50 mg, 0.19 mmol) was dissolved in 5 ml toluene. The solution was stirred at 80°C 
for 1 h, then an 10 fold excess (or more) of nucleophile a-f was added and the 
mixture was stirred for another hour at 80°C. Solvents were removed under reduced 
pressure and the crude products were analysed. 
15: IR (cm-1 KBr): 2267 
16a: IR (cm-1 KBr): 1744, 1726, 1715; Calc. for Mr (C14H18N2O4) 278.3; ESI-MS [m/z] 
(CH3OH): 279.1 [M+H]+; 1H NMR (400 MHz, CDCl3, in ppm): 6.10 – 5.97 (m, 1H, CH), 
5.60 – 5.36 (m, 1H, CH), 3.76 (s, 3H, CH3), 3.71 (s, 3H, CH3), 3.38 – 3.29 (m, 1H, CH), 2.87 
– 2.77 (m, 1H, CH), 2.62 - 2.56 (m, 1H, CH), 2.43 - 2.38 (m, 1H, CH), 2.34 - 2.26 (m, 1H, 
CH), 2.12 - 2.02 (m, 1H, CH), 1.83 - 1.76 (m, 1H, CH), 1.76 - 1.68 (m, 1H, CH). 
16b: Calc. for Mr (C26H28N4O2) 428.5; ESI-MS [m/z] (CH3OH): 429.2 [M+H]+; 1H NMR (400 
MHz, CDCl3, in ppm): 7.38 - 7.10 (m, 10H, Ar), 6.60 – 6.44 (m, 1H, CH), 5.20 – 5.05 (m, 
1H, CH), 4.41 - 4.06 (m, 4H, CH2), 3.27 – 3.16 (m, 1H, CH), 2.81 – 2.71 (m, 1H, CH), 2.60 - 
2.48 (m, 2H, CH), 2.33 - 2.21 (m, 1H, CH), 2.12 - 2.01 (m, 1H, CH), 1.79 - 1.62 (m, 1H, 
CH). 
 
3.5.5 Cp-CH2COR 
 
(17-18) 
NaCp (2M in THF, 4 ml, 8.0 mmol) was cooled with a water/Ice-bath to 0 °C. 
Bromoacetic acid methylester (836 l, 8.8 mmol) was added dropwise via syringe 
over 10minutes A cream colored precipitate formed instantly and the dark red 
colour gradually diminished. The suspension was stirred for 1h at 0 °C and for 3h at 
room temperature. The solid salts were removed by filtration and the filtrate was 
concentrated under flushing nitrogen. The liquid residue was purified by distillation at 
60 °C (0.4 mbar) (17, 30 – 50 %, isomeric mixture). 
1H NMR (400 MHz, CDCl3, in ppm): 6.54 – 6.48 (m, 1H, CH), 6.48 – 6.40 (m, 2H, CH), 
6.37 – 6.32 (m, 2H, CH) 6.24 – 6.19 (m, 1H, CH), 3.70 (s, 3H, CH3), 3.69 (s, 3H, CH3), 3.47 – 
3.44 (m, 2H, CH2), 3.44 – 3.40 (m, 2H, CH2), 3.05 – 2.97 (m, 4H, CH2); 13C NMR (125 MHz, 
CDCl3, in ppm): 172.1 (CO), 172.0 (CO), 148.4 (olefinic Cp), 140.2 (olefinic Cp), 138.8 
(olefinic Cp), 134.8 (olefinic Cp), 134.4 (olefinic Cp), 134.3 (olefinic Cp), 132.8 (olefinic 
Cp), 132.4 (olefinic Cp), 130.6 (olefinic Cp), 130.1 (olefinic Cp), 108.4 (olefinic Cp), 
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52.0 (2xCH3), 51.0 (CH3), 43.8 (CH2), 41.7 (CH2), 36.4 (CH2), 35.7 (CH2), 33.5 (CH2), 30.0 
(CH2). 
 
Hydrolysis of the ester function was performed with LiOH (5 eq.) in a mixture of 
H2O/MeOH/THF (1:2:2). The solution was stirred for 2h at 0 °C and for another 5h at 
room temperature. Concentration under reduced pressure and acidification with 1M 
HCl to pH 3 produced a cream colored precipitate. EtOAc was added and the 
aqueous phase was extracted three times. The combined organic fractions were 
dried over Na2SO4 and evaporated under reduced pressure. 18 was obtained as a 
yellowish cream (74 % isomeric mixture). 
1H NMR (400 MHz, CDCl3, in ppm): 6.51 – 6.49 (m, 1H, CH), 6.48 – 6.40 (m, 2H, CH), 
6.37 – 6.32 (m, 2H, CH) 6.24 – 6.19 (m, 1H, CH), 3.49 – 3.40 (m, 4H, CH2), 3.05 – 2.97 (m, 
4H, CH2); 13C NMR (125 MHz, CDCl3, in ppm): 178.3 (CO), 178.2 (CO), 139.3 (olefinic 
Cp), 138.1 (olefinic Cp), 134.6 (olefinic Cp), 134.2 (olefinic Cp), 133.1 (olefinic Cp), 
132.3 (olefinic Cp), 131.1 (olefinic Cp), 130.7 (olefinic Cp), 43.7 (CH2), 41.6 (CH2), 36.2 
(CH2), 35.5 (CH2). 
 
(21a/b) 
18 (103 mg, 0.81 mmol) was dissolved in 2 ml dry DMF and N-methylmorpholine (132 
l, 1.20 mmol) and O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexa-
fluorophosphate (456 mg, 1.20 mmol) were added. The mixture was stirred for 45 min, 
then triethylamine (111.5 l, 0.81 mmol) and the appropriate amine (0.81 mmol) was 
added. After stirring for 16 h, the solvent was removed under reduced pressure and 
the crude product was purified by silica gel column chromatography using CH2Cl2 
(a) or CH2Cl2/MeOH 100:5 (b) respectively (20-55 %). Crystals were grown from 
CH2Cl2/Hexane. Analyses revealed a rearrangement of the double bonds in the 
cyclopentadienyl-ring for both amide substituted compounds 66a and b. The "true" 
cyclopentadienyl form was not obtained. 
21a: Calc. for Mr (C14H15NO) 213.3; ESI-MS [m/z] (CH3OH): 235.9 [M+Na]+, 449.1 
[2M+Na]+; 1H NMR (400 MHz, CDCl3, in ppm): 7.40 – 7.30 (m, 5H, Ar), 6.54 (m, 1H, 
Cp), 6.25 (m, 1H, Cp), 5.68 (m, 1H, CH), 3.11 (m, 2H, CH2), 2.62 (m, 2H, CH2). 
21b: Calc. for Mr (C10H13NO3) 195.2; ESI-MS [m/z] (CH3OH): 217.9 [M+Na]+, 413.0 
[2M+Na]+; 1H NMR (500 MHz, CDCl3, in ppm): 6.56 (m, 1H, CH), 6.26 (m, 1H, CH), 5.74 
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(m, 1H, CH), 4.11 (d, J=5.4 Hz, 2H, CH2), 3.77 (s, 3H, CH3), 3.07 (m, 2H, CH2), 2.61 (m, 2H, 
CH2). 
 
3.5.6 Cp-CH2CH2COR 
 
(19-20) 
NaCp (4 ml, 8.0 mmol) was cooled with a water/Ice-bath to 0 °C. Methyl-3-
brompropionate (960 l, 8.8 mmol) was added dropwise via syringe over 10minutes A 
cream colored precipitate formed instantly and the dark red colour gradually 
dininished.The suspension was stirred for 1h at 0 °C and for 3h at room temperature. 
The solid salts were removed by filtration and the filtrate was concentrated under a 
stream of nitrogen. The liquid brown residue was purified by distillation at 70 °C (0.4 
mbar) (19, 30 – 50 %, isomeric mixture). 
1H NMR (400 MHz, CDCl3, in ppm): 6.44 – 6.40 (m, 3H, CH), 6.30 – 6.26 (m, 1H, CH), 
6.21 – 6.17 (m, 1H, CH) 6.06 – 6.02 (m, 1H, CH), 3.68 (s, 6H, CH3), 2.99 – 2.93 (m, 2H, 
CH2), 2.93 – 2.88 (m, 2H, CH2), 2.80 – 2.67 (m, 4H, CH2), 2.62 – 2.54 (m, 4H, CH2); 13C 
NMR (125 MHz, CDCl3, in ppm): 173.9 (2x CO), 147.7 (olefinic Cp), 145.5 (olefinic 
Cp), 134.5 (2x olefinic Cp), 132.5 (olefinic Cp), 131.3 (olefinic Cp), 127.1 (olefinic Cp), 
126.6 (olefinic Cp), 51.8 (2x CH3), 43.5 (CH2), 41.6 (CH2), 34.2 (CH2), 33.6 (CH2), 26.1 
(CH2), 25.3 (CH2). 
 
Hydrolysis of the ester function was performed with LiOH (5 eq.) in a mixture of 
H2O/MeOH/THF (1:2:2). The solution was stirred for 2h at 0 °C and for another 5h at 
room temperature. Concentration under reduced pressure and acidification with 1M 
HCl to pH 3 produced a cream colored precipitate. EtOAc was added and the 
aqueous phase was extracted three times. The combined organic fractions were 
dried over Na2SO4 and evaporated under reduced pressure. 20 was obtained as a 
yellowish cream (69 %, isomeric mixture). 
Calc. for Mr (C8H10O2) 138.2; ESI-MS [m/z] (CH3OH): 139.0 [M+H]+, 277.0 [2M+H]+; 1H 
NMR (400 MHz, CDCl3, in ppm): 6.48 – 6.40 (m, 3H, CH), 6.32 – 6.27 (m, 1H, CH), 6.24 
– 6.19 (m, 1H, CH) 6.10 – 6.05 (m, 1H, CH), 3.00 – 2.95 (m, 2H, CH2), 2.95 – 2.90 (m, 2H, 
CH2), 2.82 – 2.59 (m, 8H, CH2). 
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(69) 
20 (40 mg, 0.29 mmol) was dissolved in 3 ml dry CH2Cl2. Oxalylchloride (75 l, 0.87 
mmol) and a catalytic amount of DMF was added. The suspension was stirred at 0 °C 
for 1h and at room temperature for another 5h. The solvent was evaporated and the 
residue was redissolved in dry THF. 
In a separate flask 6-aminopenicillanic acid (94.1 mg, 0.435 mmol) was suspended in 
2 ml EtOH. Trimethylsilyl chloride (138.3 l, 1.09 mmol) was added, whereas the 
mixture turned clear instandly and was stirred for 2h. Solvents and excess of 
trimethylsilyl chloride were removed under reduced pressure. The colourless residue 
was redissolved in dry THF and triethylamine (120.6 l, 0.87 mmol) was added. 
Both solutions were slowly mixed together at 0 °C and stirred for 1h, then the mixture 
was allowed to reach room temperature and was stirred for another 2h. THF was 
evaporated under reduced pressure and the residue was purified by silica gel 
column chromatography using CH2Cl2/MeOH/AcOH 100:2:1 (64 %). 
Calc. for Mr (C18H24N2O4S) 364.5; ESI-MS [m/z] (CH3OH): 383.2 [M+H3O]+; 1H NMR (400 
MHz, MeOD, in ppm): 6.56 – 6.07 (m, 3H, Cp), 5.00 (d, J=7.5 Hz, 1H, CH), 4.55 (d, 
J=7.5 Hz, 1H, CH), 4.21 (q, J=3x7.2 Hz, 2H, CH2 ester), 3.75 (s, 1H, CHCOOEt), 2.98 – 2.90 
(m, 2H, CH2), 2.80 – 2.65 (m, 2H, CH2), 2.58 – 2.50 (m, 2H, CH2), 1.63 (s, 3H, CH3), 1.30 (t, 
J=2x7.2, 3H, CH3 ester), 1.30 (s, 3H, CH3); 13C NMR (125 MHz, CDCl3, in ppm): 175.7 
(CO), 172.4 (CO), 171.7 (CO), 149.2 (Cp), 147.0 (Cp), 135.4 (Cp), 135.0 (Cp), 133.3 
(Cp), 132.0 (Cp), 128.2 (Cp), 127.6 (Cp), 73.9 (CHCO), 67.4 (CHS), 62.6 (tert. C), 60.0 
(CH2 ester), 59.2 (CHNH), 44.3 (CH2), 42.2 (CH2), 36.9 (CH2), 36.3 (CH2), 28.2 (CH3), 27.6 
(CH3), 26.9 (CpCH2CH2), 15.6 (CH3 ester). 
 
3.6 Labeling with 99mTc 
 
(61/62) 
A vial was charged with [H3BCOOH] (4 mg), Na2[C4H4O6]*2H2O (7 mg), 
Na2B4O7*10H2O (7 mg) and the ligand 58 or 59 respectively (1-1.5 mg). The vial was 
sealed and flushed with nitrogen for 5 minutes Freshly eluted Na[TcO4] (1 ml) was 
injected into the vial and the mixture was heated at 85-90 °C. After cooling to room 
temperature and filtering, the products were analysed by HPLC. Quantitative 
conversion of [TcO4]- to the desired product was observed after 60 or 90 minutes 
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respectively. The nature of the product was identified by coinjection of the 
corresponding Re-complex.  
 
(60) 
A vial was charged with [H3BCOOH] (4 mg), Na2[C4H4O6]*2H2O (7 mg), 
Na2B4O7*10H2O (7 mg) and the ligand 56 (5 mg). The vial was sealed and flushed 
with nitrogen for 5 minutes Freshly eluted Na[TcO4] (1 ml) was injected into the vial 
and the mixture was heated at 85-90 °C. After cooling to room temperature and 
filtering, the products were analysed by HPLC. 72 % conversion of [TcO4]- to the 
desired product was observed after 90 minutes. 27 % of the activity was observed as 
unreacted [Tc(CO)3(OH2)3] and 1 % as [TcO4]-.The nature of the product was 
identified by coinjection of the corresponding Re-complex.  
 
(43) 
A vial was charged with [H3BCOOH] (4 mg), Na2[C4H4O6]*2H2O (7 mg), 
Na2B4O7*10H2O (7 mg) and the ligand 41 (5 mg). The vial was sealed and flushed 
with nitrogen for 5 minutes Freshly eluted Na[99mTcO4] (1 ml) was injected and the 
mixture was heated at 85-90 °C. After cooling to room temperature and filtering, the 
products were analysed by HPLC. 87 % conversion of [99mTcO4]- was observed after 
80 minutes. 12 % of the activity was observed as unreacted [Tc(CO)3(OH2)3]. 
Coinjection of the corresponding Re-complex confirmed the nature of the product. 
 
(43/76) 
A vial was charged with [H3BCOOH] (4 mg), Na2[C4H4O6]*2H2O (7 mg), 
Na2B4O7*10H2O (7 mg) and the ligand 74 (8 mg). The vial was sealed and flushed 
with nitrogen for 5 minutes Freshly eluted Na[99mTcO4] (1 ml) was injected and the 
mixture was heated at 85-90 °C. After cooling to room temperature and filtering, the 
products were analysed by HPLC. 80 % conversion of [99mTcO4]- was observed after 
150 minutes. 10 % of the activity was observed as unreacted [Tc(CO)3(OH2)3] and 10 
% as undefined sideproducts. The product radio (43:76) was 45:55. The nature of the 
products was confirmed by coinjection of the corresponding Re-complex. 
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(43/3) 
A vial was charged with [H3BCOOH] (4 mg), Na2[C4H4O6]*2H2O (7 mg), 
Na2B4O7*10H2O (7 mg) and the ligand 73 (3-4 mg). The vial was sealed and flushed 
with nitrogen for 5 minutes Freshly eluted Na[99mTcO4] (1 ml) was injected and the 
mixture was heated at 85-90 °C. After cooling to room temperature and filtering, the 
products were analysed by HPLC. Quantitative conversion of [99mTcO4]- was 
observed after 200 minutes. The product radio (43:3) was nearly 50:50. The nature of 
the products was confirmed by coinjection of the corresponding Re-complex.  
 
(43/62) 
To a commercially available Isolink-kit freshly eluted Na[99mTcO4] (1 ml) was injected 
and the mixture was heated at 85-90 °C. The full conversion of [99mTcO4]- to 
[99mTc(OH2)3(CO)3]+ was confirmed by HPLC after 30 minutes. A new vial was 
charged with 71 (3-5 mg), sealed and flushed with nitrogen for 5 minutes 
[99mTc(OH2)3(CO)3]+-solution (1 ml) was injected into the vial and the mixture was 
heated at 85 – 90 °C. After cooling to room temperature and filtering, the products 
were analysed by HPLC. 81 % conversion of [99mTc(OH2)3(CO)3]+ to the products was 
observed after 150 minutes. 7 % of [99mTcO4]- was formed as a side product. The 
product radio (43:62) was 45:55. The nature of the products was confirmed by 
coinjection of the corresponding Re-complexes. 
 
(28) 
A vial was charged with [H3BCOOH] (4 mg), Na2[C4H4O6]*2H2O (7 mg), 
Na2B4O7*10H2O (7 mg) and the ligand 18 (4-6 mg). The vial was sealed and flushed 
with nitrogen for 5 minutes Freshly eluted Na[TcO4] (1 ml) was injected and the 
mixture was heated at 85-90 °C. After cooling to room temperature, the products 
were analysed by HPLC. Quantitative conversion of [TcO4]- to the desired product 
was observed after 30 minutes. The nature of the product was identified by 
coinjection of the corresponding Re-complex. 
 
(29) 
A vial was charged with [H3BCOOH] (4 mg), Na2[C4H4O6]*2H2O (7 mg), 
Na2B4O7*10H2O (7 mg) and the ligand 20 (4-6 mg). The vial was sealed and flushed 
with nitrogen for 5 minutes Freshly eluted Na[TcO4] (1 ml) was injected and the 
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mixture was heated at 85-90 °C in a heating block. After cooling to room 
temperature, the products were analysed by HPLC. 65 % conversion of [TcO4]- to the 
desired product was observed after 5h. Microwave heating at 130 °C results in the 
same yield after 30 minutes The nature of the product was identified by coinjection 
of the corresponding Re-complex. 
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4. Crystallographic Data 
 
 
 
 45  52 
Empirical formula  C14H11N2O5ReS  C16H15N2O7ReS 
Formula weight  505.51  565.56 
Crystal system  Orthorhombic  Triclinic 
Space group  Pbcn  P-1 
a [Å] 33.1611(3)  10.0414(17) 
b [Å] 6.8940(8)  10.7314(16) 
c [Å] 13.7984(16)  10.7480(16) 
 [°] 90  65.930(14) 
 [°] 90  65.719(15) 
 [°] 90  88.243(13) 
Volume [Å3] 3154.5(6)  950.8(3) 
Z 8  2 
Crystal size [mm3] 0.20 x 0.19 x 0.14  0.33 x 0.25 x 0.11 
Crystal description orange block  colourless plate 
Reflections collected 46378  10267 
Independent refl. [R(int)] 4808 [0.0307]  5791 [0.0203] 
Refl. observed [I>2 (I)] 3748  4320 
Completeness to  100.0 % to 30.51°  99.7 % to 30.51° 
Goodness-of-fit on F2 1.038  0.875 
Final R indices [I>2 (I)] R1 = 0.0223  R1 = 0.0263 
 wR2 = 0.0479  wR2 = 0.0430 
Diff. peak and hole [e/Å3] 1.023 and -0.729  0.898 and -0.849 
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 34b  4 
Empirical formula  C17H20MnNO6  C18H22N2O14Re2S2 
Formula weight  398.28  926.90 
Crystal system  Monoclinic  Monoclinic 
Space group  P21/c  P21/c 
a [Å] 12.2182(4)  16.3126(6) 
b [Å] 19.1058(7)  8.4958(6) 
c [Å] 7.5939(3)  9.4921(11) 
 [°] 90  90 
 [°] 90.240(3)  101.248(8) 
 [°] 90  90 
Volume [Å3] 1772.69(11)  1290.23(18) 
Z 4  2 
Crystal size [mm3] 0.35 x 0.23 x 0.17  0.23 x 0.21 x 0.14 
Crystal description colourless block  colourless block 
Reflections collected 12863  13140 
Independent refl. [R(int)] 5402 [0.0334]  2490 [0.0901] 
Refl. observed [I>2 (I)] 4080  2137 
Completeness to  99.7 % to 30.51°  94.7 % to 26.36° 
Goodness-of-fit on F2 1.066  0.982 
Final R indices [I>2 (I)] R1 = 0.0460  R1 = 0.0305 
 wR2 = 0.1119  wR2 = 0.0748 
Diff. peak and hole [e/Å3] 0.400 and -0.914  1.783 and -1.654 
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 51  5 
Empirical formula  C16H15N2O8ReS  C8H4ClO5ReS 
Formula weight  581.56  433.82 
Crystal system  Triclinic  Triclinic 
Space group  P-1  P-1 
a [Å] 10.1572(13)  6.8766(2) 
b [Å] 10.5517(13)  7.0479(3) 
c [Å] 10.6043(13)  12.0274(3) 
 [°] 107.528(14)  83.440(3) 
 [°] 90.995(15)  75.831(2) 
 [°] 115.459(14)  72.196(3) 
Volume [Å3] 964.2(2)  537.62(3) 
Z 2  2 
Crystal size [mm3] 0.67 x 0.60 x 0.20  0.34 x 0.25 x 0.12 
Crystal description yellow plate  light yellow plate 
Reflections collected 11737  12712 
Independent refl. [R(int)] 4326 [0.1676]  5445 [0.0261] 
Refl. observed [I>2 (I)] 3691  4797 
Completeness to  90.6 % to 28.23°  99.9 % to 30.44° 
Goodness-of-fit on F2 1.050  0.994 
Final R indices [I>2 (I)] R1 = 0.0566  R1 = 0.0263 
 wR2 = 0.1355  wR2 = 0.0559 
Diff. peak and hole [e/Å3] 3.213 and -3.236  1.218 and -3.291 
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 63  24b 
Empirical formula  C13H18ClN4O6ReS  C18H11BrO7Re2 
Formula weight  580.02  791.58 
Crystal system  Triclinic  Monoclinic 
Space group  P-1  P21/c 
a [Å] 9.20508(12)  13.62640(17) 
b [Å] 9.54693(11)  10.26800(13) 
c [Å] 11.51214(15)  13.47480(17) 
 [°] 84.3940(10)  90 
 [°] 76.6940(10)  93.9328(12) 
 [°] 87.2470(10)  90 
Volume [Å3] 979.48(2)  1880.90(4) 
Z 2  4 
Crystal size [mm3] 0.42 x 0.27 x 0.08  0.24 x 0.20 x 0.13 
Crystal description colourless plate  colourless plate 
Reflections collected 56216  13876 
Independent refl. [R(int)] 6868 [0.0281]  6271 [0.0251] 
Refl. observed [I>2 (I)] 6397  5633 
Completeness to  99.9 % to 30.44°  99.9 % to 30.44° 
Goodness-of-fit on F2 1.048  1.112 
Final R indices [I>2 (I)] R1 = 0.0190  R1 = 0.0309 
 wR2 = 0.0490  wR2 = 0.0536 
Diff. peak and hole [e/Å3] 1.918 and -1.327  1.056 and -1.783 
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 24a  21a 
Empirical formula  C10H7O5Re  C14H15NO 
Formula weight  393.36  213.27 
Crystal system  Triclinic  Triclinic 
Space group  P-1  P-1 
a [Å] 6.59246(9)  9.5988(3) 
b [Å] 6.91029(13)  9.8084(3) 
c [Å] 13.1124(2)  13.3768(3) 
 [°] 91.7016(15)  106.403(2) 
 [°] 97.9610(13)  90.368(2) 
 [°] 116.1410(16)  94.364(2) 
Volume [Å3] 528.305(15)  1204.14(6) 
Z 2  4 
Crystal size [mm3] 0.35 x 0.22 x 0.21  0.70 x 0.55 x 0.28 
Crystal description colourless block  brown block 
Reflections collected 50233  30310 
Independent refl. [R(int)] 5609 [0.0336]  7327 [0.0247] 
Refl. observed [I>2 (I)] 5411  5948 
Completeness to  99.2 % to 36.23°  99.8 % to 30.51° 
Goodness-of-fit on F2 1.237  0.937 
Final R indices [I>2 (I)] R1 = 0.0191  R1 = 0.0577 
 wR2 = 0.0457  wR2 = 0.1561 
Diff. peak and hole [e/Å3] 0.800 and -2.107  0.299 and -0.194 
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 65  27 
Empirical formula  C11H10ClN6O3Re  C11H9O5Re 
Formula weight  495.90  407.38 
Crystal system  Monoclinic  Triclinic 
Space group  P21/c  P-1 
a [Å] 14.8937(3)  7.0099(3) 
b [Å] 7.76476(15)  7.3494(2) 
c [Å] 13.4271(3)  11.5145(3) 
 [°] 90  102.217(2) 
 [°] 100.284(2)  94.765(2) 
 [°] 90  104.059(3) 
Volume [Å3] 1527.84(5)  556.72(3) 
Z 4  2 
Crystal size [mm3] 0.22 x 0.19 x 0.08  0.55 x 0.42 x 0.32 
Crystal description orange plate  colourless block 
Reflections collected 20160  19486 
Independent refl. [R(int)] 5302 [0.0310]  5352 [0.0664] 
Refl. observed [I>2 (I)] 4139  5104 
Completeness to  99.9 % to 30.44°  99.1 % to 36.23° 
Goodness-of-fit on F2 1.071  1.141 
Final R indices [I>2 (I)] R1 = 0.0272  R1 = 0.0252 
 wR2 = 0.0501  wR2 = 0.0626 
Diff. peak and hole [e/Å3] 1.692 and -0.968  1.509 and -3.642 
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 9   
Empirical formula  C11H11NO4S   
Formula weight  253.27   
Crystal system  Monoclinic   
Space group  P21/n   
a [Å] 15.4647(3)   
b [Å] 6.35360(10)   
c [Å] 22.8489(4)   
 [°] 90   
 [°] 91.2560(15)   
 [°] 90   
Volume [Å3] 2244.51(7)   
Z 8   
Crystal size [mm3] 0.26 x 0.24 x 0.05   
Crystal description colourless plate   
Reflections collected 31636   
Independent refl. [R(int)] 6832 [0.0449]   
Refl. observed [I>2 (I)] 4198   
Completeness to  99.9 % to 30.44°   
Goodness-of-fit on F2 0.954   
Final R indices [I>2 (I)] R1 = 0.0454   
 wR2 = 0.0891   
Diff. peak and hole [e/Å3] 0.337 and -0.376   
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